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Abstract 
The Hippo/MST signalling cascade regulates cell survival and proliferation in metazoans and 
numerous reports indicate its further role in tumour suppression, especially in the liver. C-
RAF, indirect activator of ERK in MAPK pathway, can interact with, and inhibit, MST2. In 
addition, C-Raf is implicated in the protection from apoptosis in mouse liver, and found 
overexpressed in human liver tumours. We investigate the possible interaction between the 
Hippo/Mst pathway and C-Raf in liver tumorigenesis. 
Results from experiments on c-raf single knock-out animals revealed that C-Raf ablation in 
the hepatocyte leads to increased liver size, tumour mass and tumour number after chemical 
liver carcinogenesis. Similarly, ablation of C-Raf in hepatocyte and liver non-parenchymal 
cells before, but not after, tumour initiation leads to increased number of tumours, although 
not liver mass or tumour mass. The ablation of C-Raf in hepatocyte and liver non-
parenchymal cells after development of macroscopic tumours did not affect their further 
growth or maintenance. 
Further, we have crossed animals with hepatocyte-specific deletion of c-raf gene with animals 
harbouring a germline disruption of the gene encoding for Rassf1a, an upstream regulator of 
Hippo/Mst signalling with tumour suppressor functions lost in liver cancer through 
methylation of the isoform-specific promoter. The phenotype of hepatocyte-restricted c-raf 
knock-out after chemical carcinogenesis was absent on a rassf1a knock-out background, 
indicating genetic interaction between c-raf and rassf1a. 
In most livers with c-raf-deficient hepatocytes we could detect progression to carcinoma 
stage, whereas in wild-type animals we detected almost exclusively benign nodules. On the 
other hand, double knock-out animals had similar numbers of carcinomas in comparison to 
those with sole rassf1a deletion. Similarly proliferation in tumour unaffected tissue was 
increased in livers with c-raf-deficient hepatocytes on the WT but not rassf1a knock-out 
background. Both c-raf-deficient and double KO livers exhibit increased numbers of Kupffer 
cells indicating increased inflammation. We correlate observed phenotypic changes in 
tumour-bearing livers with changes in activation of MAPK, Hippo and inflammatory 
signalling pathways. Finally, we use primary cell cultures to investigate acute effects of 
oxidative stress on Hippo pathway activation. 
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We propose a tumour suppressive function of C-Raf in the hepatocyte and tumour promoting 
role in liver non-parenchymal cells derived from hematopoetic line. Furthermore we unravel 
interaction between c-raf and rassf1a in chemically-induced mouse liver cancer model. 
 
ZUSAMMENFASSUNG 
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Zusammenfassung 
Der Hippo/MST Signaltransduktionsweg reguliert das Zellwachstum in Metazoen und 
fungiert als potentieller Tumorsuppressor in Leberkarzinomen. C-RAF, der indirekte 
Aktivator von ERK im MAPK Signaltransduktionsweg, kann MST2 binden und inhibieren. 
Auβerdem schützt C-Raf Zellen vor Apoptose und zeigt eine deutliche Überexpression in 
humanen Leberkarzinomen. Diese Arbeit untersucht die potentielle Interaktion zwischen dem 
Hippo/Mst Signaltransduktionsweg und C-Raf in der Entstehung von Leberkrebs. 
Chemische Tumorinduktion in c-raf Knock-out Mäusen zeigen, dass die Ablation von C-Raf 
in Hepatozyten zu einem gesteigerten Tumorwachstum und einer höheren Anzahl von 
Tumoren führt. Auf ähnliche Weise führt die Ablation von C-Raf in Hepatozyten und den 
nicht-perenchymalen Zellen vor der Tumorinitiation zu einer höheren Zahl von Tumoren, 
jedoch zu keinem gesteigerten Tumorwachstum. Die Ablation von C-Raf in Hepatozyten und 
den nicht-parenchymalen Zellen nach der Entstehung von makroskopische Tumoren zeigt 
keine Auswirkung auf deren Zahl und Wachstum. 
Im nächsten Schritt wurde die chemische Tumorinduktion in einem c-raf/rassf1a doppel 
Knock-out Stamm durchgeführt. Rassf1a reguliert den Hippo/Mst Signaltransduktionsweg, 
und fungiert als Tumorsuppressor in der Leber, verliert diese Funktion jedoch im Zuge der 
Tumorprogression durch Promotor-Methylierung. Der Phänotyp Verlust des c-raf Knock-outs 
nach der chemischen Tumorinduktion im rassf1a Knock-out Hintergrund deutet auf die 
genetische Interaktion zwischen c-raf und rassf1a hin. 
Die Mehrzahl der c-raf-Knock-out Lebern zeigt Tumore im fortgeschrittenen 
Karzinomstadium, während in Wildtyp-Mäusen nur Dysplasien detektiert werden konnten. 
Doppel Knockout Mäuse aber zeigen eine ähnliche Zahl an Karzinomen wie jene mit der 
alleinigen Deletion von rassf1a. Weiters war in tumorfreien Arealen in c-raf Knock-out 
Mäusen im Vergleich zum Wild-Typ eine erhöhte Proliferation zu beobachten, nicht jedoch 
im rassf1a-Knock-out Hintergrund. Sowohl C-raf- als auch c-raf/rassf1a doppel Knock-outs 
weisen eine erhöhte Anzahl von der Kupfferzellen auf, was auf eine Entzündungsreaktion 
hindeuten könnte. Die beobachteten Phänotypen der Lebertumore wurden mit veränderten 
Aktivitäten in MAPK-, Hippo- und Enzündungs Signaltransduktionswegen korreliert. Im 
letzten Schritt wurden die Akuteffekte von, oxidativem Stress auf den Hippo 
Signaltransduktionsweg analysiert. 
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Zusammenfassend konnten wir zeigen, dass C-Raf in Hepatozyten als potentieller 
Tumorsuppressor, in nicht-parenchymalen Leberzellen, die aus dem Knochenmark stammen, 
aber als Tumorpromoter fungiert. Weiters wurde die Interaktion zwischen c-raf und rassf1a 
im chemisch-induzierten Leberkrebsmodel analysiert. 
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Introduction 
Liver physiology and architecture 
Liver is the largest internal organ in human body divided into four lobes (right, left, caudate 
and quadrate). It is surrounded by external (Glisson) capsule of connective tissue and 
penetrated by portal vein that delivers nutrient-rich blood from intestines, hepatic artery that 
delivers oxygen-rich blood from the heart, hepatic vein that drains blood from the liver back 
to heart, bile-ducts that collect bile from the liver to the gall bladder, lymphatics that drain 
excess fluid and protein from the interstitial space of the liver and nerve fibres. Portal vein 
and hepatic artery branch in the liver into smaller portal veins followed by venules and 
hepatic arteries followed by arterioles, respectively, that finally open into sinusoids. Having 
perfused liver parenchyma via sinusoids blood enters terminal hepatic venules and is drained 
from the liver by the system of hepatic veins. Hepatocytes adjacent to each other form 
between their plasma membranes tight-junction-limited space that constitutes bile canaliculi, 
where the bile is secreted. Canaliculi drain into Canals of Hering that open to cholangioles 
(bile ductules), where the bile is collected from by the system of bile ducts and directed to the 
gall bladder (Figure 1) (Burt, Portmann et al. 2007). 
Arrangement of vessels that penetrate the liver determines its microanatomy and functional 
unit. On the cross section portal triads (composed of artery, portal vein and bile duct) have 
hexagonal arrangement in the liver parenchyma with terminal hepatic vein placed in the 
middle - structure called classical hepatic lobule. Flow of oxygenated and nutrient-rich blood 
proceeds from the portal triads (periportal areas) in the direction of terminal hepatic veins 
(centrilobular areas) and determines microenvironment and metabolic function of hepatocytes 
depending on their localisation between portal triad and terminal hepatic vein. Functionally 
more relevant unit is liver acinus composed of 2 terminal hepatic veins from adjacent hepatic 
lobules with a portal triad in between. Space in the liver accinus that lies between portal triad 
and terminal hepatic vein is divided into 3 zones (1,2 and 3) with zone 1 being closest to the 
portal triad, zone 2 being intermediate, and zone 3, adjacent to terminal hepatic vein. Zonation 
along this porto-central axis is reflected by different ultrastructure, enzyme activities of 
hepatocytes and their metabolic function (Figure 2) (Burt, Portmann et al. 2007). 
Hepatoctes constitute for 70% of liver cells and perform most of the functions of this organ: 
they secrete bile, release glucose and store it in the form of glycogen, biotransform and 
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detoxify drugs, metabolise heam, synthesise lipids and some amino acids, maintain nitrogen 
balance, produce plasma proteins and store iron and copper. They are large (30-40µm in 
diameter) epithelial cells facing sinusoidal space with their basolateral surface, bounding bile 
canaliculis with their canalicular surface and facing rest of extracellular space with their 
lateral surface. They maintain polarity by forming tight junctions in the lateral surface with 
neighbouring hepatocytes. They are often bi-nucleated, their nuclei are large and round 
encompassing 5-10% volume of the cell, and with age they become progressively polyploid. 
Endoplasmatic reticulum (ER) encompasses 15% of cytoplasm volume, with smooth ER 
twice as abundant in centrilobular as in periportal hepatocytes, what reflects their different 
metabolic functions. Hepatocyte has around 50 Golgi zones participating in bile secretion and 
30 lysosomes used for autophagy and degradation of endocytosed extracellular proteins. It 
contains also around 300-600 peroxisomes that oxidise number of substrates including ethanol 
and as much as 1000 mitochondria that occupy around 20% of its cytoplasm and produce 
energy used in all metabolic processes. Cholangiocytes (bliary epithelial cells) are other type 
of epithelial cells of the liver that line bile ducts and modify composition of the secreted bile 
(Figure 1) (Burt, Portmann et al. 2007). 
Normally quiescent hepatocytes maintain throughout the life of the organism the capability to 
re-enter cell cycle and repopulate liver in case of organ injury. Nevertheless, liver contains 
also population of stem cells named oval cells, that are reside in the vicinity of portal vein and 
are able to differentiate into hepatocytes as well as biliary epithelial cells (Figure 1). They are 
mobilized in case hepatocytes are not able to efficiently contribute to liver regeneration 
processes. For instance, in rodents in the protocol of choline deficient diet liver injury is 
accompanied by inhibition of hepatocyte proliferation. This leads to proliferation of oval 
cells, and in case of prolonged treatment, to HCC development. Oval cell activation is 
induced, among other stimuli, by growth factors like TGF-α and HGF secreted by stellate 
cells, and various inflammatory cytokines, like TNF superfamily members (TNF-α, TWEAK, 
lymphotoxins α and β, LIGHT) and activators of GP130 (Il-6, oncostatin M, leukaemia 
inhibitory factor) secreted by Kupffer cells and liver associated lymphocytes (Bird, Lorenzini 
et al. 2008). Research in the last years indicates that at least some human HCCs might result 
from abnormal oval cell proliferation as their number is elevated in various pathological liver 
conditions that precede HCC development (Knight, Matthews et al. 2005). Recently, HCC 
development associated with expansion of oval cell compartment in mice was found to be 
suppressed by Hippo/Mst signalling (Lee, Lee et al. 2010; Lu, Li et al. 2010). 
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Non-parenchymal cells of the liver localise to the sinusoids lined by endothelial cells that 
have numerous fenestrae which allows for the blood filtration and pass-through of solutes that 
contact hepatocytes. Endothelial cells produce some inflammatory cytokines and have 
endocytic activity that enables them removing protein aggregates and immune complexes 
from filtered blood. Stellate cells reside between endothelial cells and hepatocytes (in the 
space of Disse) and are of mesenchymal origin. They produce extracellular matrix that 
constitutes structural meshwork of the liver what is controlled by cytokines secreted by 
Kupffer cells and endothelial cells. They also store vitamin A, can stimulate hepatocyte 
proliferation during liver regeneration, and act as pericytes around the sinusoids by 
responding to vasoactive agents. Kupffer cells belong to mononuclear phagocytic system and 
play role of resident liver macrophages. They are able to proliferate in the liver, but in some 
part they are also derived from circulating monocytes. They phagocyte microorganisms, 
degenerated cells, tumour cells and various macromolecules, and by releasing cytokines they 
influence behaviour of hepatocytes, endothelial cells and stellate cells. Liver-associated 
lymphocytes are comprised in 65% of natural-killer (NK) cells, γδ T-cells and NK-
molecules-expressing T- (NKT) cells. They are participating in response against various 
pathogens and tumour cells; especially hepatic NK cells, that comprise 50% of all liver-
associated lymphocytes, have ability to lyse tumour cells and their number greatly increases 
in case of hepatic malignancy (Figure 1) (Burt, Portmann et al. 2007). 
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Figure 1. Architecture of the liver sinusoid with localisation of various cell types. For clarity only hepatocytes adjacent 
to the single sinusoid are depicted. Details in text. 
HA - hepatic artery; PV - portal vein; BD - bile duct; ThV - terminal hepatic vein (also known as central vein); arrows 
indicate direction of blood and bile flow; 
 
 
 
Figure 2. Architecture of hepatic lobule and liver accinus. Arrangement of portal triads (PT) consisting of portal vein 
(red), hepatic artery (blue) and bile duct (green) and two terminal hepatic veins of two adjacent hepatic lobules is 
depicted with cords of hepatocytes (light yellow) belonging to one liver accinus. Red dashed lines indicate division to 
different zones of the accinus. Details in text. 
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Hepatocellular carcinoma epidemiology, aetiology and treatment 
Hepatocellular carcinoma (HCC) is the third cause of cancer-related death worldwide with 
more than 600000 patients succumbing to this disease each year. Its incidence is more 
frequent in men and geographically highly prevails in Asia and sub-Saharan Africa, though 
recently in Western countries number of diagnosed cases per year is increasing. HCC belongs 
to epithelial tumours and is the most common liver cancer comprising 83% of all primary 
tumours of this organ (Farazi and DePinho 2006; Ferenci, Fried et al. 2010). 
HCC is usually preceded by liver cirrhosis, caused by excessive fibrosis resulting from 
continuous liver injury and inflammation. The main risk factors of HCC are infections with 
hepatitis B and C viruses (HBV and HCV). Virus-related factors that contribute to HCC 
development are complex and consist of both viral and host components. HBV integration 
into host’s genome may cause microdeletions that include cancer-relevant genes. Some of 
HBV-encoded proteins, like HBx, function as activators of host’s proto-oncogenic pathways. 
Host-viral interactions in case of HBV infection drive robust immune-response that triggers 
necrosis, inflammation and regeneration, leading to hepatocyte transformation. Moreover 
HBV, as well as HCV, is interacting with endoplasmic reticulum (ER), what induces 
oncogenic oxidative stress. As HCV is a RNA-virus, it cannot integrate into host’s genome 
and has higher replication error rate that underlies its ability to evade immunological system. 
This results in higher rate of chronic infections, causing recurrent cycles of immune response 
and subsequent liver regeneration, what leads to liver cirrhosis with 10-20 times higher 
frequency than for HBV (Farazi and DePinho 2006). Another HCC risk factor is alcohol 
abuse that might contribute to HCC by activating monocytes and Kupffer cells to release 
proinflammatory cytokines. It also damages liver by oxidative stress, which in turn activates 
stellate cells, oncogenic pathways and causes mutations in DNA and telomere shortening 
(Farazi and DePinho 2006). Ingestion of aflatoxin B, a mycotoxin, can also be the cause of 
HCC, but unlike viruses or alcohol, it does not cause liver fibrosis - rather functions as a 
direct mutagen specific for gene encoding TP53. Other aetiological factors associated with 
HCC are genetic disorders like hemochromatosis, α1-antitrypsin deficiency, tyrosinaemia and 
porphyria cutanea tarda; long-term contraceptive consumption in woman; diabetes and non-
alcoholic fatty liver disease (Farazi and DePinho 2006). 
Lack of early biomarkers makes it difficult to detect HCC at early stage. Current therapies are 
available almost exclusively for limited disease and include surgical tumour resection, local 
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ethanol injection, radiofrequency and transarterial chemoembolisation. Liver transplantation 
is also applied, although patients need to meet stringent criteria, and donor shortage also poses 
a great problem. In advanced disease only symptomatic treatment is applied, as there is no 
beneficial chemotherapy available. Just recently sorafenib, a multikinase inhibitor designed 
primarily against C-RAF, has been shown to increase survival of patients with unresectable 
disease by 3 months. In some countries it has been approved for clinical use, but its high cost 
(up to 7300$ dollars for one month of treatment in China) makes it impossible to use in 
developing countries, where HCC has especially high incidence (Ferenci, Fried et al. 2010). 
Mouse models of HCC 
Numerous mouse models are used to investigate molecular mechanism of HCC as well as 
responses to potential therapeutic interventions, as they allow achieving physiologically most 
relevant research conditions. Liver cancer in rodents may be induced by chemical 
carcinogens, modification of genes involved in tumorigenesis or transplantation of 
transformed cells. 
Chemical liver carcinogenesis in mice 
Chemicals that can induce liver cancer in mice are divided into genotoxic and non-genotoxic. 
The former ones are able to introduce mutations, usually by forming DNA-adducts, and in 
this way initiate cell transformation. The latter ones do not affect DNA structure directly, but 
rather create tumour-promoting conditions in the liver, i.e. by inducing uncontrolled 
hepatocyte proliferation or liver inflammation, that favour cell transformation and tumour 
growth (Leenders, Nijkamp et al. 2008). 
Chemically-induced development of HCC in animal models is divided into initiation, 
progression and promotion. Initiation is an irreversible step induced by carcinogen in which 
hepatocytes undergo transformation. Promotion, a clonal expansion of these transformed cells 
to macroscopic-size foci, is reversible and may be enhanced by chemical compounds or 
regenerative stimuli that drive hepatocyte proliferation. In progression stage, growth of 
tumours from dysplastic lesions takes place what is accompanied by further genetic changes 
that eventually lead to malignancy of primary tumour (Durr and Caselmann 2000). 
Numerous compounds have been shown to induce transformation of hepatocytes (Williams 
1997), and some of them are used in animal liver cancer models. N-diethylnitrosoamine 
(DEN) is the most often used carcinogen to induce HCC in rodents. The efficiency of tumour 
induction by DEN is strain- (susceptible 129/Sv versus resistant C57BL/6), sex- (males more 
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prone than females) and age-dependent. Typically injection around 2 weeks of age with a low 
dose (5mg per g body weight) leads to 100% tumour penetrance by around 40 weeks of age. 
(Vesselinovitch and Mihailovich 1983). Injection may also be performed in older mice (4-6 
weeks of age) but much higher dose is required (80-100mg per g body weight) and tumour 
latency is much longer. This is a result of lower proliferation in the livers of older animals that 
positively correlates with tumour initiation rate. In such case combination with partial 
hepatectomy or proliferation stimulation with other chemical, like phenobarbital (Pb), may be 
used to accelerate tumorigenesis. 
Administration of DEN, apart from HCC might cause neoplasms of Kupffer cells, and 
tumours in other organs like skin, gastrointestinal tract, respiratory system and hematopoietic 
system. DEN is bio-activated in pericentral hepatocytes with the help of microsomal 
cytochromes P450, mainly CYP2E1 that is highly expressed in liver centrilobular area. 
Activated form of DEN is able to form DNA adducts on all 4 bases at positions with high 
electron density as well as phosphodiester bond, that may result in point mutations and single 
strand DNA breaks, respectively. Therefore DEN introduces mutations that, if affect sequence 
of cancer-relevant gene, may contribute to hepatocyte transformation. Apart from that DEN is 
cytotoxic and shortly after administration induces apoptosis of centrilobular hepatocytes that 
is compensated by proliferation in periportal areas (Verna, Whysner et al. 1996). 
Phenobarbital function in liver tumorigenesis is not completely understood, i.e. Pb inhibits 
tumorigenesis if administered before, and promotes growth of DEN-initiated hepatocytes if 
administered after DEN-treatment. It induces cytochromes P450, promotes proliferation and 
inhibits apoptosis of initiated hepatocytes and selects for cells with activated β-catenin 
(Whysner, Ross et al. 1996). 
Chemical models of liver carcinogenesis can help to establish relationship between 
carcinogen exposure and other environmental factors or specific genetic changes. But it 
usually takes months from the tumour initiation until macroscopic nodules appear and 
furthermore, nodules that arise carry heterogeneous, often unidentified mutations. 
Transgenic mouse models 
Transgenic mouse technology enabled generation of genetic HCC models based, first on 
transgenic expression of proto-oncogenes or viral proteins, and further on knock-outs of 
tumour suppressors. Induction of tumour growth in the liver is achieved by exploiting various 
hepatocyte-specific promoters (α-1-antitripsin, metallothionein, albumin) to express 
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oncogenes and growth factors like large T-antigen of SV40 (Sepulveda, Finegold et al. 1989), 
c-myc (Sandgren, Quaife et al. 1989), TGF-α (Jhappan, Stahle et al. 1990) E2F1 and c-
myc/E2F1 (Conner, Lemmer et al. 2000) or c-myc/TGF-α combinations (Murakami, 
Sanderson et al. 1993). Investigation of hepatocarcinogenic viruses lead to development of 
mouse HCC models based on transgenic expression of HBV viral envelope protein HBsAg 
(Chisari, Klopchin et al. 1989) and gene expression transactivator protein HBx (Kim, Koike et 
al. 1991; Yu, Moon et al. 1999) or HCV core E1 and E2 proteins (Moriya, Fujie et al. 1998). 
Liver-restricted ablation of genes encoding components of NF-κB (Luedde, Beraza et al. 
2007; Bettermann, Vucur et al. 2010; Inokuchi, Aoyama et al. 2010), Hippo (Zhou, Conrad et 
al. 2009; Lee, Lee et al. 2010; Lu, Li et al. 2010; Song, Mak et al. 2010) or PI3 kinase 
signalling (Horie, Suzuki et al. 2004) also lead to spontaneous liver tumour development in 
mice. 
Great limitation of classical transgenic models is genetic modification of all cells in the target 
organ, including tumour microenvironment. Therefore conditional activation/ablation of 
HCC-regulating genes is applied to mimic somatic mutations that initiate single cells without 
initially affecting surrounding tissue. Polyoma virus middle T antigen (PyMT) viral delivery 
to hepatocytes expressing virus-receptor (Lewis, Klimstra et al. 2005), SV40 T-Ag transgene 
controlled with adeno-Cre-excisable “stop” cassete (Lou, Molina et al. 2005) or also adeno-
Cre-mediated conditional ablation of Apc-encoding gene leading to β-catenin activation 
(Colnot, Decaens et al. 2004) are examples of such approach. 
Numerous transgenic models of HCC induce hepatocyte transformation in cell non-
autonomous manner. Mice knock-out for mdr2, gene encoding transporter of bile contents, 
develop cholangitis, inflammation and subsequent HCC (Mauad, van Nieuwkerk et al. 1994). 
Transgenic overexpression of urokinase plasminogen-activator (uPA) in hepatocytes induces 
their death, and repopulation of the liver with transgene-negative hepatocytes that later on 
form tumours (Sandgren, Palmiter et al. 1992). Similarly mouse livers that have genetically 
disrupted damaged DNA-binding protein 1 (DDB1) are repopulated by DDB1-positive 
hepatocytes and develop tumours after few months (Yamaji, Zhang et al. 2010). 
Such transgenic models enable studying role of other genes or environmental factors in HCC, 
but often require long time until complete disease development and in case of multiple 
transgenics require time consuming mice crossing. 
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Xenograft mouse models 
Immunologically compromised mouse strains allow xenotransplantation of HCC-derived cells 
or tumours from mice and men and study their growth under the skin of the animal. Such 
approach offers highly repeatable conditions of tumour growth that can be examined non-
invasively and very rapidly. But models based on that technology are lacking in vivo 
relevance, as involve introducing often much modified cells into physiologically unusual 
locations. Othotopic transplantation models, though more laborious, can help to overcome 
these limitations (Leenders, Nijkamp et al. 2008). 
Lately “mosaic” mouse HCC models have been introduced that bear some similarity with 
xenotransplantation models. They involve transformation of hepatic progenitors, their 
fluorescent labelling and manipulation of genetic element of interest. Such cells are then 
introduced to recipient liver and their orthotopic growth can be monitored by in vivo imaging. 
These models are rapid, offer defined genetic context and microenvironment of cancer cell 
that resembles physiologic conditions (Zender, Xue et al. 2005). 
Conditional gene ablation in the liver 
To study in vivo the role of genes in liver carcinogenesis that are also required during 
development, conditional gene ablation needs to be applied. Such approach has also 
advantage of affecting gene of interest only in certain cell types, what allows avoiding effects 
of gene deletion in other parts of the body. 
Hepatocyte-specific gene ablation can be achieved with alfp-cre mouse line that bears a 
transgene encoding Cre-recombinase cDNA under the control of albumin promoter and α-
fetoprotein and albumin enhancers. Expression from this transgene is activated during 
embryogenesis between day 9,5 and 10,5 post coitus in liver parenchyma, and leads to 
deletion of floxed alleles in hepatocytes, biliary epithelial cells and presumably, oval cells 
(Kellendonk, Opherk et al. 2000). 
Other mouse line that can be applied to ablate gene expression in the liver is mx-cre line, in 
which Cre-recombinase cDNA is controlled by interferon-responsive promoter. It can be 
indirectly activated by inducing innate immune response and interferon-production with 
polyinosinic-polycytidilic acid (poly(I:C)). Cre recombinase is then expressed in any 
interferon-sensitive cell type, and so deletion is much less restricted then in alfp-cre line, 
encompassing liver, spleen, duodenum, and to some extent heart, lung, uterus, thymus and 
kidney (Kuhn, Schwenk et al. 1995). Specifically in the liver, Cre recombinase in mx-cre 
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mice is expressed not only in parenchyma but also in most non-parenchymal cells - Kupffer 
cells and liver associated lymphocytes (as coming from hematopoietic line) and partially in 
endothelial cells (unpublished data). 
Molecular hallmarks of HCC 
Main characteristics that cells need to acquire to become “successful” cancer cell have been 
summarised more than 10 years ago (Hanahan and Weinberg 2000) and recently revised 
(Hanahan and Weinberg 2011), and in an accompanying review we remind them in the 
context of C-RAF role in tumour biology (Maurer, Tarkowski et al. 2011). 
Research on HCC done until now revealed numerous molecular pathways that need to be 
affected in hepatocytes to enable them acquiring each of six classical hallmarks of cancer. 
Moreover, recent studies indicate tumour-promoting inflammation as having a key role in 
HCC development. In the following sections for each hallmark I summarise briefly most 
significant pathways affected in HCC, elaborating in more detail on those important for 
MAPK signalling with emphasis on C-RAF, and MST/Hippo signalling, that are in the focus 
of this dissertation. 
Sustaining proliferative signalling 
C-MYC transcription factor is the central oncogene that sustains abnormal proliferative 
signalling in hepatocytes. Its overexpression in mouse liver drives spontaneous tumour 
development (Sandgren, Quaife et al. 1989; Shachaf, Kopelman et al. 2004), and deregulation 
of its activity in patients is associated with malignant tumour conversion (Kaposi-Novak, 
Libbrecht et al. 2009). Cyclin-dependent kinases (CDK) system that drives progression 
through cell cycle is also often deregulated in HCC. Cyclin D1 is overexpressed in 11% of 
clinical advanced HCC cases (Nishida, Fukuda et al. 1994), and in mouse liver can 
independently drive tumorigenesis. Moreover, CDK inhibitors are suppressed in HCC either 
by oncomiRs like in the case of p27 in HCC patients (Pineau, Volinia et al. 2010) or by JNK 
signalling like in the case of p21 in mouse chemically-induced HCC (Hui, Zatloukal et al. 
2008) that also suppresses tumorigenesis in chronically inflamed liver in hereditary 
tyrosinemia I mouse genetic model (Willenbring, Sharma et al. 2008). 
Cell proliferation is controlled from its outside by small peptides - growth factors (GFs), 
which upon binding to their respective receptors on the cell membrane activate intracellular 
signalling pathways. GFs relevant for HCC development are EGF receptor ligand TGF-α, 
which is upregulated in serum of patients suffering from HCC (Yeh, Tsai et al. 1987) and 
RESULTS 
17 | P a g e  
enhances liver regeneration and tumorigenesis in various mouse models (Jhappan, Stahle et 
al. 1990; Lee, Merlino et al. 1992; Murakami, Sanderson et al. 1993; Sandgren, Luetteke et al. 
1993), EGF, which accelerates tumorigenesis in c-myc transgenic mouse model (Tonjes, 
Lohler et al. 1995), and probably IGFII, whose scavenger receptor encoded by IGF2R gene is 
often lost in human HCC (De Souza, Hankins et al. 1995). Hepatocyte growth factor (HGF) 
and its receptor C-MET are another GF-receptor system relevant for hepatocyte homeostasis. 
C-MET is overexpressed in HCC patients (Ueki, Fujimoto et al. 1997) and mutated in the 
kinase domain in childhood HCC (Park, Dong et al. 1999). In mice c-Met drives spontaneous 
HCC development (Wang, Ferrell et al. 2001) and is required for liver regeneration by 
enabling Akt and Erk activation and hepatocyte cell-cycle re-entry (Borowiak, Garratt et al. 
2004). Transgenic overexpression of HGF in the liver leads to spontaneous HCC (Sakata, 
Takayama et al. 1996) and accelerated DEN-induced hepatocarcinogenesis in mice, 
accompanied by c-Met activation (Horiguchi, Takayama et al. 2002). Still, function of 
HGF/C-MET system in HCC might also be tumour-suppressive, depending on the stage and 
aspect of liver tumorigenesis (Shiota, Rhoads et al. 1992; Santoni-Rugiu, Preisegger et al. 
1996; Takami, Kaposi-Novak et al. 2007). 
After ligand binding and transmitting the signal across cell membrane, cytoplasmic domains 
of the receptor assemble protein complexes that activate, among other signalling mediators, 
small GTPase proteins from RAS family. RAS-encoding genes are most frequently mutated 
genes in human cancers, mainly in codons 12, 13 and 61, what decreases their ability to 
hydrolyse bound GTP and causes their constitutive activation. Nevertheless such mutations 
are not found in human hepatocellular hepatomas or carcinomas, but rather 
cholangiocarcinomas (Tada, Omata et al. 1990). Still, in spontaneous and chemically induced 
rodent liver tumours mutations or elevated expression of genes encoding Ras proteins is found 
(Reynolds, Stowers et al. 1986; Wiseman, Stowers et al. 1986; Stowers, Wiseman et al. 1988; 
Buchmann, Bauer-Hofmann et al. 1991). Moreover, H-Ras expression is upregulated in rats 
during DNA synthesis phase after partial hepatectomy - strong proliferative stimulus to 
normally quiescent hepatocytes (Goyette, Petropoulos et al. 1983; Thompson, Mead et al. 
1986), and recent studies indicate that HCC cell lines and tumours that do not have mutations 
in any of RAS-encoding genes, down-regulate at least one of their inactivating proteins, 
GTPase-activating proteins (GAPs) (Calvisi, Ladu et al. 2006; Jin, Wang et al. 2007; Calvisi, 
Ladu et al. 2011). 
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Activated RAS recruits one of three RAF proteins to the membrane compartments and by 
physical interaction increases their kinase activity, allowing further transmission of the signal 
by subsequent two core kinases of the pathway, MEK and ERK. B-Raf-encoding gene bears 
activatory mutations in chemically-induced mouse liver tumours (Jaworski, Buchmann et al. 
2005) and C-RAF is overexpressed in human liver cancer (Hwang, Choi et al. 2004). 
Moreover, RKIP protein, whose function is to inhibit MEK activation by competing for 
binding to C-RAF, is found down-regulated in HCC cell lines and tumours (Schuierer, 
Bataille et al. 2006). MEK overexpression is found in human HCC specimens, and assays in 
vitro and mouse xenografts show sensitivity of HCC cell lines in terms of proliferation and 
survival towards numerous MEK inhibitors alone (Huynh, Nguyen et al. 2003; Klein, 
Schmidt et al. 2006; Huynh, Soo et al. 2007) or together with inhibitors of RTK and RAF 
(Huynh, Ngo et al. 2010). Finally, ERK activation is elevated in clinical HCC samples (Ito, 
Sasaki et al. 1998) similarly to other MAP kinase JNK1, which is also required for efficient 
chemical carcinogenesis and liver regeneration in mice. JNK1 performs this function by 
suppressing expression of cell cycle inhibitor p21 and inducing c-Myc oncogene, what drives 
proliferation of hepatocyte (Hui, Zatloukal et al. 2008). 
Evading growth suppressors 
TP53 is the most often lost tumour suppressor in all cancers, including human HCC where it 
is frequently deleted or mutated (Bressac, Galvin et al. 1990; Bressac, Kew et al. 1991; Hsu, 
Metcalf et al. 1991) and its even brief reactivation in mouse mosaic HCC model is sufficient 
to induce irreversible tumour regression (Xue, Zender et al. 2007). PTEN is another classical 
tumour suppressor that inhibits spontaneous HCC in mouse (Horie, Suzuki et al. 2004) and 
promoter of its gene is methylated in around half of HCC patients (Wang, Wang et al. 2007). 
Transforming growth factor β (TGF-β) and its receptor have tumour suppressive role in 
cancer, but in late carcinogenesis they drive metastatic behaviour of transformed cells 
(Massague 2008). TGF-β inhibits proliferation of hepatocytes in vitro, and together with its 
receptor during rodent liver regeneration (Russell, Coffey et al. 1988; Romero-Gallo, Sozmen 
et al. 2005). TGF-β receptor inhibits chemical liver carcinogenesis in mice (Tang, Bottinger et 
al. 1998; Kanzler, Meyer et al. 2001), in human HCC its expression is lost (Kiss, Wang et al. 
1997), and its effector Smad3 transcription factor protects murine liver form chemical 
carcinogenesis by sensitising HCC cells to apoptosis in a p38 activation-dependent manner 
(Yang, Zhang et al. 2006). p38 is a MAP kinase activated by stress stimuli with tumour 
suppressive functions in various cancer types. In the liver it inhibits chemically-induced 
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carcinogenesis by suppressing activity of JNK-c-Jun pathway and in this way restricting 
proliferation of hepatocyte (Hui, Bakiri et al. 2007). 
In recent years the Hippo/Mst signalling pathway that restricts cell proliferation and organ 
growth appeared to be crucial for suppressing development of liver cancer. Its main 
components and their mechanism of action are described in detail in a separate chapter, but in 
a nutshell, at least in vitro, the pathway inactivates YAP proto-oncogene by phosphorylation 
signal, transduced through MST-LATS kinase cascade. Mst kinases and WW45 protein 
required for their activation play tumour suppressive role in mouse liver, most likely by 
restricting oval cell proliferation, and MST activation is decreased in majority of human 
HCCs (Zhou, Conrad et al. 2009; Lee, Lee et al. 2010; Lu, Li et al. 2010; Song, Mak et al. 
2010). LATS2-encoding gene is located in a region frequently lost in human HCC (Chen, Yeh 
et al. 2005) and YAP-encoding gene amplification leads to its overexpression in HCC 
samples what in mouse models drives growth of liver tumours (Zender, Spector et al. 2006; 
Camargo, Gokhale et al. 2007; Dong, Feldmann et al. 2007). Also upstream regulators of 
MST signalling seem to be affected in HCC. Nf2, which orthologue of activates drosophila 
Hippo, suppresses tumorigenesis in mouse liver, although whether this is because of Mst 
activation (Zhang, Bai et al. 2010) or suppression of Egfr activity (Benhamouche, Curto et al. 
2010) is still debated. Expression of Ras-associated factor 1A (RASSF1A), that regulates Mst 
activity by direct association mammalian cells as well as in flies, is epigenetically silenced in 
majority of HCC cases (Schagdarsurengin, Wilkens et al. 2003). 
Resisting cell death 
In case of DNA damage or oncogenic stress TP53 stabilisation leads to programmed cell 
death through induction of proapoptotic genes, like some Bcl-2 protein family members 
(Vousden and Lane 2007). Therefore frequent TP53 inactivation might desensitise HCC cells 
from intrinsic apoptotic cues (Bressac, Galvin et al. 1990; Bressac, Kew et al. 1991; Hsu, 
Metcalf et al. 1991). Moreover Tp53 function is found antagonised by c-Jun at early stages of 
DEN-induced liver carcinogenesis (Eferl, Ricci et al. 2003). BCL-XL, anti-apoptotic member 
of Bcl-2 family, is overexpressed in human HCC and protects HCC cell lines from various 
apoptotic stimuli in vitro (Takehara, Liu et al. 2001). Other Bcl-2 family member with similar 
properties, Mcl-1, is a target of miR-101, down-regulated in HCC cell lines and clinical 
samples (Su, Yang et al. 2009). Target gene of MST/Hippo pathway encoding inhibitor of 
apoptosis protein (IAP) is amplified in human liver cancer and is crucial for unhalted growth 
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of tumours in mosaic mouse HCC model with 9qA1 amplifications that also contains gene 
encoding YAP (Zender, Spector et al. 2006).  
Autophagy is in many aspects apoptosis-related process and recent data indicate its role in 
development of various cancers. Autophagy is a degradation of cellular organelles within 
autophagosomes - double-membrane compartments with lysosomal hydrolases. It provides 
cell with required nutrients during starvation or allows for degradation of damaged organelles. 
In cancer it plays pivotal role, where at early stages it suppresses tumorigenesis by limiting 
detrimental influence of aberrantly functioning organelles (like damaged ROS-overproducing 
mitochondria) on cellular homeostasis. At the late carcinogenesis stages it supports tumour 
progression by providing cell with additional nutrients for fast and uncontrolled proliferation 
(Kirkin and Dikic 2011). In HCC tumours, especially those that are Bcl-XL positive, 
autophagy regulator Beclin-1 is down-regulated, and its decreased expression correlates with 
poor patient survival (Ding, Shi et al. 2008). In mice, Beclin 1 and other regulator of 
autophagy Atg7, suppress spontaneous liver carcinogenesis by degrading p62 protein. p62 
accumulation may lead to ROS accumulation (Mathew, Karp et al. 2009) and/or stabilisation 
of oncogenic transcription factor Nrf2, found in 25% of human HCCs (Inami, Waguri et al. 
2011). Therefore, similarly to apoptosis, autophagy in HCC may play tumour suppressive role 
by limiting amount of aberrantly functioning organelles in the tissue. 
Activating invasion and metastasis 
Unrestricted TGF-β signalling is required for efficient epithelial-to-mesenchymal transition 
(EMT) in HCC cell lines and patient tissues (Fransvea, Angelotti et al. 2008) and for vascular 
invasion of HCC cells (Fransvea, Mazzocca et al. 2009). TGF-β also regulates disintegrase 
and metalloproteinases (ADAMs) expression that allow efficient HCC cell line migration and 
invasion in the livers of nude mice and are targeted by miR-122, often down-regulated in 
human HCC (Tsai, Hsu et al. 2009). β-catenin activating mutations are associated with liver 
cancer progression in the clinic (Ogawa, Yamada et al. 1999; Zucman-Rossi, Jeannot et al. 
2006; Rebouissou, Amessou et al. 2009) and in HCC mouse models, where β-catenin is 
present mostly in the cells at the invasive front of tumours (Calvisi, Ladu et al. 2004), induces 
spontaneous HCC (Colnot, Decaens et al. 2004) and accelerates progression of activated c-
Met-driven HCC (Tward, Jones et al. 2007).  
Rho is a family of small GTPases that plays substantial role in HCC progression (Grise, 
Bidaud et al. 2009). Its members are regulated similarly to RAS by GAPs and guanine-
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nucleotide-exchange factors (GEFs) and influence actin dynamics, cell shape and migration. 
They achieve this by controlling cytoskeletal kinases ROCK1 and ROCK2, the latter one 
being inhibited in mouse by direct interaction with activated C-Raf (Ehrenreiter, Kern et al. 
2009; Niault, Sobczak et al. 2009). RhoA GAP deleted in liver cancer 1 (DLC1) is encoded 
by the gene lying in the region on chromosome 8p frequently lost in human HCC through 
LOH or promoter methylation (Yuan, Miller et al. 1998; Wong, Lee et al. 2003), its knock-
down accelerates c-Myc-driven tumorigenesis (Xue, Krasnitz et al. 2008), and similarly to its 
orthologue DLC2, it suppresses migration of HCC cell lines in vitro (Leung, Ching et al. 
2005; Wong, Yam et al. 2005). RhoA and Rac1 activity is modulated by translation initiation 
factor eIF5A2 that induces EMT, cell motility and metastasis in mouse models (Tang, Dong 
et al. 2010), and whose localization is regulated by exportin 4 (XPO4) indicated in the 
screening for tumour suppressors of HCC in mouse mosaic HCC model (Zender, Xue et al. 
2008). Transcription of GEF of another Rho GTPase Cdc42, ARHGEF9, is elevated in HCC 
as a result of overexpression of helicase domain-containing protein CHD1. This leads to 
uncontrolled Rho activation, EMT induction and increased migration on cellular level, and 
metastasis in mouse models and patients (Chen, Chan et al. 2010). RhoA direct effector Rho-
associated kinase 2 (ROCK2) is overexpressed in human HCC and regulates cell motility in 
vitro and tumorigenicity of HCC cell line in orthotopic xenograft model (Wong, Wong et al. 
2009). Activities of its close orthologue ROCK1 together with RhoA are required for 
migration of hepatoma cells in intraperitoneal-invasion model (Itoh, Yoshioka et al. 1999; 
Yoshioka, Nakamori et al. 1999). Moreover, apart from influence on cell motility, RhoA and 
RhoC might induce expression of matrix metalloproteinases (MMPs) to facilitate HCC 
progression (Xue, Takahara et al. 2008). MMPs secretion and cell migration in malignant 
HCC might also be regulated by GTPases form RAS family. Sprouty-related Spread 1 and 2 
negative RAS regulators expression is found down-regulated in 70% of human HCCs, and in 
HCC cell lines Spreads inhibit ERK activation and tumour invasiveness by limiting secretion 
of MMPs and cell motility (Yoshida, Hisamoto et al. 2006). 
Inducing angiogenesis 
As in case of each solid tumour, growth of HCC is limited by diffusion of nutrients what is 
eventually overcome by induction of neovascularisation (Semela and Dufour 2004). 
Neovascularisation is induced by hypoxia in the tumour through up-regulation of transcription 
factor hypoxia-inducible factor 1α (HIF1α) that induces expression of vascular-endothelial 
growth factors (VEGFs). Secreted VEGFs bind to their receptors on endothelial cells and 
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pericytes and activate them to loosen their cell-cell contacts, proliferate and form new vessels 
within the tumour. In HCC cell lines HIF1α expression and transcriptional activity on VEGF 
promoter is regulated by inhibitor of differentiation 1 protein (Id-1), up-regulated in advanced 
HCC, and required in xenografted tumours for efficient neovascularisation (Lee, Poon et al. 
2006). Moreover, subset of human HCCs has gains of chromosomal region 6p21 that contains 
gene encoding VEGFA, (Chiang, Villanueva et al. 2008) what might be one of the reasons for 
frequent VEGF overexpression in HCC (Mise, Arii et al. 1996; Suzuki, Hayashi et al. 1996; 
Yamaguchi, Yano et al. 1998). In mouse xenograft and orthotopic transplantation models 
HCC cell line growth is accelerated by VEGF overexpression in a VEGFR2-dependent 
manner (Yoshiji, Kuriyama et al. 1998; Yoshiji, Kuriyama et al. 1999). Here it is worth to 
mention that the first successful molecularly-targeted therapy against HCC applies sorafenib, 
the broad-specificity kinase inhibitor that most likely is imposing its positive effect on patient 
survival by inhibiting angiogenic signalling (Liu, Cao et al. 2006). The control of angiogenic 
signalling between transformed hepatocyte and endothelial cells is also performed by GFs like 
FGF and HGF. Mice with hepatocyte-restricted FGF receptor 1 activation or overexpression 
of HGF are more prone to DEN-induced liver carcinogenesis. In both cases it is associated 
with higher tumour vascularization and higher VEGF production (Horiguchi, Takayama et al. 
2002; Huang, Yu et al. 2006). The stability of the vessels is provided by angiopoietin-1 (Ang-
1) which binds to Tie-2 receptors on endothelial cells, inducing their maturation, process 
inhibited by Ang-2. Ang-2 levels in tumour tissue of HCC patients are increased and its 
overexpression in HCC cell lines injected to nude mice causes haemorrhage of developing 
tumours (Tanaka, Mori et al. 1999). 
Enabling replicative immortality 
Cancer cells are characterised by capability of unlimited divisions, and to achieve that they 
need to overcome “Hayflick limit”, resulting in normal cells from telomere shortening with 
each division. Replicative immortality is achieved by sustaining expression of telomerase, but 
in HCC development this enzyme seems to play a pivotal role. At early stages of liver 
carcinogenesis, telomere length is shortened and correlated with chromosomal aberrations 
(Plentz, Caselitz et al. 2004). Therefore telomerase might perform tumour suppressive 
functions by limiting genomic instability required for generation of dysplastic lesions. On the 
other side, telomerase activity is detected already in patient cirrhotic liver tissue on low levels 
and is further increased in HCC (Tahara, Nakanishi et al. 1995). Furthermore various 
chemical and genetic mouse HCC models indicate that eventually re-expression of telomerase 
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is required for sustaining proliferation and viability of transformed cells and progression to 
advanced HCC stage (Farazi, Glickman et al. 2003). Therefore at the advanced HCC stages 
telomerase performs oncogenic role by providing cancer cell limitless replicative potential. 
Tumour-promoting inflammation 
NF-κB pathway responds to wide variety of stimuli transduced i.e. by TNFα-receptor family, 
interleukin-receptors, or intracellular receptors RIG-I. Ligand binding to the receptor induces 
recruitment of TRAF and RIP proteins that, together with kinases NIK and TGFβ-activated 
MAP3K (TAK1), facilitate phosphorylation-mediated activation of IKK complex. IKK 
complex consists of two kinases, IKKα and β and regulatory protein NEMO. When activated 
it phosphorylates inhibitory proteins of the pathway from IκB family, what leads to their 
ubiquitinylation and degradation. This allows for import of NF-κB heterodimers consisting of 
p65 and p50 from cytoplasm to the nucleus, where they can activate transcription of their 
target genes that determine the survival of the cell (Hayden and Ghosh 2008). NF-κB pathway 
is activated by stimuli associated with inflammation which in turn lies at the very basis of 
liver carcinogenesis. Therefore it is maybe not surprising that NF-κB signalling plays role in 
liver cancer, although what is the exact influence of NF-κB on this process is a subject of 
vigorous debate. 
In Mdr2-KO mice, where ablation of multi-drug resistance 2 membrane channel leads to 
chronic inflammation in the liver followed by hepatitis and cancer development, NF-κB 
pathway has an oncogenic function. It is activated in paracrine manner by TNF-α, and 
protects hepatocytes from apoptosis in condition of chronic liver inflammation, therefore 
sustaining carcinoma development (Pikarsky, Porat et al. 2004). Moreover in HCC from 
virus-infected livers higher expression of lymphotoxins α and β is present and in mice their 
overexpression leads to HCC development in NF-κB-dependent manner (Haybaeck, Zeller et 
al. 2009). But other reports indicate NF-κB pathway to have rather tumour-suppressive 
functions in the liver inflammation-associated tumorigenesis. Regulatory subunit of Ikk 
complex NEMO suppresses chronic liver inflammation and spontaneous liver cancer (Luedde, 
Beraza et al. 2007) and Ikkβ kinase suppresses liver chemical carcinogenesis (Maeda, Kamata 
et al. 2005). In both cases, NF-κB pathway activity is required for inhibition of ROS 
production that may induce cell death and lead to extensive compensatory hepatocyte 
proliferation. Similarly Tak1 protects mouse liver from fibrosis and hepatocyte compensatory 
proliferation resulting in spontaneous HCC, by restricting hepatocyte sensitivity to apoptosis 
induced by TNF-α-NF-κB pathway (Bettermann, Vucur et al. 2010; Inokuchi, Aoyama et al. 
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2010). Tumour suppressive role of NF-κB pathway in liver cancer likely depends on 
inhibition of JNK activity. JNK is required for efficient chemical carcinogenesis, acute 
apoptosis induction and following compensatory proliferation response after carcinogen 
administration (Sakurai, Maeda et al. 2006). 
The confusion regarding NF-κB in liver cancer may partially arise from differences between 
models in terms of conditions of cancer development, timepoint of NF-κB inactivation or cell 
type-specific NF-κB function. In Mdr2-KO model tumour growth is driven by constant 
inflammation and NF-κB activity is required by tumours only at the late stages of their 
development for survival of transformed hepatocytes (Pikarsky, Porat et al. 2004). In the 
DEN-model accompanied by tissue-damage inflammation after carcinogen administration is 
only transient, and NF-κB activity also in this case protects hepatocytes from cell death. But 
this in turn restricts compensatory proliferation of remaining hepatocytes, and therefore in 
DEN-model NF-κB behaves as an “indirect tumour suppressor” (Maeda, Kamata et al. 2005). 
During progression of initiated hepatocytes in chronically damaged liver NF-κB pathway also 
may suppress tumour development. It limits ROS accumulation and maintains activity of Shp 
phosphatases that inhibits STAT3 activation (He, Yu et al. 2010). On the second hand in liver 
non-parenchymal cells NF-κB is sustaining tumour growth by mediating growth-promoting 
cytokine-release (Maeda, Kamata et al. 2005). For instance Kupffer cells can produce IL-6 in 
response to IL-1α released by dying hepatocytes, process inhibited by Ikkβ and p38α through 
suppression of ROS accumulation in the liver (Sakurai, He et al. 2008). 
Interleukins are intercellular messenger molecules of immunological system that activate 
JAK-STAT signalling. Interleukin binding to their receptors causes receptor oligomerisation 
and recruitment of Janus kinases (JAK) that phosphorylate receptor cytoplasmic domains. 
This creates docking sites for STAT transcription factors, their phosphorylation while being 
bound to receptor cytoplasmic domains and subsequent translocation to the nucleus. There as 
dimers they activate transcription of target genes (Schindler, Levy et al. 2007). Lower 
susceptibility of females to HCC, at least in mouse models, is attributed to inhibition of Il-6 
production by oestrogens (Naugler, Sakurai et al. 2007). Transgenic mice overexpressing Il-6 
and soluble binding subunit of its receptor gp80 develop nodules of hepatocellular hyperplasia 
and adenomas (Maione, Di Carlo et al. 1998). Gene encoding GP130, co-receptor for IL-6, 
bears activatory mutations or is overexpressed in most benign hepatocellular tumours in 
human (Rebouissou, Amessou et al. 2009). Activation of STAT3 is observed in human HCC 
and growth of HCC-derived cell lines in vitro and in nude mice is dependent on STAT3 
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activity (Lin, Amin et al. 2009). Negative regulator of JAK-STAT signalling suppressor of 
cytokine signalling 3 (SOCS3) suppress liver regeneration, DNA-replicative capacity of 
hepatocytes and chemical liver carcinogenesis in mice (Riehle, Campbell et al. 2008). Other 
negative regulator of Stats, Shp2 phosphatase, protects mouse liver from inflammation, 
cirrhosis, spontaneous HCC late in life and, by suppressing STAT3 activation, from 
chemically-induced HCC (Bard-Chapeau, Li et al. 2011). In the liver Shp2 is inhibiting 
signalling through Stat1 and Stat3 transcription factors in response to pro-inflammatory 
stimuli like LPS or Il-6, but is required for Erk and Jnk activation. 
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REVIEW
Raf kinases in cancer–roles and therapeutic opportunities
G Maurer, B Tarkowski and M Baccarini
Max F Perutz Laboratories, Center for Molecular Biology, University of Vienna, Vienna, Austria
Raf are conserved, ubiquitous serine/protein kinases
discovered as the cellular elements hijacked by transforming
retroviruses. The three mammalian RAF proteins (A, B and
CRAF) can be activated by the human oncogene RAS,
downstream from which they exert both kinase-dependent
and kinase-independent, tumor-promoting functions. The
kinase-dependent functions are mediated chieﬂy by the
MEK/ERK pathway, whose activation is associated with
proliferation in a broad range of human tumors. Almost 10
years ago, activating BRAF mutations were discovered in a
subset of human tumors, and in the past year treatment with
small-molecule RAF inhibitors has yielded unprecedented
response rates in melanoma patients. Thus, Raf qualiﬁes as
an excellent molecular target for anticancer therapy. This
review focuses on the role of BRAF and CRAF in different
aspects of carcinogenesis, on the success of molecular
therapies targeting Raf and the challenges they present.
Oncogene advance online publication, 16 May 2011;
doi:10.1038/onc.2011.160
Keywords: Raf; Ras; ERK pathway; hallmarks of
cancer; kinase inhibitors
Raf proteins and their effectors
The ﬁrst member of the Raf family, C-Raf-1 (also
known as Raf-1), was identiﬁed in a oncogene capture
experiment in which its catalytic domain was found
fused to the retroviral Gag protein, resulting in the
constitutive activation of the serine/threonine kinase
activity of C-Raf (Rapp et al., 1983; Moelling et al.,
1984); 4 years later, B-Raf was discovered in a similar
experiment (Marx et al., 1988). Within 10 years of its
discovery, C-Raf was identiﬁed both as an interaction
partner and activator of mitogen-activated protein
kinase (MAPK)/ERK kinase (MEK), the dual-speciﬁ-
city kinase responsible for activation of extracellular
signal-regulated kinase (ERK), and an effector of Ras,
which was reported to recruit C-Raf to the membrane
and stimulate its activation by mechanisms, which,
roughly 18 years later, are still incompletely understood.
Both the history and the regulation of Raf have been
reviewed recently (Wellbrock et al., 2004; Niault and
Baccarini, 2010). Sufﬁce it to say here that a wealth
of studies have led to a widely accepted model in which
Raf activation primarily consists in the relief of the
inhibition imposed on the Raf catalytic domain by
an N-terminal regulatory domain, featuring both a Ras-
binding domain and a cysteine-rich domain responsible
for interaction with the kinase domain and for Raf
autoinhibition (Figure 1a). This basic mechanism
applies to all three Raf proteins (A-Raf, B-Raf and
C-Raf), although both A-Raf and C-Raf need additional
steps, such as phosphorylation of activating residues
and dephosphorylation of negative regulatory residues,
to reach maximal activation. Thus, B-Raf is the family
member most easily activated by Ras (Wellbrock et al.,
2004; Niault and Baccarini, 2010). In addition, the basal
kinase activity of B-Raf is higher than that of C-Raf
and, likely, A-Raf (Pritchard et al., 1995; Emuss et al.,
2005). This provides a potential rationale for the
frequent mutational activation of BRAF (for example
by the prominent BRAFV600E mutation; (Davies et al.,
2002)), but not CRAF or ARAF, observed in human
tumors. A major advance of the past few years was the
discovery that Raf kinases can homo- and heterodimer-
ize (Garnett et al., 2005; Rushworth et al., 2006), and
that, in fact, the structure of an active Raf kinase is that
of a side-to-side dimer in which only one partner must
have catalytic activity (Rajakulendran et al., 2009).
Dimerization is enhanced by Ras (Weber et al., 2001)
and is subject to negative feedback regulation by ERK
(Rushworth et al., 2006; Ritt et al., 2010) (Figure 1b).
In the Raf/Mek/Erk pathway, dimerization can be
used to exert tight temporal control of the signal, in
cases in which one dimer subunit is more prone to
negative feedback regulation than the other (C-RafoB-
Raf (Dougherty et al., 2005; Ritt et al., 2010) and
Mek1oMek2 (Catalanotti et al., 2009); reviewed by
Wimmer and Baccarini (2010)). A further level of
control is exerted by the interaction with inhibitory
proteins (Kolch, 2005). In the context of cancer, the
most relevant of these is the Raf kinase-inhibitory
protein, RKIP (Zeng et al., 2008) (Figure 1b). In addition,
a high degree of spatial control is provided by the inter-
action of pathway components with scaffolds that direct
them to distinct subcellular compartments (Kolch, 2005;
McKay and Morrison, 2007).
Overexpression of full-length Raf or the truncated
catalytic domain leads to the activation of the ERK
pathway and increases proliferation in cultured cells and
in vivo. Thus, MEK/ERK is undoubtedly a target ofReceived 15 February 2011; revised and accepted 3 April 2011
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activated Raf in tumorigenesis. In the case of C-Raf,
other targets potentially contributing to cell transforma-
tion have been proposed, such as the nuclear factor-kB
pathway (Baumann et al., 2000), Rb (Kinkade et al.,
2008) and BAD (Polzien et al., 2009), all reviewed by
Niault and Baccarini (2010). In addition, C-Raf can
inhibit apoptosis by binding to, and inhibiting, the
stress-induced kinase ASK-1 (Chen et al., 2001) and the
homolog of Drosophila’s Hippo, the MST-2 kinase
(O’Neill et al., 2004; Matallanas et al., 2007); and ﬁnally,
C-Raf interferes, by direct binding, with the activity of
the cytoskeleton-based Rho effector Rok-a (also known
as ROCK2), resulting in defects in cell migration,
apoptosis and differentiation (Ehrenreiter et al., 2005,
2009; Piazzolla et al., 2005) (Figure 2).
Raf and the hallmarks of cancer
Six hallmarks of cancer, describing the acquired cell-
autonomous capabilities of a cancer cell, were outlined
in a legendary review by Hanahan and Weinberg (2000)
more than 10 years ago. More recently, the list has been
revised to include other features of cancer cells related to
their interaction with the environment, such as avoid-
ance of immunosurveillance (Dunn et al., 2004; Smyth
et al., 2006; Zitvogel et al., 2006) and the stress
phenotypes of cancer (Luo et al., 2009), as well as
genomic instability (Negrini et al., 2010).
In the following section, we will highlight the
contribution of Raf and of the Raf-dependent pathways
to the hallmarks and states of cancer (Figure 3).
Genomic instability is a feature of almost all human
cancers (Negrini et al., 2010). In hereditary cancers,
germline mutations in caretaker genes (DNA-repair
genes and mitotic checkpoint genes) promote tumor
development by increasing the mutational rate and
leading to chromosomal instability. In sporadic cancer,
the caretaker genes are not mutational targets, and
chromosomal instability is rather a consequence of the
DNA replication stress induced by the activation of
oncogenes, notably Ras.
Germline Raf mutations do not appear to contribute
to cancer; instead, mutation in both BRAF and CRAF
have been found in human genetic syndromes deﬁned as
‘Rasopathies’ because they are caused by mutations in
components of the Ras/ERK pathway (Tidyman and
Rauen, 2009). The observed mutations cause activation
of BRAF or CRAF, but the two kinases are not
interchangeable in this context: mutations in the regulatory
domain of CRAF are associated with the development of
Noonan Syndrome, also caused by mutations in SOS1 and
KRAS, and Leopard syndrome. By contrast, BRAF
mutations are associated with Cardio-facio-cutaneous
syndrome (CFC), also initiated by activating mutations
of MEK (reviewed by Tidyman and Rauen, 2009).
In addition to the mutations identiﬁed in Noonan
and Leopard syndrome, two weakly transforming
germline mutations in the kinase domain of CRAF
have been described in patients with therapy-related
acute myeloid leukemia, which arises from concomitant
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Figure 2 Functions of Raf. Gene ablation experiments have
shown that B-Raf is essential for MEK–ERK activation in most
systems. A-Raf and C-Raf heterodimerize with B-Raf and can
participate in ERK activation (double-headed arrows). It is unclear
whether A-Raf has functions outside the MEK/ERK pathway;
C-Raf, however, can promote nuclear factor-kB activation and
can inhibit (blunt-headed arrow) signal transducers involved in
motility (Rok-a), apoptosis (ASK-1 and MST-2), proliferation
and angiogenesis (Rb). ERK, extracellular signal-regulated kinase;
MEK, MAPK/ERK kinase.
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Figure 1 The structure of Raf and interactions within the Ras/
Raf/MEK/ERK pathway. (a) A schematic view of Raf. All three
Raf proteins consist of a regulatory and a kinase domain. In
quiescent cells, the interaction between these two domains inhibits
catalytic activity. The cysteine-rich domain (CRD) is necessary for
this inhibition (indicated by the red blunt arrow), which is relieved
by the binding of Ras to the Ras-binding domain (RBD). A-Raf
and C-Raf need additional steps for full-ﬂedged activation.
(b) Regulation of the ERK pathway. Raf kinases can be activated
by homo- and heterodimerization. Dimerization is induced by Ras
and can occur in different combinations including not only the Raf
kinases but also the pseudokinase KSR. Phosphorylation of Raf
residues by activated ERK counteracts dimerization, allowing
negative feedback control of the pathway (red blunt arrow). RKIP
is an inhibitory protein whose expression is often lost in cancer and
which can regulate pathway output at the level of Raf as well
as MEK activation. ERK, extracellular signal-regulated kinase;
MEK, MAPK/ERK kinase; RKIP, Raf kinase-inhibitory protein.
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loss of the Raf-inhibitory protein, RKIP (Zebisch
et al., 2006, 2009). In general, the frequency of muta-
tional changes of CRAF in human cancers is low (1%;
http://www.sanger.ac.uk/genetics/CGP/cosmic). However,
ampliﬁcation of CRAF and other members of the ERK
pathway have been observed during hormone escape
in androgen-independent prostate cancer (Edwards
et al., 2003), and both CRAF ampliﬁcations (4%) and
deletions (2.2%) are strongly associated with tumor
progression and an overall poorer survival in bladder
cancer (Simon et al., 2001). Similarly, activation of the
ERK pathway owing to BRAF gene duplication or
mutation has emerged as a mechanism in the pathogen-
esis of low-grade astrocytomas (Pﬁster et al., 2008).
Besides alterations in copy number, chromosomal
translocations involving CRAF are found in certain
human cancer sub-types such as stomach cancer
(Shimizu et al., 1986) and pilocytic astrocytomas (Jones
et al., 2009). The latter tumors also harbor chromoso-
mal translocations involving BRAF activation (Jones
et al., 2008); although seldom, such alterations have also
been observed in nevi (Dessars et al., 2007) and
radiation-induced thyroid cancer (Ciampi et al., 2005).
In all cases, the alterations lead to constitutive RAF
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Figure 3 Contribution of Raf to the hallmarks and phenotypes of cancer. The hallmarks of cancer are depicted in black and the stress
phenotypes associated with cancer in dark gray (adapted from Negrini et al. (2010)). The contributions of various Raf isoforms to each
hallmark/phenotype and the downstream pathway mediating them are indicated. Raf* represents activated B-Raf or C-Raf; the red
arrows indicate kinase-dependent functions of Raf; the red blunt arrows represent kinase-dependent inhibition of downstream
pathways and the green blunt arrows represent kinase-independent inhibition processes. For clarity, only the hallmarks/phenotypes in
which Raf has been implicated are depicted; mitotic stress and proteotoxic stress have been omitted.
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activation through loss of the autoinhibitory N-terminal
domain.
More recently, chromosomal translocations yielding
gene fusion transcripts containing the C-terminal kinase
domain of CRAF or BRAF have been identiﬁed at low
frequency in prostate cancer, gastric cancer and
melanoma. Both fusion proteins promoted MEK/
ERK-dependent cell proliferation, migration and an-
chorage-independent growth in human prostate cells,
but whereas expression of the BRAF fusion protein in
NIH 3T3 cells induced tumor formation in nude mice,
the CRAF fusion protein failed to do so (Palanisamy
et al., 2010), implying crucial signaling differences
between the BRAF and the CRAF fusion proteins.
Interestingly, prostate cancer also harbored the recipro-
cal CRAF fusion, containing the CRAF-regulatory
domain; this protein, however, has not been investigated
in detail.
Besides being the target of chromosomal rearrange-
ments, RAF has also been implicated in the induction
of genomic instability. Two types of mutations have
been associated with increased genomic instability thus
far: BRAFV600E, the activating mutation observed
with the highest frequency in melanoma and other
cancers, induces genomic instability in a thyroid cell
line (Mitsutake et al., 2005); in addition, expression
of B-RafD594A, a transforming B-Raf mutant with
impaired MEK kinase activity, can promote aneuploidy
in a C-Raf-dependent, MEK-independent manner in
mouse splenocytes and embryonic ﬁbroblasts (Kamata
et al., 2010).
C-Raf, too, has been implicated in promoting
genomic instability, albeit indirectly. A balance between
C-Raf and RKIP, the Raf inhibitor often lost in breast,
prostate and melanoma tumors (Granovsky and
Rosner, 2008), is necessary to guarantee ﬁdelity of
chromosome segregation. Loss of RKIP or C-Raf
overexpression lowers the activity of the Aurora-B
kinase, allowing cells to bypass the spindle assembly
checkpoint and potentially resulting in genomic in-
stability (Eves et al., 2006).
Self-sufﬁciency in proliferative signals is a crucial step
on the road to transformation. In healthy tissues,
soluble mitogenic growth factors are produced by one
cell type and stimulate the proliferation of another.
Many cancer cells are able to produce and respond to
their own growth factors, resulting in a positive
feedback signaling loop (autocrine stimulation), which
makes them independent from their tissue environment.
These proliferative signals include production of growth
factors, overexpression/constitutive activation of growth
factor receptors and alterations in downstream signaling
cascades. The ﬁrst two changes are likely to activate the
Raf pathway, although the degree to which the resulting
proliferation may depend on it may vary. In the context
of alterations in signaling components, apart from
mutational activation of RAF itself, the most direct
connection is that between RAF and the members of the
RAS gene family, which are activated in 33% of human
cancers, particularly in those of epithelial origin (http://
www.sanger.ac.uk/genetics/CGP/cosmic).
Several RAF mutations driving the proliferation of
cancer cells have been described. The most frequent
BRAF mutation, BRAFV600E, causes constitutive
activation of the kinase as well as insensitivity to
negative feedback mechanisms (Davies et al., 2002;
Pratilas et al., 2009). In addition, less frequent BRAF
mutations have been described that can stimulate the
MEK/ERK pathway by activating wild-type CRAF in
the context of a heterodimer (Davies et al., 2002;
Garnett et al., 2005; Kamata et al., 2010). Mutations
in CRAF itself are extremely rare, but overexpression
has been reported at high frequency in subsets of human
cancers, including hepatocellular carcinoma and squa-
mous cell carcinoma of the head and neck (Riva et al.,
1995; Hwang et al., 2004). CRAF overexpression is
regarded as an early tumor marker for human lung
adenocarcinoma (Cekanova et al., 2007); consistent with
this, lung-restricted overexpression of full-length CRAF
or of its truncated kinase domain causes the MEK-
dependent formation of lung adenomas (Kerkhoff et al.,
2000; Kramer et al., 2004). Similarly, elevated BRAF
and CRAF expression and kinase activity have been
observed in human glioblastomas, and a constitutive
active CRAF mutant contributes to glioma formation in
mice (Lyustikman et al., 2008). Cumulatively, these
results imply that most alterations in Raf drive
proliferation through stimulation of the MEK/ERK
pathway. In addition to the dominant role played by
BRAF oncogenic mutants, endogenous, wild-type
BRAF mediates ERK activation and proliferation in
uveal melanoma cells lacking RAS/RAF mutations
(Calipel et al., 2006); conversely, CRAF, but not BRAF,
is required for these process downstream from mutated
NRAS in melanoma cell lines (Dumaz et al., 2006) or
from mutated KRAS in non-small cell lung cancer cell
lines (Takezawa et al., 2009). Studies in cultured cells
and in vivo studies suggest that autocrine/paracrine
factors resulting from ERK activation play a role in the
self-sufﬁciency of cells harboring activating Raf muta-
tions (Troppmair et al., 1998; Schulze et al., 2001, 2004;
Vale et al., 2001), generating a feed-forward loop and
promoting the concomitant activation of parallel pro-
liferative pathways.
In addition to generating their own proliferative
signals, either in a cell-autonomous or in a paracrine
manner, cancer cells must develop insensitivity to
antiproliferative signals that maintain tissue homeosta-
sis. A crucial inducer of antiproliferative signals is
transforming growth factor-b (TGFb) (Seoane, 2008).
Many tumors disable TGFb signaling by downregula-
tion or mutation of the TGFb receptor, or through
inactivation of its downstream targets SMAD4, p15INK4B
and the retinoblastoma protein Rb (Hanahan and
Weinberg, 2000). Activation of Raf and ERK induces
TGFb production but at the same time protects cells
from differentiation and apoptosis (Lehmann et al.,
2000; Park et al., 2000; Schulze et al., 2001, 2004; Wang
et al., 2004; Riesco-Eizaguirre et al., 2009), enabling
them to draw on the pro-tumorigenic effects of
this cytokine such as promotion of proliferation,
invasiveness, radioresistance and immunosuppression.
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In addition, C-Raf interacts with, and phosphorylates,
Rb. This interaction results in the recruitment of the Rb/
C-Raf complex to proliferative promoters and increases
E2F1-dependent transcriptional activity, counteracting
the antiproliferative function of Rb (Wang et al., 1998;
Dasgupta et al., 2006; Kinkade et al., 2008).
Induction of differentiation is a powerful obstacle to
proliferative signals. As long as the initiated stem cells or
early progenitor cells giving rise to a tumor have not lost
sensitivity to differentiating signals, these can be
exploited in therapy. A particularly good illustration
of this is the introduction of a combination of
chemotherapy and differentiation therapy, which has
revolutionized the treatment of leukemia (Wang and
Chen, 2008). Recently, we have shown that endogenous
C-Raf is essential to maintain an undifferentiated status
in Ras-driven epidermal tumors. Conditional ablation
of C-Raf results in rapid regression of established
tumors through MEK/ERK-independent activation of
a differentiation program induced by hyper-activation
of the cytoskeleton-based kinase Rok-a (Ehrenreiter
et al., 2009). These data show that Ras-driven tumors
are addicted to non-oncogenic C-Raf, and offer proof of
principle that differentiation (co)therapy may be feasible
in solid tumors.
Conﬁrming the importance of Raf in the maintenance
of an undifferentiated state, recent work has shown that
ampliﬁcation of CRAF leads to the ERK-dependent
activation of b-catenin, and to the expansion of breast
tumor-initiating cells in culture and cancer progression
in xenografts (Chang et al., 2011). Thus, both MEK/
ERK-dependent and -independent mechanisms can
contribute to the maintenance of an undifferentiated
state in tumor cells.
Evasion of senescence and apoptosis
From the above, it is clear that overexpression of full-
length RAF or the truncated catalytic domain leads to
the activation of the ERK pathway in cultured cells and
in vivo. In both situations, strong activation of the
pathway correlates with the induction of senescence,
which has to be bypassed before hyper-proliferation
ensues (Sewing et al., 1997; Woods et al., 1997; Ravi
et al., 1998; Zhu et al., 1998; Roper et al., 2001). Thus,
senescence is the Achilles’ heel of the Ras/Raf/Erk
pathway. Possible bypass mechanisms include direct
regulation of the activity of the B-RafV600E mutant, to
lower it to a level that would not induce senescence. In
this context, candidates are Akt3, which can decrease
the activity by phosphorylating negative-regulatory
residues on BRAF (Cheung et al., 2008), and endo-
genous C-Raf, which has been shown to restrain
B-RafV600E activity in the context of a heterodimer
(Karreth et al., 2009).
Typically, however, senescence is disabled when
tumor suppressors such as p16INK4a, p19ARF, p53
or PTEN are lost (Fedorov et al., 2003; Michaloglou
et al., 2005; Goel et al., 2006, 2009; Gray-Schopfer et al.,
2006; Dankort et al., 2007, 2009; Lyustikman et al.,
2008; Dhomen et al., 2009; Yu et al., 2009; Carragher
et al., 2010), or cooperating proto-oncogenes such as
c-myc or Rac1b are expressed (Matos et al., 2008;
Zhuang et al., 2008).
While RAF activation does not contribute to
senescence evasion, it does have multiple, in part
isoform-speciﬁc, roles in counteracting apoptosis.
Downstream from activated Raf and Ras, but also
from other oncogenes, the ERK pathway restrains
apoptosis by regulating the expression and/or the
activity of BCL-2 family members (Balmanno and
Cook, 2009). In addition, MEK-independent pro-
survival mechanisms, such as activation of MEKK1
and the nuclear factor-kB pathway (Baumann et al.,
2000) and inactivation of the BH3-only BCL-2 family
member BAD (Polzien et al., 2009), have been proposed
for C-Raf (all reviewed by Niault and Baccarini, 2010).
Reinforcing the connection between C-Raf and the Bcl2
family, Bcl2 deletion hinders the development of lung
adenomas induced by the truncated, oncogenic form of
C-Raf (Fedorov et al., 2002). In addition, endogenous
C-Raf can restrain apoptosis in a kinase-independent
manner by binding to, and inhibiting, the stress-induced,
mitochondria-based kinase ASK-1 (Chen et al., 2001) as
well as the homolog of Drosophila’s Hippo, the MST-2
kinase (O’Neill et al., 2004; Matallanas et al., 2007), and
by regulating Fas trafﬁcking through its interaction with
the cytoskeleton-based kinase Rok-a (Piazzolla et al.,
2005). By conferring a survival advantage, any of these
events might potentially promote tumorigenesis,
although their signiﬁcance in this context has not yet
been shown in vivo.
Limitless replicative potential can be achieved through
avoidance of telomere shortening, which causes a DNA-
damage response mediated by p53 and p21, and ﬁnally
senescence. This senescent program, induced by telo-
mere attrition, differs from the fast, oncogene-induced
proliferation barrier observed, for instance, in
BRAFV600E-expressing premalignant nevi (Michalo-
glou et al., 2005; Gray-Schopfer et al., 2006). An 85–
90% portion of all cancer cells escape telomere attrition
by upregulating telomerase, a reverse transcriptase that
restores telomeric repeats after every cell division (Chan
and Blackburn, 2004). Ets transcription factors, well-
established targets of activated ERK, can stimulate the
transcriptional activation of the telomerase catalytic
subunit gene downstream from oncogenic growth factor
receptor, Ras and Raf (Goueli and Janknecht, 2004;
Dwyer et al., 2007), thereby potentially antagonizing
telomere shortening and supporting the replicative
potential of the mutated cells.
Sustained angiogenesis is absolutely required for
growth of solid tumors beyond a size of about 3mm3.
Tumor cells are able to initiate an angiogenic shift
toward angiogenic initiating signals (for example,
vascular endothelial growth factor (VEGF) and ﬁbro-
blast growth factor-1 and 2 and suppress inhibitory
signals (thrombospondin-1 and interferon-b). The
impact of Raf on angiogenesis in vivo has been
established by the delivery of a kinase-dead C-Raf
construct to the tumor-associated vasculature in mice.
The kinase-dead protein induced the apoptosis of both
endothelial and tumor cells, leading to tumor regression
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(Hood et al., 2002). C-Raf can promote endothelial cell
survival by either MEK-dependent or -independent
pathways, including ASK-1 inhibition (Alavi et al.,
2003, 2007). In addition, selective disruption of the
interaction between C-Raf and Rb inhibits the develop-
ment of tumor-associated microvessels and suppresses
the growth of tumor xenografts (Dasgupta et al., 2004;
Kinkade et al., 2008). Thus, several C-Raf-dependent
pathways can contribute to angiogenesis. By contrast,
induction of angiogenesis by B-RAFV600E, involving
expression of hypoxia-inducible factor-1a (Kumar et al.,
2007) and VEGF (Sharma et al., 2005, 2006; Sumimoto
et al., 2006), is entirely MEK-dependent. Conversely,
conditional ablation of endogenous B-Raf prevents the
angiogenic switch in a mouse model of pancreatic islet
carcinoma driven by loss of function of the tumor
suppressors p53 and Rb. B-Raf-deﬁcient tumor cells
proliferate normally despite decreased ERK activation,
but produce insufﬁcient amounts of the proangiogenic
factors VEGF and TGFb, resulting in reduced blood
vessel density and tumor proliferation, and delayed
tumor progression (Sobczak et al., 2008).
Tissue invasion and metastasis depends upon all the
other hallmarks acquired during the process of tumor
formation as well as on changes in proteins tethering
cells to their surroundings. Changes in the expression of
cell–cell adhesion molecules and/or in the binding
speciﬁcities of integrins, as well as upregulation and
activation of extracellular proteases, result in the ability
of cancer cells to invade and colonize new terrain. Raf
can inﬂuence invasion at several levels. First, activated
Raf is involved in the production of TGFb, which
promotes invasion and metastasis (Lehmann et al.,
2000; Sobczak et al., 2008; Riesco-Eizaguirre et al.,
2009), as well as the epithelial–mesenchymal transition
that precedes invasion in response to this factor (Janda
et al., 2002). Second, both B-Raf and C-Raf have
essential, if opposite, roles in cell contractility and
migration: B-Raf increasing Rho-dependent contracti-
lity and opposing migration in an ERK-dependent
manner (Pritchard et al., 2004), and C-Raf reducing
contractility and increasing migration by inhibiting the
Rho effector Rok-a (Ehrenreiter et al., 2005). In
addition, B-RAFV600E/MEK/ERK are responsible
for upregulation of several proteins involved in migra-
tion, and support integrin signaling, inducing melanoma
cell invasion and metastases (Liang et al., 2007; Klein
et al., 2008; Argast et al., 2009; Old et al., 2009). The
B-RafV600E/MEK/ERK axis can also increase mela-
noma cell contractility and invasion by repressing the
gene coding for a cGMP-speciﬁc phospshodiesterase,
PDE5A (Arozarena et al., 2010). The resulting increase
in the cGMP pool causes a raise in intracellular Caþ þ
and ultimately increased contractility, which boosts the
rounded, bleb-associated mode of motility adopted
during invasion (Sahai and Marshall, 2003).
PDE5A expression was found to be lower in
metastasis-derived patient material than in primary
tumors. As ERK is likely activated in both samples, it
would have been interesting to know at which level is
PDE5A expression further regulated, and what are the
secondary events leading to full-ﬂedged downregula-
tion in metastasis. One possibility here are changes
in tissue architecture, which in itself can exert strong
antiproliferative effects and counteract invasion.
Cadherin-based cell–cell adhesion, for instance,
efﬁciently counteracts tumor proliferation, angiogenesis
and metastasis in CRAF-driven lung adenomas (Ceteci
et al., 2007). Additional regulators of tissue architecture
are matrix metalloproteases, which are often over-
expressed in cancer (Kessenbrock et al., 2010). Increased
expression of one of these enzymes, matrix metallopro-
tease-9, by the Raf/MEK/ERK pathway in three-
dimensional breast tissue cultures leads to a remodeling
of the microenvironment, which induces loss of tissue
polarity and re-initiation of proliferation (Beliveau
et al., 2010).
In keeping with a role for the Raf/MEK/ERK
pathway in invasion, the Raf-inhibitor protein RKIP
has been identiﬁed as a suppressor of metastasis in many
cancers (Granovsky and Rosner, 2008). Recently, a
pathway has been discovered in which RKIP, through
inhibition of the Raf/MEK/ERK module, increases the
processing of the let-7miRNA. This, in turn, inhibits the
chromatin-remodeling factor HMGA2, which contri-
butes to the expression of several metastasis-promoting
genes (Dangi-Garimella et al., 2009).
To colonize a new site, tumor cells must extravasate
from the blood vessels. In melanoma cells, BRAFV600E
promotes this process by causing the production of
both tumor- and microenvironment-derived inter-
leukin-8. This cytokine recruits polymorphonuclear
leukocytes, which bind to melanoma cells ultimately
facilitating their trans-endothelial passage (Liang et al.,
2007).
Avoidance of immunosurveillance enables tumors to
evade recognition and destruction by the immune
system. Cancers escape surveillance by selecting for
non-immunogenic tumor cells, such as those that
have downregulated human leukocyte antigen class-I
molecules and/or have become resistant to cytotoxic
T-lymphocyte-induced killing (immunoselection). Alter-
natively, tumors can actively repress immune cells in
various ways, creating an immune-privileged environ-
ment (immunosubversion) (reviewed by Zitvogel et al.
(2006)). BRAFV600E, for instance, mediates immuno-
subversion by inducing the cytokines interleukin-10 and
interleukin-6 (Sumimoto et al., 2006), and contributes to
immune evasion by inducing an MEK/ERK-dependent
decrease in the expression of melanoma differentia-
tion antigens, which is recognized by antigen-speciﬁc
T-lymphocytes (immunoselection). Unlike MEK inhibi-
tors, treatment with a BRAF-speciﬁc inhibitor leaves
the function of T-lymphocytes intact, raising hopes
that such inhibitors might bypass immunoevasion
(Boni et al., 2010).
Implementing the hallmark events described above
comes at a high stress cost for tumor cells. Recently, ﬁve
stress phenotypes of cancer have been deﬁned (Luo
et al., 2009): (1) DNA damage, resulting from telomere
shortening, replication stress and oncogene activation,
and from mutations of DNA-repair and DNA-damage
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checkpoint genes; (2) mitotic stress, a consequence of
chromosomal instability; (3) proteotoxic stress, caused
by accumulation of misfolded proteins; (4) oxidative
stress mediated by the generation of reactive oxygen
species within a cancer cell and (5) metabolic stress
(Kroemer and Pouyssegur, 2008), a consequence of
enhanced aerobic glycolysis used by cancer cells for
energy production.
How does RAF contribute to overcoming stress? In
the case of genotoxic stress, activated Ras and Raf can
induce the expression of the mdm2 gene, leading to p53
degradation; at least in cells lacking the Mdm2 inhibitor
p19ARF, this leads to reduced p53-dependent apoptosis
following DNA damage (Ries et al., 2000). Downstream
from p53, Ras or Raf activation by HB-EGF is
responsible for the ERK-mediated induction of the
cyclooxygenase-2 gene, which inhibits genotoxic stress-
induced apoptosis (Han et al., 2002). Scatter Factor
(hepatocyte growth factor), another growth factor that
protects tumors from genotoxicity, uses Raf to signal
survival through activation of nuclear factor-kB (Fan
et al., 2007). In addition, an interplay between
oncogenic Raf/ERK and ATM has been shown to
promote homologous recombination repair in response
to radiation (Golding et al., 2007), in line with previous
reports showing a correlation between oncogenic Raf
and radioresistance in tumors (Kasid et al., 1987, 1989,
1996). Finally, the RAF/MEK/ERK pathway protects
multiple myeloma cells from DNA damage induced by
treatment with a Chk1 inhibitor (Dai et al., 2008). These
ﬁndings suggest that Raf and MEK inhibitors could be
combined with cytostatic drugs or radiation in the
therapy of cancer.
The relationships between Raf and oxidative stress
are manifold: RAF/MEK/ERK activation can prevent
the onset of oxidative stress in growth factor-deprived
cells (Kuznetsov et al., 2008); on the other hand,
generation of reactive oxygen species by derivatives of
geldanamycin, a chemotherapeutic that inhibits the
chaperone function of HSP90 and enforces the degrada-
tion of their client proteins, including Raf, is able to
inhibit the activity of BRAFV600E (Fukuyo et al.,
2008). Finally, a most interesting connection, relevant in
terms of oncogene-selective therapy, has been reported
recently between oncogenic activation of RAS and
RAF, and the small-molecule drug erastin. Erastin
causes mitochondrial dysfunction and oxidative cell
death by activating voltage-dependent ion channels
(voltage-dependent anion channels (VDACs)) on the
mitochondria. In a panel of cancer cell lines of different
origin, RAS and BRAF activation potentiated the
lethality of the drug by inducing the expression of the
VDACs (Yagoda et al., 2007). Thus, VDAC expression
may represent a targetable weak spot in RAS- and
RAF-driven tumors.
Metabolic stress, particularly lack of nutrients,
imposes a number of metabolic checkpoints that cancer
cells must bypass to continue proliferating under the
dire conditions often found in the tumor microenviron-
ment. BRAFV600E-expressing melanoma cells appear
to solve this problem through ERK-mediated phosphor-
ylation of the tumor suppressor and energy sensor
LKB1. This phosphorylation, which occurs in the
context of a physical complex including B-Raf
V600E, prevents the LKB1-mediated activation
of the AMP-activated protein kinase, which restricts
protein synthesis (Zheng et al., 2009). The net result is
normal operation despite nutrient shortage, and there-
fore a competitive advantage under conditions of
metabolic stress.
RAF inhibitors–clinical success and challenges
From the above it is clear that Raf kinases are prime
target for the design and application of molecule-target
therapies of cancer, particularly melanoma. Several
companies have generated Raf inhibitors currently
in preclinical and clinical trials, and a drug speciﬁcally
targeting BRAFV600E (PLX4032/RG7204; Plexxikon/
Roche, Berkeley, CA, USA (Tsai et al., 2008; Joseph
et al., 2010)) has recently produced dramatic results,
with response rates of 70–80% as single agent in
metastatic melanoma patients (Bollag et al., 2010;
Flaherty et al., 2010). Similar results have been obtained
with another ATP competitive BRAF inhibitor
(GSK 2118436; GlaxoSmithKline, Brentford, UK
(Kefford et al., 2010)). These drugs, which are currently
being tested in clinical trials in patients affected by
other solid tumors with BRAFV600E mutations, such
as thyroid carcinomas or colon cancers (Arkenau et al.,
2010; Puzanov et al., 2011), are reasonably well-
tolerated. However, one intriguing and potentially
worrying issue is the paradoxical increase in the
proliferation and activation of the MEK–ERK pathway
in cells not harboring the BRAFV600E mutation.
The underlying mechanism is an allosteric effect of
the drug, which enforces the dimerization of endogenous
BRAF with CRAF or ARAF (Hatzivassiliou et al.,
2010; Heidorn et al., 2010; Poulikakos et al., 2010).
Within these dimers, only one active component is
required for activation of the MEK–ERK pathway;
therefore, at non-saturating concentrations, the inhibi-
tors activate the pathway rather than disabling it,
particularly in the presence of activated RAS, and it
is possible that the rapid development of benign skin
tumors in patients treated with RAF inhibitors might
be fueled by such a mechanism (Degen et al., 2010;
Robert et al., 2010) (Figure 4).
More troublesome is the fact that melanoma cells
develop chemoresistance by a number of different
molecular mechanisms (reviewed by Poulikakos and
Rosen, 2011), leading to relapse of drug-responsive
disease. Unlike the case of imatinib resistance, often
caused by mutations in the kinase domain of the target
BCR-ABL (Weisberg et al., 2007), de novo mutations in
B-RAF have not been observed in relapsing tumors.
Rather, acquired resistance involved reactivation of the
ERK pathway by switching to other MEK kinases
(other RAF isoforms (Villanueva et al., 2010) or COT/
Tpl2 (Johannessen et al., 2010)), or by activating
mutations in NRAS (Nazarian et al., 2010), but also
upregulation of receptor tyrosine kinases driving other
pathways (Nazarian et al., 2010; Villanueva et al., 2010)
RAF kinases in cancer
G Maurer et al
7
Oncogene
(Figure 4). Therefore, overcoming melanoma resistance
might require modulation of multiple pathways.
Conclusions
The study of the Raf pathways has been extremely
rewarding. The ﬁrst serine/threonine kinase oncogene
discovered has proven an excellent target in single-agent
therapy of the disease it is most frequently associated
with; in turn, investigation of the mode of action of
RAF inhibitors has shed light on the mechanism of
regulation of the cellular Raf enzyme. Animal models
continue to delineate essential functions of the pathway
components and the discovery of protein–protein
interactions within the pathway and cross-pathways
provides further potential leads for novel therapeutic
strategies. Almost 30 years after its discovery, Raf is still
a fascinating topic for basic and clinical researchers, and
will remain so for many years to come.
Conﬂict of interest
The authors declare no conﬂict of interest.
Acknowledgements
We thank all the members of the Baccarini lab for helpful
discussions and apologize to all the colleagues whose work
could not be cited in this review for reasons of space. The
Baccarini lab is supported by the Austrian Scientiﬁc Research
Fund (Grants P19530 and SFB 021) and the European
Community (Grants INFLA-CARE and GROWTHSTOP).
References
Alavi A, Hood JD, Frausto R, Stupack DG, Cheresh DA. (2003). Role
of Raf in vascular protection from distinct apoptotic stimuli.
Science 301: 94–96.
Alavi AS, Acevedo L, Min W, Cheresh DA. (2007). Chemoresistance
of endothelial cells induced by basic ﬁbroblast growth factor
depends on Raf-1-mediated inhibition of the proapoptotic kinase,
ASK1. Cancer Res 67: 2766–2772.
Argast GM, Croy CH, Couts KL, Zhang Z, Litman E, Chan DC et al.
(2009). Plexin B1 is repressed by oncogenic B-Raf signaling and
functions as a tumor suppressor in melanoma cells. Oncogene 28:
2697–2709.
Arkenau HT, Kefford R, Long GV. (2010). Targeting BRAF for
patients with melanoma. Br J Cancer 104: 392–398.
Arozarena I, Sanchez-Laorden B, Packer L, Hidalgo-Carcedo C,
Hayward R, Viros A et al. (2010). Oncogenic BRAF
induces melanoma cell invasion by downregulating the
cGMP-speciﬁc phosphodiesterase PDE5A. Cancer Cell 19:
45–57.
Balmanno K, Cook SJ. (2009). Tumour cell survival signalling by the
ERK1/2 pathway. Cell Death Differ 16: 368–377.
Baumann B, Weber CK, Troppmair J, Whiteside S, Israel A, Rapp
UR et al. (2000). Raf induces NF-kappa B by membrane shuttle
ERK
RAF
RAS
MEK
RTKs
V600E
RAS
MEK
ERK
RTKs
RAS
MEK
ERK
RTKs
DRUG
COT
Proliferation/Survival
normal melanoma response drug-related tumors
MEK
ERK
RTKs
other pathways
resistance
DRUG
Raf inhibitors
V600E V600E
ERK
RAF
MEK
RTKs
DRUG
non-saturating
concentrations or
fast off-rates
RAF
RAS* RAS*
Figure 4 RAF inhibitors: response, resistance and drug-related tumors. In normal cells, RAF activation drives ERK activation
downstream from RAS. In melanoma, BRAF mutants (V600E) with high kinase activity drive ERK activation (red arrows)
independently of RAS. Cancer cells harboring these mutants are sensitive to BRAF inhibitors, which blunt kinase activity and reduce
ERK activation as well as proliferation (thin arrows). Unfortunately, however, resistance arises, by mechanisms involving activation of
other MEK kinases, such as COT, but also upregulation of receptor tyrosine kinases (RTKs) and of other pathways downstream from
RAS (purple arrows). Finally, drug-related epidermal tumors have been observed in patients treated with RAF inhibitors. They
correlate with ERK activation, which results from the ability of the drug to promote RAF dimerization. If only one subunit of the
dimer is bound to the inhibitor (for instance at non-saturating inhibitor concentrations, or in the case of inhibitors with fast off-rates),
the other subunit is activated and is capable of phosphorylating MEK with high efﬁciency, generating a tonic signal leading to
increased proliferation. Thus, RAF inhibitors can paradoxically function as ERK activators, and potentially induce the development
of drug-related tumors. ERK, extracellular signal-regulated kinase; MEK, MAPK/ERK kinase.
RAF kinases in cancer
G Maurer et al
8
Oncogene
kinase MEKK1, a signaling pathway critical for transformation.
Proc Natl Acad Sci USA 97: 4615–4620.
Beliveau A, Mott JD, Lo A, Chen EI, Koller AA, Yaswen P et al.
(2010). Raf-induced MMP9 disrupts tissue architecture of human
breast cells in three-dimensional culture and is necessary for tumor
growth in vivo. Genes Dev 24: 2800–2811.
Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H et al. (2010).
Clinical efﬁcacy of a RAF inhibitor needs broad target blockade in
BRAF-mutant melanoma. Nature 467: 596–599.
Boni A, Cogdill AP, Dang P, Udayakumar D, Njauw CN, Sloss CM
et al. (2010). Selective BRAFV600E inhibition enhances T-cell
recognition of melanoma without affecting lymphocyte function.
Cancer Res 70: 5213–5219.
Calipel A, Mouriaux F, Glotin AL, Malecaze F, Faussat AM,
Mascarelli F. (2006). Extracellular signal-regulated kinase-depen-
dent proliferation is mediated through the protein kinase
A/B-Raf pathway in human uveal melanoma cells. J Biol Chem
281: 9238–9250.
Carragher LA, Snell KR, Giblett SM, Aldridge VS, Patel B, Cook SJ
et al. (2010). V600EBraf induces gastrointestinal crypt senescence
and promotes tumour progression through enhanced CpG methyla-
tion of p16INK4a. EMBO Mol Med 2: 458–471.
Catalanotti F, Reyes G, Jesenberger V, Galabova-Kovacs G, de Matos
Simoes R, Carugo O et al. (2009). A Mek1–Mek2 heterodimer
determines the strength and duration of the Erk signal. Nat Struct
Mol Biol 16: 294–303.
Cekanova M, Majidy M, Masi T, Al-Wadei HA, Schuller HM. (2007).
Overexpressed Raf-1 and phosphorylated cyclic adenosine
30-50-monophosphatate response element-binding protein are early
markers for lung adenocarcinoma. Cancer 109: 1164–1173.
Ceteci F, Ceteci S, Karreman C, Kramer BW, Asan E, Gotz R et al.
(2007). Disruption of tumor cell adhesion promotes angiogenic
switch and progression to micrometastasis in RAF-driven murine
lung cancer. Cancer Cell 12: 145–159.
Chan SR, Blackburn EH. (2004). Telomeres and telomerase. Philos
Trans R Soc Lond B Biol Sci 359: 109–121.
Chang CJ, Yang JY, Xia W, Chen CT, Xie X, Chao CH et al. (2011).
EZH2 promotes expansion of breast tumor initiating cells
through activation of RAF1–beta-catenin signaling. Cancer Cell
19: 86–100.
Chen J, Fujii K, Zhang L, Roberts T, Fu H. (2001). Raf-1 promotes
cell survival by antagonizing apoptosis signal-regulating kinase 1
through a MEK–ERK independent mechanism. Proc Natl Acad Sci
USA 98: 7783–7788.
Cheung M, Sharma A, Madhunapantula SV, Robertson GP. (2008).
Akt3 and mutant V600E B-Raf cooperate to promote early
melanoma development. Cancer Res 68: 3429–3439.
Ciampi R, Knauf JA, Kerler R, Gandhi M, Zhu Z, Nikiforova MN
et al. (2005). Oncogenic AKAP9–BRAF fusion is a novel
mechanism of MAPK pathway activation in thyroid cancer. J Clin
Invest 115: 94–101.
Dai Y, Chen S, Pei XY, Almenara JA, Kramer LB, Venditti CA et al.
(2008). Interruption of the Ras/MEK/ERK signaling cascade
enhances Chk1 inhibitor-induced DNA damage in vitro and
in vivo in human multiple myeloma cells. Blood 112: 2439–2449.
Dangi-Garimella S, Yun J, Eves EM, Newman M, Erkeland SJ,
Hammond SM et al. (2009). Raf kinase inhibitory protein
suppresses a metastasis signalling cascade involving LIN28 and
let-7. EMBO J 28: 347–358.
Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN,
Damsky Jr WE et al. (2009). Braf(V600E) cooperates with Pten loss
to induce metastatic melanoma. Nat Genet 41: 544–552.
Dankort D, Filenova E, Collado M, Serrano M, Jones K, McMahon
M. (2007). A new mouse model to explore the initiation,
progression, and therapy of BRAFV600E-induced lung tumors.
Genes Dev 21: 379–384.
Dasgupta P, Rastogi S, Pillai S, Ordonez-Ercan D, Morris M, Haura E
et al. (2006). Nicotine induces cell proliferation by beta-arrestin-
mediated activation of Src and Rb–Raf-1 pathways. J Clin Invest
116: 2208–2217.
Dasgupta P, Sun J, Wang S, Fusaro G, Betts V, Padmanabhan J et al.
(2004). Disruption of the Rb–Raf-1 interaction inhibits tumor
growth and angiogenesis. Mol Cell Biol 24: 9527–9541.
Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al.
(2002). Mutations of the BRAF gene in human cancer. Nature 417:
949–954.
Degen A, Satzger I, Voelker B, Kapp A, Hauschild A, Gutzmer R.
(2010). Does basal cell carcinoma belong to the spectrum
of sorafenib-induced epithelial skin cancers. Dermatology 221:
193–196.
Dessars B, De Raeve LE, El Housni H, Debouck CJ, Sidon PJ,
Morandini R et al. (2007). Chromosomal translocations as a
mechanism of BRAF activation in two cases of large congenital
melanocytic nevi. J Invest Dermatol 127: 1468–1470.
Dhomen N, Reis-Filho JS, da Rocha Dias S, Hayward R, Savage K,
Delmas V et al. (2009). Oncogenic Braf induces melanocyte
senescence and melanoma in mice. Cancer Cell 15: 294–303.
Dougherty MK, Muller J, Ritt DA, Zhou M, Zhou XZ, Copeland TD
et al. (2005). Regulation of Raf-1 by direct feedback phosphoryla-
tion. Mol Cell 17: 215–224.
Dumaz N, Hayward R, Martin J, Ogilvie L, Hedley D, Curtin JA et al.
(2006). In melanoma, RAS mutations are accompanied by switching
signaling from BRAF to CRAF and disrupted cyclic AMP
signaling. Cancer Res 66: 9483–9491.
Dunn GP, Old LJ, Schreiber RD. (2004). The three Es of cancer
immunoediting. Annu Rev Immunol 22: 329–360.
Dwyer J, Li H, Xu D, Liu JP. (2007). Transcriptional regulation of
telomerase activity: roles of the Ets transcription factor family. Ann
NY Acad Sci 1114: 36–47.
Edwards J, Krishna NS, Witton CJ, Bartlett JM. (2003). Gene
ampliﬁcations associated with the development of hormone-
resistant prostate cancer. Clin Cancer Res 9: 5271–5281.
Ehrenreiter K, Kern F, Velamoor V, Meissl K, Galabova-Kovacs G,
Sibilia M et al. (2009). Raf-1 addiction in Ras-induced skin
carcinogenesis. Cancer Cell 16: 149–160.
Ehrenreiter K, Piazzolla D, Velamoor V, Sobczak I, Small JV, Takeda
J et al. (2005). Raf-1 regulates Rho signaling and cell migration.
J Cell Biol 168: 955–964.
Emuss V, Garnett M, Mason C, Marais R. (2005). Mutations of C-
RAF are rare in human cancer because C-RAF has a low basal
kinase activity compared with B-RAF. Cancer Res 65: 9719–9726.
Eves EM, Shapiro P, Naik K, Klein UR, Trakul N, Rosner MR.
(2006). Raf kinase inhibitory protein regulates aurora B kinase and
the spindle checkpoint. Mol Cell 23: 561–574.
Fan S, Meng Q, Laterra JJ, Rosen EM. (2007). Ras effector pathways
modulate scatter factor-stimulated NF-(kappa)B signaling and
protection against DNA damage. Oncogene 26: 4774–4796.
Fedorov LM, Papadopoulos T, Tyrsin OY, Twardzik T, Gotz R,
Rapp UR. (2003). Loss of p53 in craf-induced transgenic lung
adenoma leads to tumor acceleration and phenotypic switch. Cancer
Res 63: 2268–2277.
Fedorov LM, Tyrsin OY, Papadopoulos T, Camarero G, Gotz R,
Rapp UR. (2002). Bcl-2 determines susceptibility to induction of
lung cancer by oncogenic CRaf. Cancer Res 62: 6297–6303.
Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman
JA et al. (2010). Inhibition of mutated, activated BRAF in
metastatic melanoma. N Engl J Med 363: 809–819.
Fukuyo Y, Inoue M, Nakajima T, Higashikubo R, Horikoshi NT,
Hunt C et al. (2008). Oxidative stress plays a critical role in
inactivating mutant BRAF by geldanamycin derivatives. Cancer Res
68: 6324–6330.
Garnett MJ, Rana S, Paterson H, Barford D, Marais R. (2005). Wild-
type and mutant B-RAF activate C-RAF through distinct mechan-
isms involving heterodimerization. Mol Cell 20: 963–969.
Goel VK, Ibrahim N, Jiang G, Singhal M, Fee S, Flotte T et al. (2009).
Melanocytic nevus-like hyperplasia and melanoma in transgenic
BRAFV600E mice. Oncogene 28: 2289–2298.
Goel VK, Lazar AJ, Warneke CL, Redston MS, Haluska FG. (2006).
Examination of mutations in BRAF, NRAS, and PTEN in primary
cutaneous melanoma. J Invest Dermatol 126: 154–160.
RAF kinases in cancer
G Maurer et al
9
Oncogene
Golding SE, Rosenberg E, Neill S, Dent P, Povirk LF, Valerie K.
(2007). Extracellular signal-related kinase positively regulates ataxia
telangiectasia mutated, homologous recombination repair, and the
DNA damage response. Cancer Res 67: 1046–1053.
Goueli BS, Janknecht R. (2004). Upregulation of the catalytic
telomerase subunit by the transcription factor ER81 and oncogenic
HER2/Neu, Ras, or Raf. Mol Cell Biol 24: 25–35.
Granovsky AE, Rosner MR. (2008). Raf kinase inhibitory protein: a
signal transduction modulator and metastasis suppressor. Cell Res
18: 452–457.
Gray-Schopfer VC, Cheong SC, Chong H, Chow J, Moss T, Abdel-
Malek ZA et al. (2006). Cellular senescence in naevi and immortalisa-
tion in melanoma: a role for p16? Br J Cancer 95: 496–505.
Han JA, Kim JI, Ongusaha PP, Hwang DH, Ballou LR, Mahale A
et al. (2002). p53-mediated induction of Cox-2 counteracts p53- or
genotoxic stress-induced apoptosis. EMBO J 21: 5635–5644.
Hanahan D, Weinberg RA. (2000). The hallmarks of cancer. Cell 100:
57–70.
Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ,
Alvarado R et al. (2010). RAF inhibitors prime wild-type RAF
to activate the MAPK pathway and enhance growth. Nature 464:
431–435.
Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I,
Dhomen N et al. (2010). Kinase-dead BRAF and oncogenic RAS
cooperate to drive tumor progression through CRAF. Cell 140:
209–221.
Hood JD, Bednarski M, Frausto R, Guccione S, Reisfeld RA, Xiang R
et al. (2002). Tumor regression by targeted gene delivery to the
neovasculature. Science 296: 2404–2407.
Hwang YH, Choi JY, Kim S, Chung ES, Kim T, Koh SS et al. (2004).
Overexpression of c-raf-1 proto-oncogene in liver cirrhosis and
hepatocellular carcinoma. Hepatol Res 29: 113–121.
Janda E, Lehmann K, Killisch I, Jechlinger M, Herzig M, Downward J
et al. (2002). Ras and TGF(beta) cooperatively regulate epithelial
cell plasticity and metastasis: dissection of Ras signaling pathways.
J Cell Biol 156: 299–313.
Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L,
Johnson LA et al. (2010). COT drives resistance to RAF inhibition
through MAP kinase pathway reactivation. Nature 468: 968–972.
Jones DT, Kocialkowski S, Liu L, Pearson DM, Backlund LM,
Ichimura K et al. (2008). Tandem duplication producing a novel
oncogenic BRAF fusion gene deﬁnes the majority of pilocytic
astrocytomas. Cancer Res 68: 8673–8677.
Jones DT, Kocialkowski S, Liu L, Pearson DM, Ichimura K, Collins
VP. (2009). Oncogenic RAF1 rearrangement and a novel
BRAF mutation as alternatives to KIAA1549:BRAF fusion in
activating the MAPK pathway in pilocytic astrocytoma. Oncogene
28: 2119–2123.
Joseph EW, Pratilas CA, Poulikakos PI, Tadi M, Wang W, Taylor BS
et al. (2010). The RAF inhibitor PLX4032 inhibits ERK signaling
and tumor cell proliferation in a V600E BRAF-selective manner.
Proc Natl Acad Sci USA 107: 14903–14908.
Kamata T, Hussain J, Giblett S, Hayward R, Marais R, Pritchard C.
(2010). BRAF inactivation drives aneuploidy by deregulating
CRAF. Cancer Res 70: 8475–8486.
Karreth FA, DeNicola GM, Winter SP, Tuveson DA. (2009). C-Raf
inhibits MAPK activation and transformation by B-RafV600E.Mol
Cell 36: 477–486.
Kasid U, Pfeifer A, Brennan T, Beckett M, Weichselbaum RR,
Dritschilo A et al. (1989). Effect of antisense c-raf-1 on tumor-
igenicity and radiation sensitivity of a human squamous carcinoma.
Science 243: 1354–1356.
Kasid U, Pfeifer A, Weichselbaum RR, Dritschilo A, Mark GE.
(1987). The raf oncogene is associated with a radiation-resistant
human laryngeal cancer. Science 237: 1039–1041.
Kasid U, Suy S, Dent P, Ray S, Whiteside TL, Sturgill TW. (1996).
Activation of Raf by ionizing radiation. Nature 382: 813–816.
Kefford R, Arkenau H, Brown MP, Millward M, Infante JR, Long
GV et al. (2010). Phase I/II study of GSK2118436, a selective
inhibitor of oncogenic mutant BRAF kinase, in patients with
metastatic melanoma and other solid tumors. ASCO Meeting
Abstracts 28: 8503.
Kerkhoff E, Fedorov LM, Siefken R, Walter AO, Papadopoulos T,
Rapp UR. (2000). Lung-targeted expression of the c-Raf-1 kinase in
transgenic mice exposes a novel oncogenic character of the wild-type
protein. Cell Growth Differ 11: 185–190.
Kessenbrock K, Plaks V, Werb Z. (2010). Matrix metalloproteinases:
regulators of the Tumor Microenvironment. Cell 141: 52–67.
Kinkade R, Dasgupta P, Carie A, Pernazza D, Carless M, Pillai S et al.
(2008). A small molecule disruptor of Rb/Raf-1 interaction inhibits
cell proliferation, angiogenesis, and growth of human tumor
xenografts in nude mice. Cancer Res 68: 3810–3818.
Klein RM, Spofford LS, Abel EV, Ortiz A, Aplin AE. (2008). B-RAF
regulation of Rnd3 participates in actin cytoskeletal and focal
adhesion organization. Mol Biol Cell 19: 498–508.
Kolch W. (2005). Coordinating ERK/MAPK signalling through
scaffolds and inhibitors. Nat Rev Mol Cell Biol 6: 827–837.
Kramer BW, Gotz R, Rapp UR. (2004). Use of mitogenic cascade
blockers for treatment of C-Raf induced lung adenoma in vivo: CI-
1040 strongly reduces growth and improves lung structure. BMC
Cancer 4: 24.
Kroemer G, Pouyssegur J. (2008). Tumor cell metabolism: cancer’s
Achilles’ heel. Cancer Cell 13: 472–482.
Kumar SM, Yu H, Edwards R, Chen L, Kazianis S,
Brafford P et al. (2007). Mutant V600E BRAF increases hypoxia
inducible factor-1alpha expression in melanoma. Cancer Res 67:
3177–3184.
Kuznetsov AV, Smigelskaite J, Doblander C, Janakiraman M,
Hermann M, Wurm M et al. (2008). Survival signaling by
C-RAF: mitochondrial reactive oxygen species and Ca2+ are
critical targets. Mol Cell Biol 28: 2304–2313.
Lehmann K, Janda E, Pierreux CE, Rytomaa M, Schulze A,
McMahon M et al. (2000). Raf induces TGFbeta production while
blocking its apoptotic but not invasive responses: a mechanism
leading to increased malignancy in epithelial cells. Genes Dev 14:
2610–2622.
Liang S, Sharma A, Peng HH, Robertson G, Dong C. (2007).
Targeting mutant (V600E) B-Raf in melanoma interrupts immu-
noediting of leukocyte functions and melanoma extravasation.
Cancer Res 67: 5814–5820.
Luo J, Solimini NL, Elledge SJ. (2009). Principles of cancer therapy:
oncogene and non-oncogene addiction. Cell 136: 823–837.
Lyustikman Y, Momota H, Pao W, Holland EC. (2008). Constitutive
activation of Raf-1 induces glioma formation in mice. Neoplasia 10:
501–510.
Marx M, Eychene A, Laugier D, Bechade C, Crisanti P, Dezelee P
et al. (1988). A novel oncogene related to c-mil is transduced in
chicken neuroretina cells induced to proliferate by infection with an
avian lymphomatosis virus. EMBO J 7: 3369–3373.
Matallanas D, Romano D, Yee K, Meissl K, Kucerova L, Piazzolla D
et al. (2007). RASSF1A elicits apoptosis through an MST2 pathway
directing proapoptotic transcription by the p73 tumor suppressor
protein. Mol Cell 27: 962–975.
Matos P, Oliveira C, Velho S, Goncalves V, da Costa LT, Moyer MP
et al. (2008). B-Raf(V600E) cooperates with alternative spliced
Rac1b to sustain colorectal cancer cell survival. Gastroenterology
135: 899–906.
McKay MM, Morrison DK. (2007). Integrating signals from RTKs to
ERK/MAPK. Oncogene 26: 3113–3121.
Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C,
Kuilman T, van der Horst CM et al. (2005). BRAFE600-associated
senescence-like cell cycle arrest of human naevi. Nature 436:
720–724.
Mitsutake N, Knauf JA, Mitsutake S, Mesa Jr C, Zhang L, Fagin JA.
(2005). Conditional BRAFV600E expression induces DNA synth-
esis, apoptosis, dedifferentiation, and chromosomal instability in
thyroid PCCL3 cells. Cancer Res 65: 2465–2473.
Moelling K, Heimann B, Beimling P, Rapp UR, Sander T. (1984).
Serine- and threonine-speciﬁc protein kinase activities of puriﬁed
gag-mil and gag-raf proteins. Nature 312: 558–561.
RAF kinases in cancer
G Maurer et al
10
Oncogene
Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H et al. (2010).
Melanomas acquire resistance to B-RAF(V600E) inhibition by
RTK or N-RAS upregulation. Nature 468: 973–977.
Negrini S, Gorgoulis VG, Halazonetis TD. (2010). Genomic instabil-
ity—an evolving hallmark of cancer. Nat Rev Mol Cell Biol 11:
220–228.
Niault TS, Baccarini M. (2010). Targets of Raf in tumorigenesis.
Carcinogenesis 31: 1165–1174.
O’Neill E, Rushworth L, Baccarini M, Kolch W. (2004). Role of the
kinase MST2 in suppression of apoptosis by the proto-oncogene
product Raf-1. Science 306: 2267–2270.
Old WM, Shabb JB, Houel S, Wang H, Couts KL, Yen CY et al.
(2009). Functional proteomics identiﬁes targets of phosphorylation
by B-Raf signaling in melanoma. Mol Cell 34: 115–131.
Palanisamy N, Ateeq B, Kalyana-Sundaram S, Pﬂueger D, Ramnar-
ayanan K, Shankar S et al. (2010). Rearrangements of the RAF
kinase pathway in prostate cancer, gastric cancer and melanoma.
Nat Med 16: 793–798.
Park BJ, Park JI, Byun DS, Park JH, Chi SG. (2000). Mitogenic
conversion of transforming growth factor-beta1 effect by oncogenic
Ha-Ras-induced activation of the mitogen-activated protein
kinase signaling pathway in human prostate cancer. Cancer Res
60: 3031–3038.
Pﬁster S, Janzarik WG, Remke M, Ernst A, Werft W, Becker N et al.
(2008). BRAF gene duplication constitutes a mechanism of MAPK
pathway activation in low-grade astrocytomas. J Clin Invest 118:
1739–1749.
Piazzolla D, Meissl K, Kucerova L, Rubiolo C, Baccarini M. (2005).
Raf-1 sets the threshold of Fas sensitivity by modulating Rok-
{alpha} signaling. J Cell Biol 171: 1013–1022.
Polzien L, Baljuls A, Rennefahrt UE, Fischer A, Schmitz W, Zahedi
RP et al. (2009). Identiﬁcation of novel in vivo phosphorylation sites
of the human proapoptotic protein BAD: pore-forming activity
of BAD is regulated by phosphorylation. J Biol Chem 284:
28004–28020.
Poulikakos PI, Rosen N. (2011). Mutant BRAF melanomas—
dependence and resistance. Cancer Cell 19: 11–15.
Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. (2010).
RAF inhibitors transactivate RAF dimers and ERK signalling in
cells with wild-type BRAF. Nature 464: 427–430.
Pratilas CA, Taylor BS, Ye Q, Viale A, Sander C, Solit DB et al.
(2009). (V600E)BRAF is associated with disabled feedback inhibi-
tion of RAF–MEK signaling and elevated transcriptional output of
the pathway. Proc Natl Acad Sci USA 106: 4519–4524.
Pritchard CA, Hayes L, Wojnowski L, Zimmer A, Marais RM,
Norman JC. (2004). B-Raf acts via the ROCKII/LIMK/coﬁlin
pathway to maintain actin stress ﬁbers in ﬁbroblasts. Mol Cell Biol
24: 5937–5952.
Pritchard CA, Samuels ML, Bosch E, McMahon M. (1995).
Conditionally oncogenic forms of the A-Raf and B-Raf protein
kinases display different biological and biochemical properties in
NIH 3T3 cells. Mol Cell Biol 15: 6430–6442.
Puzanov I, Burnett P, Flaherty KT. (2011). Biological challenges of
BRAF inhibitor therapy. Mol Oncol 5.: 116–123.
Rajakulendran T, Sahmi M, Lefrancois M, Sicheri F, Therrien M.
(2009). A dimerization-dependent mechanism drives RAF catalytic
activation. Nature 461: 542–545.
Rapp UR, Goldsborough MD, Mark GE, Bonner TI, Groffen J,
Reynolds Jr FH et al. (1983). Structure and biological activity of v-
raf, a unique oncogene transduced by a retrovirus. Proc Natl Acad
Sci USA 80: 4218–4222.
Ravi RK, Weber E, McMahon M, Williams JR, Baylin S, Mal A et al.
(1998). Activated Raf-1 causes growth arrest in human small cell
lung cancer cells. J Clin Invest 101: 153–159.
Ries S, Biederer C, Woods D, Shifman O, Shirasawa S, Sasazuki T
et al. (2000). Opposing effects of Ras on p53: transcriptional
activation of mdm2 and induction of p19ARF. Cell 103: 321–330.
Riesco-Eizaguirre G, Rodriguez I, De la Vieja A, Costamagna E,
Carrasco N, Nistal M et al. (2009). The BRAFV600E oncogene
induces transforming growth factor beta secretion leading to sodium
iodide symporter repression and increased malignancy in thyroid
cancer. Cancer Res 69: 8317–8325.
Ritt DA, Monson DM, Specht SI, Morrison DK. (2010). Impact of
feedback phosphorylation and Raf heterodimerization on normal
and mutant B-Raf signaling. Mol Cell Biol 30: 806–819.
Riva C, Lavieille JP, Reyt E, Brambilla E, Lunardi J, Brambilla C.
(1995). Differential c-myc, c-jun, c-raf and p53 expression in
squamous cell carcinoma of the head and neck: implication in drug
and radioresistance. Eur J Cancer B Oral Oncol 31: 384–391.
Robert C, Arnault JP, Mateus C. (2010). RAF inhibition and
induction of cutaneous squamous cell carcinoma. Curr Opin Oncol
23: 177–182.
Roper E, Weinberg W, Watt FM, Land H. (2001). p19ARF-
independent induction of p53 and cell cycle arrest by Raf in murine
keratinocytes. EMBO Rep 2: 145–150.
Rushworth LK, Hindley AD, O’Neill E, Kolch W. (2006). Regulation
and role of Raf-1/B-Raf heterodimerization. Mol Cell Biol 26:
2262–2272.
Sahai E, Marshall CJ. (2003). Differing modes of tumour cell invasion
have distinct requirements for Rho/ROCK signalling and extra-
cellular proteolysis. Nat Cell Biol 5: 711–719.
Schulze A, Lehmann K, Jefferies HB, McMahon M, Downward J.
(2001). Analysis of the transcriptional program induced by Raf in
epithelial cells. Genes Dev 15: 981–994.
Schulze A, Nicke B, Warne PH, Tomlinson S, Downward J. (2004).
The transcriptional response to raf activation is almost completely
dependent on mitogen-activated protein kinase kinase activity and
shows a major autocrine component. Mol Biol Cell 15: 3450–3463.
Seoane J. (2008). The TGFBeta pathway as a therapeutic target in
cancer. Clin Transl Oncol 10: 14–19.
Sewing A, Wiseman B, Lloyd AC, Land H. (1997). High-intensity Raf
signal causes cell cycle arrest mediated by p21Cip1.Mol Cell Biol 17:
5588–5597.
Sharma A, Tran MA, Liang S, Sharma AK, Amin S, Smith CD et al.
(2006). Targeting mitogen-activated protein kinase/extracellular
signal-regulated kinase kinase in the mutant (V600E) B-Raf
signaling cascade effectively inhibits melanoma lung metastases.
Cancer Res 66: 8200–8209.
Sharma A, Trivedi NR, Zimmerman MA, Tuveson DA, Smith CD,
Robertson GP. (2005). Mutant V599EB-Raf regulates growth and
vascular development of malignant melanoma tumors. Cancer Res
65: 2412–2421.
Shimizu K, Nakatsu Y, Nomoto S, Sekiguchi M. (1986). Structure of
the activated c-raf-1 gene from human stomach cancer. Princess
Takamatsu Symp 17: 85–91.
Simon R, Richter J, Wagner U, Fijan A, Bruderer J, Schmid U et al.
(2001). High-throughput tissue microarray analysis of 3p25 (RAF1)
and 8p12 (FGFR1) copy number alterations in urinary bladder
cancer. Cancer Res 61: 4514–4519.
Smyth MJ, Dunn GP, Schreiber RD. (2006). Cancer immunosurveil-
lance and immunoediting: the roles of immunity in suppressing
tumor development and shaping tumor immunogenicity. Adv
Immunol 90: 1–50.
Sobczak I, Galabova-Kovacs G, Sadzak I, Kren A, Christofori G,
Baccarini M. (2008). B-Raf is required for ERK activation and
tumor progression in a mouse model of pancreatic beta-cell
carcinogenesis. Oncogene 27: 4779–4787.
Sumimoto H, Imabayashi F, Iwata T, Kawakami Y. (2006). The
BRAF–MAPK signaling pathway is essential for cancer-immune
evasion in human melanoma cells. J Exp Med 203: 1651–1656.
Takezawa K, Okamoto I, Yonesaka K, Hatashita E, Yamada Y,
Fukuoka M et al. (2009). Sorafenib inhibits non-small cell lung
cancer cell growth by targeting B-RAF in KRAS wild-type cells and
C-RAF in KRAS mutant cells. Cancer Res 69: 6515–6521.
Tidyman WE, Rauen KA. (2009). The RASopathies: developmental
syndromes of Ras/MAPK pathway dysregulation. Curr Opin Genet
Dev 19: 230–236.
Troppmair J, Hartkamp J, Rapp UR. (1998). Activation of NF-kappa
B by oncogenic Raf in HEK 293 cells occurs through autocrine
recruitment of the stress kinase cascade. Oncogene 17: 685–690.
RAF kinases in cancer
G Maurer et al
11
Oncogene
Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S et al. (2008).
Discovery of a selective inhibitor of oncogenic B-Raf kinase with
potent antimelanoma activity. Proc Natl Acad Sci USA 105:
3041–3046.
Vale T, Ngo TT, White MA, Lipsky PE. (2001). Raf-induced
transformation requires an interleukin 1 autocrine loop. Cancer
Res 61: 602–607.
Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-
Kalabis M, Cipolla AK et al. (2010). Acquired resistance to BRAF
inhibitors mediated by a RAF kinase switch in melanoma can be
overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18:
683–695.
Wang S, Ghosh RN, Chellappan SP. (1998). Raf-1 physically interacts
with Rb and regulates its function: a link between mitogenic
signaling and cell cycle regulation. Mol Cell Biol 18: 7487–7498.
Wang X, Thomson SR, Starkey JD, Page JL, Ealy AD, Johnson SE.
(2004). Transforming growth factor {beta}1 is upregulated
by activated Raf in skeletal myoblasts but does not contribute to
the differentiation-defective phenotype. J Biol Chem 279:
2528–2534.
Wang ZY, Chen Z. (2008). Acute promyelocytic leukemia: from highly
fatal to highly curable. Blood 111: 2505–2515.
Weber CK, Slupsky JR, Kalmes HA, Rapp UR. (2001). Active
Ras induces heterodimerization of cRaf and BRaf. Cancer Res 61:
3595–3598.
Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Grifﬁn JD.
(2007). Second generation inhibitors of BCR-ABL for the treatment
of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 7:
345–356.
Wellbrock C, Karasarides M, Marais R. (2004). The RAF proteins
take centre stage. Nat Rev Mol Cell Biol 5: 875–885.
Wimmer R, Baccarini M. (2010). Partner exchange: protein–protein
interactions in the Raf pathway. Trends Biochem Sci 35: 660–668.
Woods D, Parry D, Cherwinski H, Bosch E, Lees E, McMahon M.
(1997). Raf-induced proliferation or cell cycle arrest is determined
by the level of Raf activity with arrest mediated by p21Cip1. Mol
Cell Biol 17: 5598–5611.
Yagoda N, von Rechenberg M, Zaganjor E, Bauer AJ, Yang WS,
Fridman DJ et al. (2007). RAS–RAF–MEK-dependent oxidative
cell death involving voltage-dependent anion channels. Nature 447:
864–868.
Yu H, McDaid R, Lee J, Possik P, Li L, Kumar SM et al. (2009). The
role of BRAF mutation and p53 inactivation during transformation
of a subpopulation of primary human melanocytes. Am J Pathol
174: 2367–2377.
Zebisch A, Haller M, Hiden K, Goebel T, Hoeﬂer G, Troppmair J
et al. (2009). Loss of RAF kinase inhibitor protein is a somatic event
in the pathogenesis of therapy-related acute myeloid leukemias with
C-RAF germline mutations. Leukemia 23: 1049–1053.
Zebisch A, Staber PB, Delavar A, Bodner C, Hiden K, Fischereder K
et al. (2006). Two transforming C-RAF germline mutations
identiﬁed in patients with therapy-related acute myeloid leukemia.
Cancer Res 66: 3401–3408.
Zeng L, Imamoto A, Rosner MR. (2008). Raf kinase inhibitory
protein (RKIP): a physiological regulator and future therapeutic
target. Expert Opin Ther Targets 12: 1275–1287.
Zheng B, Jeong JH, Asara JM, Yuan Y-Y, Granter SR, Chin L et al.
(2009). Oncogenic B-RAF negatively regulates the tumor suppressor
LKB1 to promote melanoma cell proliferation. Mol Cell 33:
237–247.
Zhu J, Woods D, McMahon M, Bishop JM. (1998). Senescence
of human ﬁbroblasts induced by oncogenic Raf. Genes Dev 12:
2997–3007.
Zhuang D, Mannava S, Grachtchouk V, Tang WH, Patil S,
Wawrzyniak JA et al. (2008). C-MYC overexpression is required
for continuous suppression of oncogene-induced senescence in
melanoma cells. Oncogene 27: 6623–6634.
Zitvogel L, Tesniere A, Kroemer G. (2006). Cancer despite immuno-
surveillance: immunoselection and immunosubversion. Nat Rev
Immunol 6: 715–727.
RAF kinases in cancer
G Maurer et al
12
Oncogene
RESULTS 
41 | P a g e  
Hippo signalling 
Hippo signalling pathway was discovered in Drosophila in genetic mosaic screens of imaginal 
disc overgrowth. Genetic epistasis experiments quickly indicated interaction between its 
various components and established their order within the pathway. Later on it became 
obvious that all core components and the basic principles of their action in cell as well as their 
function on a tissue level are conserved throughout whole metazoan kingdom (Harvey and 
Tapon 2007). Maybe the strongest support for this comes from the experiments in which 
phenotypes of many mutants of the pathway core components in flies can be rescued by 
corresponding mammalian homologues (Saucedo and Edgar 2007; Zhao, Lei et al. 2008). 
The purpose of the pathway is to maintain tissue homeostasis by restricting cell proliferation 
and survival. This is achieved by limiting activity of the pathway’s ultimate effector Yorkie 
(or YAP in mammals) that is able to co-activate expression of proliferation and survival genes 
in the assist of variety of transcription factors. Yorkie/YAP inhibition is achieved by its 
phosphorylation by Warts kinase (LATS in mammals) that by phosphorylation is activated by 
Hippo kinase (MST in mammals). Phosphorylated Yorkie/YAP undergoes cytoplasmic 
retention by means of interaction with 14-3-3 protein. 
Hippo, Warts and Yorkie together with adaptors Salvador and Mats are considered core 
components of the pathway, and their activity can be affected to various extents by many 
other Hippo pathway-associated proteins. In the following sections I summarize Hippo 
signalling principles that have been primarily deciphered in flies, similarities and differences 
that can be found in mammals Hippo/Mst pathway and its relevance for tumorigenesis. 
Hippo signalling in flies 
In flies signals from outside of the cell are reaching core components of the pathway through 
trans-membrane, atypical cadherin Fat (Ft) that interacts with other cadherin Dachsous (Ds) 
on another cell, as a receptor-ligand pair. Ft and Ds are phosphorylated on their cadherin 
domains by Golgi-resident kinase Four-jointed (Fj). Intracellular domain of Ft is also 
phosphorylated by casein kinase Discs overgrown (Dco). Ds stability is apart from that 
regulated by cytoplasmic protein Lowfat (Lft) that can bind cytoplasmic domains of both Ft 
and Ds (Pan 2010). Crumbs (Crb) is another trans-membrane protein with numerous EGF-like 
and laminin AG-like repeats, PDZ-binding motif and FERM-binding motif (FBM). With its 
FBM Crb may bind one of subsequent proteins in the pathway, Expanded (Pan 2010). 
Expanded (Ex) and Merlin (Mer) are both members of band 4.1 protein family and interact 
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with C2 and WW domain-containing protein Kibra. This triple-protein complex recruits 
pathways core components, Hippo, Warts, Salvador and Mats to the membrane for activation 
(Pan 2010). Core components activity is also regulated by Dco, but whether it is functioning 
in parallel or downstream of Ex and Mer also remains elusive. Dco and Warts are brought 
together by scaffolding protein Dachs, unconventional myosin which localisation of is 
regulated by palmitoyltransferase approximated (App) (Harvey and Tapon 2007).  
Salvador (Sav) is another scaffold with WW domain binding to Warts (Wts) and SARAH 
domain binding to Hippo (Hpo), and brings together both kinases to facilitate signal 
transduction. dRassf protein also contains SARAH (Sav-Rassf-Hpo) domain and therefore is 
able to compete for binding to Hpo and inhibit pathway activation. Lately dRassf was shown 
to recruit PP2A dSTRIPAK that is able to inactivate Hpo by dephosphorylation. Hpo is 
serine/threonine kinase from sterile-20 kinase family that is able to phosphorylate and activate 
Wts, another serine/threonine kinase, member of NDR kinase family. Wts activation depends 
also on Mats and leads to phosphorylation of Yorkie (Yki) and its inactivation through 
cytoplasmic retention (Harvey and Tapon 2007). 
When activation of upstream Hippo components is compromised Yorkie is imported to the 
nucleus by a co-transportation mechanism with associated transcription factor. As Yorkie is 
unable to bind DNA, in order to activate transcription of target genes, it needs to interact with 
transcription factors, like TEAD family member Scalloped, Homothorax or Smads. Yki is co-
activating expression of genes including those encoding inhibitor of apoptosis DIAP, cyclin 
E, and oncogenic miRNA bantam (Harvey and Tapon 2007; Zhao, Lei et al. 2008). Yki also 
controls upstream activators of Hippo signalling, like Crb, Kibra, Ex and Fj, probably to 
achieve negative feedback regulation of its own activity. Furthermore, control of expression 
of E-cadherin, dMyc, Notch ligand Serrate, Wnt-pathway ligand Wingless, EGFR ligand Vein 
and proteoglycans Dally and Dally-like by Yki allows for extensive pathway cross talk (Pan 
2010). 
MST signalling in mammals 
All components of the Hippo pathway are evolutionarily conserved in mammals, but 
functional connections of some of them with the pathway’s core remains to be determined. 
Furthermore, in mammals most of these proteins are encoded by multiple genes, providing 
higher than in flies redundancy and probably number of roles that they may perform. 
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The role of homologue of drosophila Mer, Neurofibromin 2 (NF2) in activation of MST 
kinases in vivo is supported by one report (Zhang, Bai et al. 2010), while doubted by the other 
(Benhamouche, Curto et al. 2010). Further, there are two mammalian homologues of Hippo, 
kinases MST1 and 2 and two homologues of Warts, kinases LATS1 and 2. WW45 is a 
mammalian homologue of Salvador and MOBKL1A and B homologues of drosophila Mats 
that are very similar and often collectively referred to as MOB1. Yes-activated protein (YAP) 
and closely related transcriptional co-activator with PDZ binding motif (TAZ) are performing 
gene transcription co-activating function homologous to Yorkie. Apart from cytoplasmic 
retention as it is in flies, YAP is found to be regulated by degradation. Additional 
phosphorylation site on Serine 381 targeted by LATS kinases primes YAP for 
phosphorylation by CK1δ/ε followed by recruitment of ubiquitin ligase and targeting to 
proteasome (Pan 2010). Both YAP and TAZ, when not inhibited, activate transcription 
through binding to TEAD-family transcription factors, 4 mammalian homologues of 
drosophila Scalopped. So far they are also found to activate wider repertoire of additional 
transcription factors, including p73, PEBP2α, ERBB4 and ASPP2 (Saucedo and Edgar 2007; 
Zhao, Lei et al. 2008). 
The exact external signals that send input to the Hippo pathway in mammalian cells are not 
well established. NF2 protein is known to be phosphorylated and activated in response to 
contact inhibition in cell culture (Morrison, Sherman et al. 2001). Moreover, similarly to 
LATS2 (McPherson, Tamblyn et al. 2004), it is required to inhibit cell growth upon high 
culture density (Lallemand, Curto et al. 2003). Further, NF2 is regulating transcriptional 
activity and localisation of YAP in confluent cell cultures (Zhao, Wei et al. 2007). In cell lines 
together with KIBRA and WW45 it stimulates LATS phosphorylation and in mouse livers is 
required for efficient Lats and Yap phosphorylation and cytoplasmic retention of the latter 
(Zhang, Bai et al. 2010). But in hepatoblasts Nf2 seems to be dispensable for regulation of 
Yap localisation in response to high cell density. Instead of that, it suppresses Egfr-mediated 
Akt and Stat3 activation (Benhamouche, Curto et al. 2010), probably by limiting Egfr 
availability on cell surface (Curto, Cole et al. 2007). 
MST kinases can be activated during FAS receptor stimulation and are controlled by 
inhibitory interaction with MAPK pathway activator C-RAF (O'Neill, Rushworth et al. 2004). 
In response to FASL stimulation RASSF1A is displacing C-RAF from this complex that leads 
to MST2 activation (Matallanas, Romano et al. 2007). Activity of MST kinases is also 
associated with their proteolytic cleavage, possibly by caspases, and autophosphorylation 
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(Lee, Murakawa et al. 1998; Glantschnig, Rodan et al. 2002). In mouse liver Mst1 and 2 
kinases are required for efficient Lats1/2 and Yap phosphorylation (Lu, Li et al. 2010) and in 
hepatocyte Yap is a target of Lats kinases (Benhamouche, Curto et al. 2010) but specifically 
Mst1/2-mediated Yap inactivation in the liver is likely achieved through intermediate kinase 
distinct from Lats1/2 (Zhou, Conrad et al. 2009). 
YAP is also stabilised by c-Abl-mediated phosphorylation induced by DNA damage that 
confers p73 binding and apoptosis induction (Zhao, Lei et al. 2008). One of binding partners 
and activity modulators of TP53, ASPP1 is breaking interaction between LATS1 and YAP. 
Thereby ASPP1 inhibits cytoplasmic retention and degradation of the latter, leading to 
increased YAP-mediated cell survival (Vigneron, Ludwig et al. 2010). On the other hand, 
LATS2 in response to oncogenic stress phosphorylates ASPP1 what drives its nuclear 
translocation where it directs TP53 to promoters of pro-apoptotic genes, what in turn is 
inhibited by YAP (Aylon, Ofir-Rosenfeld et al. 2010). 
Tumour suppressive functions of MST signalling 
As Hippo signalling primary biochemical function is to inhibit the activity of proto-oncogene 
YAP, it is not surprising that many of its components perform tumour suppressive functions. 
Still, most of them are not often found mutated in human cancer, with few exceptions. NF2 is 
a tumour suppressor in hereditary cancer syndrome neurofibromatosis type 2 characterised by 
tumours of central nervous system. Apart from that, mutations in MOB1 are found in human 
melanoma and mouse mammary carcinoma.  
On the other hand there is growing evidence that epigenetic silencing plays role in 
inactivation of many Hippo components in human cancers. LATS1 and 2 methylation-
dependent silencing occurs in astrocytoma and correlates with aggressiveness of breast 
cancer. Furthermore mice deficient for Lats1 develop ovarian tumours and soft tissue 
sarcomas. LATS2 expression is also negatively regulated by oncomiRs in testicular germ cell 
tumours. MOB1 expression is lost in colorectal and lung cancers irrespective of its gene 
sequence and methylation status. MST kinases-encoding genes are found hypermethylated in 
soft tissue sarcoma. They also suppress liver growth and tumorigenesis in mice by restricting 
YAP activity, what is achieved most probably without direct involvement of LATS kinases. 
YAP, apart from being tumour proto-oncogene in the liver and causing hepatomegaly when 
over-expressed in this organ, is also amplified in mouse mammary tumour model. Moreover 
genomic locus that encodes YAP in humans is amplified in numerous cancers, including 
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ovarian, liver, lung, pancreatic, oesophegal and brain. Consequently, YAP overexpression is 
frequent in lung, ovarian, pancreatic, liver, colorectal and prostate carcinomas and gene 
encoding its partner, TEAD4, is also found amplified in various cancers. TAZ function in 
cancer was until now not investigated to such an extent as of YAP, but its overexpression is 
found at least in a subset of breast cancers. Finally, RASSF1 has originally been found as a 
tumour suppressor encoded within locus 3p21,3, which is frequently deleted in human 
tumours. Members of RASSF family are generally proposed to function as tumour 
suppressors, particularly isoform A of RASSF1, which is lost in numerous cancers due to 
gene promoter methylation (Harvey and Tapon 2007; Pan 2010). 
Ras associated factors protein family 
Ras-associated factors (RASSF) protein family in humans is encoded by 6 genes (RASSF1-
6). They are putative RAS effectors, as in their sequence they contain RAS-association 
domain (RA). Nevertheless, apart from RASSF5, functionality and specificity of RA domain 
of RASSF proteins for RAS binding remains unproven. They all also contain SARAH 
(Salvador-Rassf-Hippo) domain responsible for the interaction with Hippo pathway 
components. Additional variety is provided by splicing and alternative promoter usage that 
leads to multiple isoforms in case of some of the members. Recently additional four members 
of the family have been identified that share lower homology with the previously known 
members and are lacking C-terminal SARAH domain (Avruch, Xavier et al. 2009). 
Gene encoding RASSF1 undergoes differential splicing and has two transcription start sites 
what results in production of 7 different isoforms (A-G) that differ in protein domain 
composition. Until now biological relevance could be shown only for transcripts A and C, 
which are ubiquitously expressed in non-tumour tissues. Both isoforms share SARAH and 
RA domains and ATM-phosphorylation consensus sequence. Isoform A is transcribed from 
more upstream transcription start site, and results in the protein with additional C1 domain at 
the N-terminus. C1 domain is similar to diacylglycerol (DAG)-binding domain and contains a 
zinc-finger (Richter, Pfeifer et al. 2009). 
Isoform A of Rassf1 gene is subjected to epigenetic silencing in cancers as a result of 
hypermethylation of CpG islands in its promoter, whereas expression of isoform C is usually 
retained. Moreover, isoform A has tumour suppressive functions in vitro and in vivo, what is 
not the case for isoform C. Epigenetic silencing of RASSF1A expression occurs in various 
cancer types, correlates with cancer progression and poor survival (Richter, Pfeifer et al. 
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2009). Especially in HCC up to 90% of examined cases loose RASSF1A expression due to 
promoter hypermethylation (Schagdarsurengin, Wilkens et al. 2003). 
Mice deficient for RASSF1A are tumour prone and late in life develop with varying 
frequencies spontaneous lung adenomas, lymphomas and breast adenocarcinomas (Tommasi, 
Dammann et al. 2005). They are also more susceptible to chemically induced skin 
carcinogenesis and have accelerated intestinal carcinogenesis in ApcMin mouse model (van der 
Weyden, Arends et al. 2008). 
Despite extensive research done in the last years, function of RASSF1A (and other RASSF 
proteins as well) is not ultimately determined. Apart from the role in influencing Hippo 
signalling, RASSF1A might perform its tumour suppressive function by controlling other 
apoptotic pathways, cell cycle, DNA-damage response and TP53 stability, or mictrotubule 
stability and mitotic progression. RASSF1A, by binding to MOAP-1, helps to activate BAX 
during TNF-α or TRAIL-induced apoptosis. It also inhibits accumulation of Cyclin D1 and 
AP-1 activity that positively influence cell cycle progression. In the interphase RASSF1A 
localises to microtubules (MTs) and during mitosis to centrosomes and mitotic spindle, most 
likely through the interaction with MT-associated proteins (MAPs). It also binds and is 
phosphorylated by serine/threonine mitotic kinase Aurora-A, and probably works as a 
scaffold for other Aurora-A targets. Moreover, region encompassing RA domain of 
RASSF1A confers binding of small GTPase RAN involved in mitosis. Therefore RASSF1A 
is able the influence microtubule stability and mitotic progression. Finally, because of its 
putative phosphorylation site for kinases ATM/ATR, it is proposed to sense DNA-damage. 
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Results 
Rationale and aims I: C-Raf role in liver cancer 
Previous research from the Baccarini lab shows crucial function of C-Raf in protecting mouse 
hepatocyte from apoptosis during development (Mikula, Schreiber et al. 2001) and in adult 
animal in response to FasL treatment (Matallanas, Romano et al. 2007). Apoptosis evasion is 
one of the classical hallmarks of cancer that needs to be achieved by tumour cells to resist 
anti-tumour defences of the organism (Hanahan and Weinberg 2000; Hanahan and Weinberg 
2011). Furthermore, C-Raf is overexpressed in human HCC (Hwang, Choi et al. 2004) and 
sorafenib, primarily designed as C-Raf inhibitor is a first molecularly targeted drug approved 
for HCC treatment (Llovet, Ricci et al. 2008) (although recent research indicates that its use 
might be beneficial through inhibiting other kinases (Liu, Cao et al. 2006)). Therefore we set 
out to investigate role of C-Raf in hepatocarcinogenesis in the mouse model of HCC. 
Mice with hepatocyte specific c-raf deletion are more prone to 
chemically-induced liver tumours. 
We subjected 129/Sv mice with floxed exon 3 of c-raf-1 gene and alfp-cre transgene to 
DEN/Pb chemical carcinogenesis protocol (Figure 3A). After 30 weeks carcinogenesis alfp-
cre;c-raff/f (c-rafΔhep) mice have substantially more tumour-affected livers than c-raff/f mice 
judging by their gross morphology (Figure 4A). They also have significantly increased 
liver/body weight ratio (Figure 4B), indicating increased liver mass, likely resulting from 
increased tumour load. Analysis of H&E-stained paraffin-embedded liver sections shows 
higher percentage of section affected by the tumours as well as higher number of tumours 
detected per designated area in c-rafΔhep mice (Figure 4C and D). This indicates that c-rafΔhep 
mice have more liver tissue affected by tumours and increased tumour number. 
It is known that Cre-recombinase expression in cells may have genotoxic effect (Loonstra, 
Vooijs et al. 2001), what may influence liver carcinogenesis process (Takami, Kaposi-Novak 
et al. 2007). Apart from that location of alfp-cre transgene insertion within the mouse genome 
has not been determined so far. This leaves the possibility that alfp-cre transgene might affect 
some genomic element relevant to our studies. To determine whether phenotype in c-rafΔhep 
mice is a result of hepatocyte-restricted c-raf deletion, Cre-recombinase expression or other 
alfp-cre-transgene-specific effects we conducted liver carcinogenesis with the same protocol 
on WT and alfp-cre animals without floxed c-raf alleles. With similar numbers of animals we 
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could not detect significant differences between WT and alfp-cre mice in respect to their liver 
mass, tumour-affected area or nodule number estimated on H&E-stained liver sections 
(Figure 4E). Therefore we conclude that alfp-cre transgene does not influence liver 
carcinogenesis after 30-weeks in DEN/Pb model. It also ensures that observed phenotype is a 
result of disrupted c-raf expression. 
C-Raf deletion prior to tumour initiation enhances liver carcinogenesis 
Carcinogenesis is a multistep process where primarily initiated cells need to proliferate to 
form macroscopic nodules which then by acquiring genomic and epigenomic changes evolve 
to invasive and metastatic cancers. To determine the carcinogenesis stage in which c-raf 
deletion is required for enhanced liver tumour growth in alfp-cre;c-raff/f mice we used same 
carcinogenesis protocol on mx-cre;c-raff/f mice. In these mice deletion of c-raf floxed allele is 
mediated in the liver by poly(I:C)-inducible product of mx-cre transgene in hepatocytes and 
non-parenchymal cells. By injecting these mice with poly(I:C) we induced deletion of c-raf 
before, shortly after and late during carcinogenesis protocol to study its role in tumour 
initiation, promotion and regression, respectively (Figure 3B). 
Deletion of c-raf before tumour initiation results in comparable liver gross morphology and 
liver mass of mx-cre;c-raff/f (c-rafΔliv) mice as c-raff/f (Figure 5A and B). This is in contrast to 
the alfp-cre-mediated c-raf deletion, which leads to markedly more affected livers and 
increased liver mass (Figure 4A-B). Analysis of H&E-stained liver sections showed similar 
tumour-affected area in c-rafΔliv mice, but increased nodule number per defined area (Figure 
5C and D). This indicates similar tumour mass but increased tumour number in livers of c-
rafΔliv mice. These results show that c-raf deletion in the liver before tumour initiation 
enhances tumorigenesis in this organ. Some of the features of the alfp-cre;c-raff/f phenotype, 
like increased liver mass and tumour-affected liver are not manifested in mx-cre;c-raff/f mice. 
Therefore accompanying c-raf deletion in non-parenchymal cells in mx-cre;c-raff/f mice is 
partially suppressing phenotype of sole c-raf deletion in the hepatocyte. 
Similarly to deletion before, deletion of c-raf two weeks after tumour initiation also results in 
comparable liver gross morphology and liver mass of c-rafΔliv mice as c-raff/f (Figure 5E and 
F). In contrast total tumour mass and tumour number as judged from H&E-stained liver 
sections remains unchanged (Figure 5G and H). Therefore, c-raf deletion after tumour 
initiation, unlike deletion before, is not affecting liver chemical carcinogenesis. 
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C-Raf plays role in protection of liver from apoptosis during development (Mikula, Schreiber 
et al. 2001) and in adult animal (Matallanas, Romano et al. 2007), and apoptosis evasion is 
one of classical hallmarks of cancer cells. Therefore, we checked cell death in developed 
tumours after 30 weeks carcinogenesis in c-rafΔliv mice in which c-raf deletion was induced 
after tumour initiation. We applied terminal deoxyunucleotydil transferase dUTP nick end 
labelling (TUNEL), which indicates DNA fragmentation in cells undergoing apoptosis or 
necrosis. Number of TUNEL-positive cells in tumours from livers of c-rafΔliv mice is similar 
to those from c-raff/f (Figure 5I). Therefore, c-raf deletion in hepatocytes and non-
parenchymal cells does not influence cell survival in DEN-induced liver tumours. 
Sorafenib, small molecule inhibitor designed to block C-Raf activity, has recently been shown 
to prolong survival of patients with advanced, unresectable HCC (Llovet, Ricci et al. 2008). 
We decided to investigate whether in our model C-Raf ablation affects progression of 
developed tumours or their maintenance. We subjected to carcinogenesis protocol c-raff/f and 
mx-cre;c-raff/f mice for 28 weeks, induced c-raf deletion with poly(I:C) and kept them on Pb 
food for further 16 weeks. Isolated livers from animals of both genotypes have numerous 
large, vascularised tumours (Figure 5J), their mass is very high (12,4% ±8,7 for c-raff/f and 
15,9% ± 6,1 for c-rafΔliv) (Figure 5K) and mice of both genotypes exhibit occasional lung 
metastasis (Gabriele Maurer, unpublished data). This indicates advanced stage of the disease 
and the capability of the protocol to induce fully progressed HCC able to form metastasis, 
resembling course of HCC in the clinic. Livers from c-rafΔliv and c-raff/f have comparable 
gross morphology and liver mass (Figure 5J and K). This indicates that c-raf deletion is 
neither affecting tumour progression nor tumour maintenance in the liver chemical 
carcinogenesis model. 
Deletion of floxed allele by inducible Cre recombinase might not be 100% efficient. In the 
case of negative selection against cells that have deleted targeted allele, tumours might 
preferentially arise from the clonal expansion of cells that retained it. Therefore, we checked 
efficiency of c-raf deletion by performing genotyping PCR on cell lysates from isolated 
tumours of c-raff/f and mx-cre;c-raff/f animals that were injected with poly(I:C) two weeks 
after DEN-injection. As a control, in parallel we also genotyped samples from c-raff/- 
heterozygous mouse. All genotyped tumours from mx-cre;c-raff/f animals showed efficient 
conversion of flox to Δ allele (Figure 5L). Similar genotyping PCRs were performed for 
selected tumours of each experimental mx-cre;c-raff/f and c-raff/f animal injected with 
poly(I:C) before, shortly after or late after tumour initiation, always confirming efficient c-raf 
PHD THESIS BARTOSZ TARKOWSKI        
50 | P a g e  
deletion (data not shown). Therefore mx-cre-mediated c-raf ablation in the liver is efficient 
and tumours that arise in these mice are not selected for c-raf expression. 
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Figure 3. Chemical liver carcinogenesis and conditional C-Raf ablation in mice. 
(A) In the alfp-cre line C-raf is deleted in parenchymal cells and most likely oval cells, as they also express α-
fetoprotein. Expression of Cre recombinase begins between day 9,5 and 10,5 p.c. Tumours are initiated with single 
injection of DEN at 4 weeks of age and promoted by administration of phenobarbital-containing fodder (Pb) from 8th 
week on. Animals were euthanized at 34 weeks of age (single c-raf-knock out experiments) or 36 weeks of age 
(double knock-out experiments). 
(B) In the mx-cre line c-raf is deleted in parenchymal cells (although efficiency of ablation in cholangiocytes and oval 
cells has not been investigated), cells derived from hematopoietic line (Kupffer cells, T-cells) and partially in 
endothelial cells (data not shown). Deletion is induced with 2 consecutive injections of poly(I:C) within 5 days, either 
one week before, or 2 weeks after, or 28 weeks after DEN injections. Animals were euthanized and their livers 
isolated at 32, 34 and 48 weeks of age, respectively. Details in text.  
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Figure 4. C-Raf is a tumour suppressor in a chemical model of HCC. 
(A) Gross liver morphology, (B) quantification of liver mass as a percentage of body weight, (C) H&E staining of 
paraffin-embedded liver sections and (D) quantification of tumour-affected area and number of nodules per 1cm2 of 
liver section from c-raff/f and alfp-cre;c-raff/f (c-rafΔhep) male mice 30 weeks after DEN-treatment; 
(E) Quantification of liver mass (as in B), tumour-affected area and nodule number (as in D) from WT and alfp-cre 
male mice after same treatment as in A-D; 
Data in graphs is expressed as mean values; error bars - 95% confidence interval; * - p-value<0,05 as calculated from 
two-tailed student t-test for samples with equal variation; Figures A-D with contribution of Gabriele Maurer;  
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Figure 5. C-Raf suppresses tumour initiation and is dispensable for tumour maintenance. 
(A) Gross liver morphology, (B) quantification of liver mass as a percentage of body weight, (C) H&E staining of 
paraffin-embed liver sections and (D) quantification of tumour-affected area and number of nodules per 1cm2 of liver-
section from c-raff/f and mx-cre;c-raff/f (c-rafΔliv) male mice 30 weeks after DEN-treatment that were poly(I:C)-treated 
two weeks before DEN; 
(E) Gross liver morphology, (F) quantification of liver mass (as in B), (G) H&E staining (as in C), (H) quantification of 
tumour-affected area and number of nodules (as in D) and (I) quantification of apoptotic cells detected in tumours with 
terminal deoxyunucleotydil transferase dUTP nick end labelling (TUNEL) of liver paraffin-embed sections from c-raff/f 
and c-rafΔliv male mice 30 weeks after DEN-treatment that were poly(I:C)-treated two weeks after DEN; 
(J) Gross liver morphology and (K) quantification of liver mass (as in B) from c-raff/f and c-rafΔliv male mice 44 weeks 
after DEN-treatment that were poly(I:C)-treated 28 weeks after DEN; 
(L) Genotyping PCR for c-raf flox and Δ allele on DNA isolated from tumours of c-raff/f and c-rafΔliv male mice 30 
weeks after DEN-treatment that were poly(I:C)-treated 2 weeks after DEN; 
Data in graphs is expressed as mean values; error bars - 95% confidence interval; * - p-value<0,05 as calculated from 
two-tailed student t-test for samples with equal variation; Figures A-K with contribution of Gabriele Maurer; 
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Rationale and aims II: Interplay between Rassf1a and C-Raf in liver 
cancer 
Up to 90% of HCC clinical cases exhibit isoform-specific promoter methylation of Rassf1a 
that leads to loss of its expression (Dammann, Schagdarsurengin et al. 2003). Rassf1a was 
shown to have tumour suppressive functions in vitro (Dammann, Li et al. 2000) and in vivo 
(Tommasi, Dammann et al. 2005). Together with C-RAF, RASSF1A regulates activation of 
MST2 kinase (Matallanas, Romano et al. 2007), upstream regulator of Hippo signalling that 
in mammals controls liver homeostasis (Zhou, Conrad et al. 2009). Therefore we decided to 
investigate the role of interplay between C-Raf and Rassf1a in liver cancer in chemically 
induced mouse liver cancer. 
Rassf1a is required for manifestation of c-rafΔhep phenotype in liver 
cancer 
We have crossed 129/Sv c-rafΔliv mice with 129/B6 mice bearing conventional KO of rassf1 
isoform A and obtained at the mendelian ratio c-rafΔliv;rassf1a-/- (double KO) animals that 
were viable and fertile as their c-rafΔliv littermates (data not shown). Untreated double KO 
animals do not exhibit any overt phenotype, have normal gross liver morphology and 
unaffected liver/body weight ratio at 36 weeks age (data not shown). Genotyping PCR on 
liver tissue lysate from c-rafΔhep and double KO mice amplified products both from flox and Δ 
allele, the former one presumably from non-parenchymal cells (Figure 6F). Indeed, western 
blot analysis confirmed efficient ablation of C-Raf on protein level in c-rafΔhep and double KO 
mice (Figure 8A). 
We subjected c-raff/f, c-rafΔhep, c-raff/f;rassf1a-/- (referred to as rassf1a-/-) and double KO 
animals to liver carcinogenesis protocol (Figure 3A). We could reproduce previously 
observed phenotype of c-rafΔhep mice in terms of increased liver mass, tumour-affected liver 
and number of tumours (Figure 6A-D). Strikingly, this phenotype is not exhibited on the 
background of rassf1a deletion. Gross morphology of livers from double KO mice resembles 
that of rassf1a-/- (Figure 6A) and liver mass of double KO mice is not increased in comparison 
to rassf1a-/- (Figure 6B). Furthermore, tumour-affected liver area and number of tumours is 
similar in H&E-stained liver sections from rassf1a-/- and double KO mice. Finally, nodule 
number in double KO mice is significantly decreased as compared to c-rafΔliv (Figure 6D). 
This indicates that Rassf1a deletion attenuates c-rafΔhep phenotype in chemical liver 
carcinogenesis mouse model. 
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Neoplastic nodules in the liver that result from hepatocyte transformation can be classified 
according to their morphological features like size, clear borders, congestion or invasion of 
surrounding tissue, hepatocyte size and morphology, growth pattern and eosinophylic or 
basophilic staining (Tamano, Merlino et al. 1994). They can be classified into several types of 
foci of cellular alteration, regenerative hyperplasia, adenomas and carcinomas with either 
normal or trabecular growth pattern. Different nodule classes are thought to reflect 
consecutive stages of tumour progression, with foci being the earliest, benign stage and 
carcinoma the final and most malignant one. Therefore relative amounts of each type of 
induced nodule in livers of DEN/Pb treated mice indicate rate of tumour progression. 
To determine influence of c-raf and rassf1a gene deletions on tumour progression we 
classified nodules from H&E liver sections of c-raff/f, c-rafΔhep, rassf1a-/- and double KO mice 
according to their morphological features (in collaboration with Stratigoula Sakellariou and 
Vassilis Gorgoulis, Medical School, National Kapodistrian University of Athens, Greece). We 
detected mainly foci of cellular alteration (FCA) and hepatocellular adenomas (HCA) with 
few hepatocellular carcinomas (HCC). Percentage of nodules classified as HCC is 
significantly increased in c-rafΔhep but not in double KO mice, as compared to c-raff/f mice, 
and it has tendency to increase, although without reaching statistical significance, in rassf1a-/- 
mice compared to c-raff/f (p-value=0,067) (Figure6E). Moreover number of mice with 
detected nodules classified as HCC is significantly increased in c-rafΔhep but not in double KO 
mice. Apart from that, rassf1a-/- mice also have significantly higher incidence of HCC than c-
raff/f mice (Figure 6E). Therefore c-raf ablation in the hepatocyte enhances cancer progression 
what is attenuated by concomitant rassf1a deletion. Deletion of rassf1a alone on the other 
hand also enhances tumour progression. 
Rassf1a deletion attenuates proliferation increase in c-rafΔhep liver 
One of prime functions of MAPK signalling is to regulate proliferation of the cell. 
Uncontrolled proliferative signalling is a hallmark of cancer cells that allows them for 
uncontrolled growth. Therefore we checked the proliferation index in the c-raff/f, c-rafΔhep, 
rassf1a-/- and double KO mouse livers after carcinogenesis. 
We performed immunohistochemistry for Ki67 on liver sections from experimental animals. 
In mice of all genotypes tumours exhibit ubiquitous staining for Ki67 whereas in tumour-
unaffected tissue only rare positive cells were found (Figure 7A). This indicates high 
proliferation in the tumours and known quiescence of tumour-unaffected liver tissue. Mean 
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proliferation in tumour tissue in all genotypes is comparable, but in tumour-unaffected tissue 
of c-rafΔhep animals it is significantly increased compared to c-raff/f, what was recently 
observed in our lab (Gabriele Maurer, unpublished data). In contrast, proliferation is similar in 
tumour-unaffected liver tissue of double KO mice compared to that of rassf1a-/- (Figure 7B). 
Therefore, c-raf deletion in hepatocyte increases proliferative capacity in mouse tumour-
unaffected liver tissue subjected to chemical carcinogenesis and rassf1a deletion attenuates 
this phenotype. 
Rassf1a can influence apoptosis in the cell either by regulating activation of MST kinases that 
are activated in response to Fas stimulation (Matallanas, Romano et al. 2007) or by 
facilitating activation of Bcl-2 family protein Bax, that triggers efflux of cytochrome C from 
mitochondria (Baksh, Tommasi et al. 2005). Therefore we evaluated cell death in livers of the 
same mice as in case of Ki67 expression analysis with the help of TUNEL on liver sections. 
In general apoptotic indexes in both tumour and tumour unaffected liver tissue are very low. 
Neither in tumour, nor in tumour unaffected tissue we were able to detect any differences 
between mice of different genotypes (Figure 7C-D). This indicates that at least in the 
developed liver tumours neither C-Raf nor Rassf1a ablation affects hepatocyte survival. 
Signalling pathway activation in livers after tumorigenesis 
To assess state of signalling pathways activation that might be relevant for liver tumorigenesis 
and affected by c-raf and rassf1a ablation we isolated protein lysates form tumour-unaffected 
and tumour liver tissue from c-raff/f, c-rafΔhep, rassf1a-/- and double KO animals. These lysates 
were then analysed with western blotting for levels and modifications status of selected 
proteins from MAPK, Hippo, and stress and inflammatory signalling pathways. 
The main indirect effector of RAF kinases is ERK which by phosphorylating numerous 
targets in the cytoplasm, nucleus and cellular membranes, influences cell proliferation and 
survival in response to extracellular signals. Erk activation results from threonine and tyrosine 
phosphorylation by MEK in TXY motifs. Western blot analysis of Erk activatory 
phosphorylation sites shows inconsistent Erk activation in different mice of the same 
genotype, especially in tumour tissue (Figure 8A). Still we observe lower Erk activation in 
tumour unaffected tissue of double KO animals compared to all other investigated genotypes. 
In drosophila, dRassf protein is a Hippo inhibitor (Polesello, Huelsmann et al. 2006), but 
mammalian RASSF1A activates MST by displacing C-RAF from its inhibitory complex with 
MST2 (Matallanas, Romano et al. 2007). Loss of Mst activity in mouse liver leads to 
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spontaneous liver cancer development (Zhou, Conrad et al. 2009), and Yap overexpression in 
the liver leads to hepatomegaly followed by HCC (Dong, Feldmann et al. 2007). Hippo 
pathway activation is associated with proteolytic cleavage of MST kinases (Lee, Murakawa et 
al. 1998), phosphorylation of LATS kinases on specific serines and threonine residues (Chan, 
Nousiainen et al. 2005), and inhibitory YAP phosphorylation on S127 (Oka, Mazack et al. 
2008). Western blot analysis of Mst2 levels shows decreased Mst2 levels in both tumour-
unaffected and tumour tissue of rassf1a-/- and double KO animals compared to c-raff/f and c-
rafΔhep animals (Figure 8B). This might indicate either lower expression or enhanced 
proteolytic Mst2 cleavage in cells lacking Rassf1a. Analysis of Lats1 phosphorylation on 
S908 (homologous to human S909) shows increased Lats1 activation in tumour unaffected 
and tumour tissue of double KO animals compared to 3 other investigated genotypes (Figure 
8B). This indicates that deletion of both C-Raf and Rassf1a in the hepatocyte leads to 
enhanced Lats1 activatory phosphorylation. Surprisingly, western blot analysis of total Yap 
and its inhibitory phosphorylation site shows no differences depending on the genotype. But 
expression of total Yap is increased in c-rafΔhep mice compared to c-raff/f and double KO 
animals compared to rassf1a-/- in both tumour unaffected and tumour tissue (Figure 8B). This 
indicates either higher expression or increased Yap stability in C-Raf-deficient hepatocytes. 
Finally, in tumour tissue Lats1 phosphorylation inversely correlates with Yap levels, apart 
from tissue of double KO animals, where both Lats1 phosphorylation and Yap levels are 
relatively high (Figure 8B). This indicates that concomitant c-raf and rassf1a deletion leads to 
uncoupling of Mst signalling and Yap levels in liver tumours. 
Chronic inflammation is associated with HCC development and signalling pathways like NF-
κB or p38 that respond to inflammatory or stress stimuli influence liver homeostasis. NF-κB 
transcription factor can be activated downstream of TNF-α-receptors, it regulates cell survival 
and its activation is either suppressing or enhancing liver cancer development depending on 
experimental model (Pikarsky, Porat et al. 2004; Luedde, Beraza et al. 2007). NF-κB is 
normally inhibited by IκB which degradation of occurs upon phosphorylation by IKK kinases. 
We investigated IκB status and observed its similar levels in animals of all genotypes. This 
indicates that neither Rassf1a nor C-Raf ablation influences NF-κB pathway activation in the 
liver. 
p38 is a MAP kinase implicated in stress signalling with tumour suppressive function in 
various settings, including liver (Wagner and Nebreda 2009). p38 suppresses liver tumour 
development by antagonising c-Jun (Hui, Bakiri et al. 2007) and is itself suppressed by c-Jun 
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during liver regeneration (Stepniak, Ricci et al. 2006). Its activation, similarly to ERK, is a 
consequence of dual phosphorylation on TXY motif. We evaluated p38 activation by using 
phospho-specific antibodies and found decreased p38 phosphorylation in tumour unaffected 
tissue only from double KO animals. This indicates that genetic inactivation of both C-Raf 
and Rassf1a leads to lower activation of p38. 
Macrophage number is increased in c-rafΔhep irrespectively of Rassf1a 
Although HCC is a primary liver tumour that arises as a result of hepatocyte transformation, 
non-parenchymal cells of the liver also influence hepatocyte transformation, progression of 
neoplastic nodules and growth of tumours. For instance, inflammatory cells can secrete 
cytokines and produce ROS that might enhance cell growth and transformation. Kupffer cells, 
resident liver macrophages, seem to play crucial role in mediating tumour-promoting 
inflammation in this organ. They are for instance activated by factors released from dying 
hepatocytes to release Il-6 and TNF-α that in return can stimulate proliferation of surviving 
hepatocytes (Sakurai, He et al. 2008).  
To assess numbers of macrophages in livers after tumorigenesis we performed 
immunohistochemistry for macrophage marker F4/80 on liver sections from c-raff/f, c-rafΔhep, 
rassf1a-/- and double KO animals. Livers from all genotypes showed substantial numbers of 
mostly elongated cells with abundant filopodia prevailing around portal areas, mostly with 
sinusoidal localisation. Numbers of detected macrophages were higher in c-rafΔhep compared 
to c-raff/f but also in double KO compared to rassf1a-/-. Therefore deletion of c-raf in 
hepatocytes leads to increased numbers of macrophages in the liver and concomitant Rassf1a 
deletion does not affect this phenotype. 
It is known that macrophages can be activated by various stimuli and the type of stimulus can 
determine subsequent macrophage behaviour. Macrophage stimulation with interferons, TNF-
α or LPS leads to classical activation of macrophage, or M1 phenotype. Such macrophages 
are considered to have higher microbicidal and tumoricidal activity and release high amounts 
of pro-inflammatory cytokines. Macrophage stimulation with IL-4 or Il-13 leads to alternative 
activation, or M2 phenotype. They express distinct set of cytokines than M1 macrophages and 
participate in parasite clearance, tissue remodelling and angiogenesis and in this way are able 
to facilitate tumour progression (Biswas and Mantovani 2010). 
To determine whether macrophages in tumour-bearing livers are activated we performed 
immunohistochemistry for INOS macrophage activation marker which shows low numbers of 
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positive cells in tumour bearing livers from mice of all genotypes. For comparison, in c-raff/f 
we detect only 19±8 INOS-positive cells per mm2 of tissue section, whereas in the same mice 
we detect 582±86 F4/80-positive cells per mm2 tissue section. Moreover INOS-positive cells 
have rounded morphology (Figure 9C) and most of F4/80-positive cells have elongated 
morphology and abundant filopodia (Figure 9A, arrows) although some of them also have 
morphology similar to that of INOS-positive cells (Figure 9A, arrowheads). Therefore most of 
F4/80-positive cells in the liver do not express classical macrophage activation markers. 
Quantification of INOS-positive cells shows no differences between c-raff/f, c-rafΔhep, rassf1a-
/- and double KO animals. This indicates that hepatocyte-restricted c-raf and rassf1a deletion 
do not influence macrophage classical activation in the liver during chemical carcinogenesis. 
Oval cells are not mobilised during early stages of liver carcinogenesis 
in c-rafΔhep mice 
Oval cells, liver progenitor cells able to differentiate into hepatocyte and cholangiocytes, 
might play role in development of HCC. At least in some carcinogenesis protocols, especially 
those accompanied by hepatocyte proliferation inhibition, oval cell expansion might be 
induced and lead to tumour development. Moreover, recently Hippo signalling pathway was 
implicated in maintaining quiescence of oval cells (Zheng, Wang et al. 2011), as mice with 
liver epithelial cell-restricted Nf2 or Mst kinases deficiency show expansion of liver 
progenitor cell compartment (Benhamouche, Curto et al. 2010; Lee, Lee et al. 2010; Lu, Li et 
al. 2010). Therefore, we decided to investigate whether increased number of tumours in c-
rafΔhep mice results from oval cell induction. 
Oval cells in normal liver reside in the vicinity of portal vein and similarly to bile duct 
epithelial cells express large amounts cytokeratins. We used immunohistochemistry for pan-
cytokeratins to visualise oval cells in c-raff/f and c-rafΔhep mice at 4 weeks of age, 5 days and 2 
weeks after DEN-treatment. In both genotypes we detect strong staining of bile ducts and 
some single positive cells around portal veins that presumably are oval cells (Figure 10A). We 
do not detect any change in abundance of cytokeratin-positive cells 5 days or 2 weeks after 
DEN-treatment. The amounts of cytokeratin-positive cells are similar in c-rafΔhep and c-raff/f 
mice. 
Recently novel antibodies with high specificity towards oval cells were generated using 
immunisation of animals with sera from rodents subjected to oval cell-chemical induction 
protocols (Dorrell, Erker et al. 2008). We applied one of these monoclonal antibodies, MIC1, 
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for immunohistochemistry on liver sections from c-raff/f and c-rafΔhep mice 8 weeks after 
DEN-injection. Again, we observed staining of bile ducts and single cells around portal veins, 
with no difference between c-rafΔhep and c-raff/f mice (Figure 10B). This indicates that during 
early stages of DEN-induced liver carcinogenesis proliferation of oval cells is generally not 
induced and c-raf deletion does not influence oval cell response in this system. 
alfp-cre transgene-specific effects on hepatocyte acute response to DEN 
c-rafΔhep mice have increased number of tumours that indicates more efficient cell 
transformation or increased survival of initially transformed cells. Apart from that, c-rafΔliv 
mice exhibit either increased or unchanged tumour number, depending whether c-raf deletion 
is induced before or after DEN-injection, respectively. Considering this, c-raf seems to play 
role during the tumour initiation. Therefore, we decided to investigate early metabolic 
response in the livers to DEN-treatment. 
DEN is a cytotoxic agent and causes extensive cell death of hepatocytes shortly after 
administration. This is followed by compensatory proliferation of surviving hepatocytes. 
Hepatocyte-metabolised form of DEN is able to form DNA-adducts and therefore is causing 
mutations in surviving hepatocytes that may lead to cellular transformation. 
We treated c-raff/f, c-rafΔhep, rassf1a-/-, double KO as well as WT and alfp-cre animals without 
floxed c-raf alleles with DEN and isolated livers after 48 hours. Extensive hepatocyte death 
was observed on similar level in c-rafΔhep and c-raff/f animals around central veins - site of 
metabolic DEN activation (Gabriele Maurer, unpublished data). Histochemical staining 
showed increased lipid accumulation around central veins in c-rafΔhep mice compared to c-
raff/f, as well as in double KO compared to rassf1a-/-, but also in alfp-cre animals compared to 
WT (Figure 11A). This indicates transgene-specific effect on metabolic response of 
hepatocyte to the DEN-treatment. 
We also observed compensatory proliferation of hepatocytes in response to DEN (Gabriele 
Maurer, unpublished data). This response is compromised in c-rafΔhep mice compared to c-
raff/f, as well as double KO compared to rassf1a-/-, but also alfp-cre animals compared to WT 
(Figure 11B-C). This indicates that not only lipid accumulation but also inhibition of 
compensatory proliferation after DEN-treatment can be attributed to alfp-cre transgene. 
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Acute effects of DEN-treatment on Hippo pathway activation  
Hippo signalling cascade regulates activity of liver proto-oncogene Yap by inhibiting its 
nuclear accumulation. Nuclear Yap can induce cell proliferation and inhibit apoptosis by 
modulating gene expression together with certain transcription factors in the nucleus. 
To investigate activity of Hippo signalling during acute response to DEN-treatment we 
performed immunohistochemistry for Yap on liver sections from c-raff/f, c-rafΔhep, rassf1a-/- 
and double KO animals without and 48 hours after DEN treatment. In untreated livers from 
mice of all investigated genotypes Yap is expressed mostly in the cytoplasm in centrilobular 
liver areas and on a lower level in the nuclei in periportal areas (Figure 12A). 48 hours after 
DEN-treatment we observe strong accumulation of Yap in nuclei around central veins to 
similar extent in mice of all investigated genotypes. Western blot analysis indicates that 48 
hours after DEN treatment there is no genotype-depending differences in total Yap amounts 
(Figure 12D). This indicates carcinogen-induced translocation of Yap from the cytoplasm to 
the cell nucleus of hepatocytes around central veins, probably as a result of Hippo pathway 
inhibition. This process as well as Yap expression is not affected by hepatocyte-restricted c-
raf or rassf1a ablation. 
To investigate even more acute effects of carcinogen-treatment on Hippo signalling in the 
hepatocyte we employed hepatocyte primary cultures. Hepatocytes from 3-4 months old male 
alfp-cre, c-rafΔhep and double KO animals were isolated with a 2-step perfusion method, 
plated on collagen-coated dishes and cultures in medium with serum and growth factors. 
Isolated cells compose homogenous population with morphological features resembling 
hepatocytes - they are bi-nucleated and relatively large (Figure 13A). 
Currently the exact ligands that specifically stimulate Hippo signalling in mammalian cells 
are not well established. In cells isolated from mouse HCCs activation of Mst kinases can be 
stimulated with H2O2 (Zhou, Conrad et al. 2009). H2O2 induces oxidative stress in cell 
culture, and in the liver ROS enhances tumorigenesis (Maeda, Kamata et al. 2005; Luedde, 
Beraza et al. 2007). Therefore we investigated the role of c-raf and rassf1a in Hippo pathway 
activation in response to oxidative stress in primary hepatocytes. After few days in culture we 
stimulated them with H2O2 for 20 minutes and harvested with Laemmli buffer to obtain 
protein lysate. Western blot analysis shows elevated YAP inhibitory phosphorylation on 
serine 112 (homologous site to human S127) after H2O2-treatment in cells of all investigated 
genotypes. Moreover, double KO hepatocytes show stronger Yap phosphorylation than alfp-
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cre or c-rafΔhep cells. Therefore H2O2-mediated oxidative stress induces Yap inhibitory 
phosphorylation in primary hepatocytes and this induction is increased in hepatocytes lacking 
both c-raf and rassf1a.  
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Figure 6. Rassf1a interacts genetically with C-Raf in chemical HCC model. 
(A) Gross liver morphology, (B) quantification of liver mass as a percentage of body weight, (C) H&E staining of 
paraffin-embedded liver sections and (D) quantification of tumour-affected area and number of nodules per 1cm2 of 
liver section from c-raff/f, c-rafΔhep, rassf1a-/- and c-rafΔhep;rassf1a-/- (double KO) male mice 30 weeks after DEN-
treatment; 
(E) Quantification of percentage of nodules classified on H&E-stained liver sections as foci of cellular alteration (FCA), 
adenoma (HCA) or carcinoma (HCC) from same animals as in A-D. Below numbers of mice with detected HCC per 
total numbers of mice analysed for each genotype; 
(F) Genotyping PCR for c-raf flox and Δ allele on DNA isolated from tumours of same animals as in A-E; (G) 
Genotyping PCR for rassf1a + and - allele on DNA isolated from tails from same animals as in A-E; 
Data in graphs is expressed as mean values; * - p-value<0,05 as calculated from two-tailed student t-test for samples 
of equal variation; # - p-value<0,05 as calculated from Fisher’s exact test; error bars - 95% confidence interval; 
Figures A-D with contribution of Zeynep Erdem and Martin Künzl; Figure E with contribution of Stratigoula Sakellariou;  
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Figure 7. In double KO livers proliferation is not increased during chemical carcinogenesis. 
(A) Immunohistochemical staining of Ki67 on paraffin-embedded liver sections - dashed line indicates border between 
unaffected and tumour (T) tissue - and (B) quantification of Ki67-positive cells per 1mm2 of tissue section in tumours 
and unaffected tissue from c-raff/f, c-rafΔhep, rassf1a-/- and double KO male mice 30 weeks after DEN-treatment; 
(C) TUNEL on paraffin-embedded liver sections (only unaffected tissue shown) and (D) quantification of TUNEL-
positive cells same as in A-B; 
Data in graphs is expressed as mean values; error bars - 95% confidence interval; * - p-value<0,05 as calculated from 
two-tailed student t-test for samples of equal variation; insets on images are 2x magnified; PV - portal vein; CV - 
central vein;  
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Figure 8. Signalling pathway activation in tumour-affected livers. 
Western blot analysis of protein lysates from liver tumour-unaffected and tumour tissue isolated from c-raff/f, c-rafΔhep, 
rassf1a-/- and double KO male mice 30 weeks after DEN-treatment. For MAPK signalling (A) total C-Raf, activatory 
Erk1 and 2 phosphorylation (T203/Y205 and T183/Y185), total Erk1 and 2 and tubulin as loading control were 
detected; For Hippo signalling (B) total Mst2, activatory Lats1 phosphorylation (S908), total Lats1, inhibitory Yap 
phosphorylation (S112), total Yap and actin as loading control were detected; For inflammatory signalling (C) 
activatory p38 phosphorylation (T180/Y182), total p38, total IκB and tubulin as loading control were detected; 
Figure A-C with contribution of Ines Jeric.  
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Figure 9. Macrophage number is increased in c-rafΔhep livers irrespectively of Rassf1a. 
(A) Immunohistochemical staining of F4/80 on paraffin-embedded liver sections, (B) quantification of F4/80-positive 
cells per 1mm2 of tissue section in tumour-unaffected tissue section from c-raff/f, c-rafΔhep, rassf1a-/- and double KO 
male mice 30 weeks after DEN-treatment; 
(C) Immunohistochemical staining of INOS and (D) quantification of F4/80-positive cells same as in A-B; (E) 
Immunohistochemical staining of INOS on liver section using antibody pre-incubated with neutralising peptide as 
negative control (left panel) and spleen section using standard procedure as positive control (right panel); 
Data in graphs is expressed as mean values; error bars - 95% confidence interval; * - p-value<0,05 as calculated from 
two-tailed student t-test for samples of equal variation; insets on images are 2x magnified; PV - portal vein;  
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Figure 10. Oval cells are not mobilised during early liver carcinogenesis in mice. 
(A) Immunohistochemical staining of pan-cytokeratins on paraffin-embedded liver sections from c-raff/f and c-rafΔhep 
mice without, 5 days after and 2 weeks after DEN-treatment; (B) Immunofluorescence of MIC1 on frozen liver-sections 
from mice of same genotypes as in A, 8 weeks after DEN-treatment and 4 weeks on Pb-containing fodder; (C) 
Immunofluorescence of MIC1 on frozen liver section without primary antibody as negative control; PV - portal vein;  
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Figure 11. alfp-cre transgene sensitises mouse liver to acute effects of DEN-treatment. 
(A) Histochemical staining of lipid droplets with OilRed on frozen liver sections from, c-raff/f, c-rafΔhep, rassf1a-/-, double 
KO, WT and alfp-cre mice 48 hours after DEN-treatment; 
(B) Immunohistochemical staining of Ki67 on paraffin-embedded liver sections and (C) quantification of Ki67-positive 
cells per 1mm2 of tissue section from same animals as in A; 
Data in graphs is expressed as mean values; error bars - 95% confidence interval; * - p-value<0,05 as calculated from 
two-tailed student t-test for samples of equal variation; insets on images are 2x magnified; PV - portal vein; CV -
central vein;  
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Figure 12. Yap nuclear accumulation in the liver shortly after DEN-treatment. 
Immunohistochemical staining of Yap on paraffin-embedded liver sections from c-raff/f, c-rafΔhep, rassf1a-/- and double 
KO animals (A) without and (B) 48 hours after DEN-treatment; (C) Immunohistochemical staining of Yap on paraffin-
embedded liver section without primary antibody; (D) Western blot analysis of Yap and actin (as loading control) in 
livers from c-raff/f, c-rafΔhep, double KO, rassf1a-/-, WT and alfp-cre mice 48 hours after treatment; 
Figure D with contribution of Ines Jeric.  
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Figure 13. Increased Hippo pathway activation in double KO primary hepatocytes in response to oxidative stress. 
(A) Phase contrast images of alfp-cre, c-rafΔhep and double KO primary hepatocytes; (B) Western blot analysis of 
inhibitory Yap phosphorylation (S112), total Yap and actin (as loading control) in lysates of primary hepatocytes 
without and after H2O2-treatment (0,5mM for 20’); for c-rafΔhep and double KO genotypes cells were isolated from 2 
different mice; numbers below p-Yap blot indicate band intensity relative to the first lane; 
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Discussion 
Tumour suppressive function of C-Raf in the liver 
Chemical liver carcinogenesis in mice deficient for C-Raf in parenchymal cells of the liver 
results in enhanced tumorigenesis (Figure 4A-D, 5C-D). This indicates surprising, not 
reported to date tumour suppressive role of C-Raf in the liver. C-Raf is one of 3 kinases of the 
first tier of the MAPK pathway core, involved in mediating proliferative and survival 
signalling in the cell. Many members of this pathway as well as upstream activators are 
therefore aberrantly activated in various cancers (Dhillon, Hagan et al. 2007; Roberts and Der 
2007), HCC in particular (Whittaker, Marais et al. 2010). C-Raf is overexpressed in the 
tumours of HCC patients (Hwang, Choi et al. 2004) and sorafenib, broad-specificity kinase 
inhibitor designed primarily against C-Raf, is already admitted in Europe for treatment of 
patients with HCC (Llovet, Ricci et al. 2008). 
On the other hand, it was suggested that main mediator of MAPK signalling in the cell is not 
C-Raf, but rather B-Raf, due to higher kinase activity of the latter (Emuss, Garnett et al. 2005) 
what is also the reason for rare C-Raf mutations in cancer in general. Moreover, work done 
mostly in our laboratory indicates that the main function of C-Raf in vivo is not the 
stimulation of Mek-Erk axis - quite the opposite - C-Raf is actually dispensable for Erk 
activation in many investigated cell types (Yamaguchi, Watanabe et al. 2004; Ehrenreiter, 
Piazzolla et al. 2005; Ehrenreiter, Kern et al. 2009) and (Reiner Wimmer, unpublished data). 
Therefore it is possible that the oncogenic signalling transmitted by the MAPK pathway is 
still mediated in the C-Raf deficient hepatocyte by B-Raf and could be investigated by 
western blotting for activatory phosphorylation sites on B-Raf. In such case role of C-Raf in 
the activation of Erk would be secondary, after its previously not described tumour 
suppressive role in the liver. 
Most of the in vivo functions of C-Raf can be performed independently of its kinase activity 
and depend on its interaction and direct inhibition of Rock-2 kinase (Niault, Sobczak et al. 
2009). Rho-Rock axis plays oncogenic roles in HCC (Xue, Krasnitz et al. 2008; Wong, Wong 
et al. 2009), mainly during progression by regulating migratory capabilities of cells (Itoh, 
Yoshioka et al. 1999; Yoshioka, Nakamori et al. 1999), EMT (Chen, Yuan et al. 2011) and 
secretion of MMPs (Xue, Takahara et al. 2008). Therefore it is possible that C-Raf deficiency 
in the hepatocyte leads to hyperactivation of Rock-2 what could facilitate transformation. This 
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could be investigated by probing phosphorylation status of direct Rock-2 targets like coffilin 
and myosin light chain phosphatase. 
Furthermore, recently it was shown that upstream positive regulator of MAPK signalling, 
Shp2 phosphatase, might also play tumour suppressive functions in spontaneous and 
chemically-induced liver cancer, what is associated with decreased Erk but increased Stat3 
activation (Bard-Chapeau, Li et al. 2011). Therefore mouse disease models begin to unravel 
previously unexpected roles of MAPK signalling in tumour suppression. This role might 
depend on inflammatory pathways inhibition, crucial for the development of HCC and maybe 
even more important than classical pro-proliferative circuits like RAF-MEK-ERK. 
Suppression of HCC initiation by C-Raf 
Deletion of C-Raf in the parenchymal cells leads to increased number of tumours after 
chemical liver carcinogenesis (Figure 4C-D), what suggests that frequency of transformation 
of C-Raf-deficient hepatocytes is increased. Consistent with this notion, when using inducible 
mx-cre system, C-Raf ablation before, but not shortly after carcinogen administration, leads to 
increased tumour number in the C-Raf-deficient livers (Figure 5A-H). Therefore C-Raf 
performs its tumour suppressive function in the hepatocyte during tumour initiation. 
Acute effect of DEN-treatment can be divided into cytotoxic and genotoxic. DEN activation 
in the centrilobular hepatocytes causes their extensive death that in turn stimulates 
compensatory proliferation of periportal hepatocytes. Activated DEN also forms DNA-
adducts introducing mutations in the hepatocyte genome that might be carcinogenic and lead 
to cellular transformation (Verna, Whysner et al. 1996). Theoretically each of these processes 
might be affected by C-Raf ablation. By participating in the activation of Erk, C-Raf might 
drive compensatory proliferation, and by inhibiting extrinsic (Piazzolla, Meissl et al. 2005; 
Galabova-Kovacs, Kolbus et al. 2006; Matallanas, Romano et al. 2007) or intrinsic apoptosis 
(Kebache, Ash et al. 2007; Polzien, Baljuls et al. 2009) it might restrict cell death. Apoptosis 
in the C-Raf-deficient hepatocytes is not affected shortly after DEN-administration (Gabriele 
Maurer, unpublished data), and compensatory proliferation is affected only by the presence of 
alfp-cre transgene, but not by the C-Raf ablation (Figure 11B). Similarly DNA damage, Tp53 
induction, DNA-adduct formation and DNA-damage seem also not to be affected by C-Raf-
deficiency during tumour initiation (Gabriele Maurer, unpublished data). Proteomic analysis 
of tissue after 30 weeks of chemical tumorigenesis revealed lower expression of liver 
carboxylesterase, enzyme involved in detoxification of xenobiotics (Gabriele Maurer, 
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unpublished data). This leaves open the possibility that C-Raf regulates expression of 
enzymes that could limit the amount toxic stress during DEN-challenge and in this way 
restrict the amount of initiated hepatocytes. 
Hepatocellular carcinoma is a disease with a poor survival rate, mainly because it is most 
often detected in an advanced stage, when most available therapies, based on the local 
intervention, are unhelpful. Classical systemic chemotherapies are not beneficial for the 
patients with spread-out HCC and recently approved sorafenib treatment is very expensive 
and rather stabilises then cures the disease. Therefore the improvement in detecting early 
HCC and therapeutic intervention at this stage could improve patient health (Ferenci, Fried et 
al. 2010). Our results on the role of C-Raf in mouse liver carcinogenesis indicate that it might 
be important for the early events in HCC development. 
Lack of C-Raf role in HCC maintenance and progression 
Deletion of C-Raf in the mouse livers after development of macroscopic nodules did neither 
affect their maintenance nor progression (Figure 5E-K). Therefore we exclude possibility that 
DEN-induced HCC in mice is dependent on the presence of C-Raf. This is in contrast to the 
situation in Ras-induced epidermal tumours, where C-Raf is required for tumour maintenance 
(Ehrenreiter, Kern et al. 2009). In the skin keratinocytes undergo divisions only in the vicinity 
of the epithelium basal membrane. During their move to the more outer layers of epidermis 
they lose the ability to proliferate, and terminally differentiate, what is regulated by Rock-2 
kinase (McMullan, Lax et al. 2003). The hepatocytes, although mostly quiescent in the adult 
organism, retain throughout their lifetime possibility to re-enter cell cycle, for instance in the 
case of extensive liver injury. Furthermore, the role of Rock-2 in hepatocyte differentiation 
has not been investigated, but its role in hepatocyte malignant conversion is well established 
(Grise, Bidaud et al. 2009). Therefore Rho-Rock axis in the liver seems to fulfil very different 
functions than in the skin, although in the latter it was also shown to be hyperactivated during 
squamous cell carcinoma development (Grossi, Hiou-Feige et al. 2005; Lefort, Mandinova et 
al. 2007). Anyways, even if C-Raf is also modulating Rock-2 activity in the hepatocyte, 
influence of C-Raf ablation on that process might lead to different responses depending on 
which function of Rock-2 C-Raf modulates in a certain cell type. 
In the clinic, use of sorafenib appeared to be beneficial for patients with advanced HCC. Still, 
it is likely, that its primary target in this setting is not C-Raf, but rather RTKs that mediate 
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angiogenic signalling (Liu, Cao et al. 2006). Our results support the notion that C-Raf activity 
is not required for maintenance and progression of HCC. 
Genetic interaction of C-Raf and Rassf1a in chemically-induced HCC 
Deletion of c-raf in the hepatocyte in the WT, but not in the rassf1a-/- mice, leads to enhanced 
liver tumorigenesis (Figure 6A-D). Therefore rassf1a-deletion modifies hepatocyte-restricted 
c-raf-deletion phenotype, what indicates possible genetic interaction between these two genes 
and function of their products in the same pathway. Indeed, RASSF1A and C-RAF are both 
binding to pro-apoptotic kinase MST2 (O'Neill 2004; Guo, Tommasi et al. 2007), with C-
RAF inhibiting its activity and RASSF1A relieving it from the inhibitory complex upon 
apoptotic stimuli (Matallanas, Romano et al. 2007). Therefore published biochemical data on 
in vitro mammalian cell cultures indicates that RASSF1A is upstream of C-RAF in the 
MST2-activation sequence. But our results indicate that, if in the mouse liver C-Raf and 
Rassf1a regulate tumorigenesis on the same pathway in the cell, Rassf1a is rather downstream 
of C-Raf, as it is required for manifestation of c-raf-deletion phenotype. 
As c-raf-deletion leads to increased tumorigenesis in the liver in the Rassf1a-dependent 
manner, it suggests that Rassf1a plays oncogenic role in the hepatocyte that is neutralised by 
C-Raf. How Rassf1a could perform this oncogenic role in the hepatocyte is rather enigmatic, 
especially taking into consideration its tumour suppressive role in various other settings 
(Tommasi, Dammann et al. 2005; van der Weyden, Arends et al. 2008) and epigenetic 
silencing of its gene in many cancers (Dammann, Schagdarsurengin et al. 2003), including 
HCC (Dammann, Schagdarsurengin et al. 2003). One possible explanation is that proposed C-
Raf-tumour suppressive control over Rassf1a plays role only during tumour initiation, and 
during advanced disease stages both proteins could perform other roles. In fact the published 
data about Rassf1a silencing in human HCC is derived from resected tumours, most likely 
advanced hepatocellular carcinomas. In our studies most observed nodules were benign foci 
of cellular alteration or adenomas, and hepatocellular carcinomas were minority. Therefore 
even if Rassf1a loss had given growth advantage to the advanced liver tumours, to observe 
this in our system we would have to allow for the further tumour progression and sacrifice our 
experimental animal after longer period of carcinogenic treatment. Interestingly, rassf1a-/- 
mice had more often HCC nodules than WT mice (Figure 6E), suggesting that indeed Rassf1a 
loss may promote liver tumour progression. 
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MST signalling cascade restricts liver tumourigenesis in mice (Zhou, Conrad et al. 2009). In 
mammalian cells RASSF1A was shown interact with WW45 and together induce MST2 
activity (Guo, Tommasi et al. 2007). But in drosophila, dRassf protein rather inhibits activity 
of MST homologue (Polesello, Huelsmann et al. 2006), Hippo, by displacing it from the 
activatory complex with Sav (WW45 homologue). dRassf is able to do that as it contains 
evolutionarily conserved SARAH domain that is also present in the sequence of Sav and 
Hippo, and is mediating direct interactions between these 3 proteins (Hwang, Ryu et al. 
2007). Therefore it would be interesting to check in hepatocytes the activity of MST in 
complexes with RASSF1A and WW45. 
In our double knock-out studies we combined hepatocyte-restricted deletion of c-raf with 
conventional, germline deletion of rassf1a. Carcinogenesis depends not only on 
characteristics of tumour cells, but also their microenvironment composed of various cell 
types of tumour stroma, vasculature and various inflammatory cells (Hanahan and Weinberg 
2011). Therefore we cannot exclude the possibility, that the modification of hepatocyte-
restricted c-raf deletion phenotype on rassf1a-/- background is a result of function impairment 
of some other cell than hepatocyte. For instance Mst1 kinase restricts naïve T-cell 
proliferation and cell polarisation upon T-cell receptor ligation, what is regulated by close 
Rassf1 orthologue Nore1B/Rassf5/Rapl (Katagiri, Imamura et al. 2006; Zhou, Medoff et al. 
2008). T-cells are present among non-parenchymal liver cells and might influence 
tumorigenesis either directly by lysing transformed cells and stimulating them with cytokines 
or indirectly by educating macrophages and activating B-cells (Grivennikov, Greten et al. 
2010). Therefore it would be interesting to investigate lymphocyte numbers and their 
activation in livers of rassf1a KO mice. To determine the exact cell type in which Rassf1a 
performs its role in modifying c-raf-ablation phenotype it would be necessary to apply 
conditional ablation if its gene in specified cell types. 
Influence of C-Raf and Rassf1a on proliferation and inflammation in 
livers with induced HCC 
Neither C-Raf, nor Rassf1a, nor the deletion of both does influence apoptosis in tumours or 
tumour unaffected tissue (Figure 7C-D). This is very surprising result taking into 
consideration role of both proteins in the regulation of apoptotic pathways. C-Raf can 
counteract apoptosis by inhibiting activation of Mst2 (O'Neill, Rushworth et al. 2004), Ask-1 
(Chen, Fujii et al. 2001) or Rock-2 that regulates availability of Fas receptor on cell surface 
(Piazzolla, Meissl et al. 2005). Rassf1a also binds to and regulates activity of Mst2 (Guo, 
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Tommasi et al. 2007; Matallanas, Romano et al. 2007), and moreover can modulate activation 
of Bcl-2-family protein Bax in response to Fas stimulation (Baksh, Tommasi et al. 2005). 
Nevertheless, regulation of these pathways by C-Raf and Rassf1a seems not to be important 
for survival of hepatocytes during chemical liver carcinogenesis, at least in the livers 30 
weeks after carcinogen treatment. 
Deletion of c-raf in hepatocytes leads to increased proliferation in tumour-unaffected tissue, 
and concomitant deletion of rassf1a attenuates this phenotype. We did not detect any 
differences in proliferation in the tumour tissue (Figure 7A-B). Therefore c-raf-deficient 
hepatocytes seem to have increased proliferative potential before transformation, what is not 
the case for double KO hepatocytes. It has been suggested that out of many initiated cells only 
a fraction is surviving long enough to form stable neoplastic foci (Boucher and Yakovlev 
1997). Taking this into consideration it is possible that higher proliferative potential of c-raf-
deficient untransformed hepatocytes allows them for more efficient formation of stable 
neoplastic foci shortly after acquiring oncogenic mutations induced by DEN. This could lead 
to increased number of nodules that we observe at later stages of carcinogenesis. The reason 
for the increased proliferation in c-rafΔhep mice is not clear, but it might be a consequence of 
increased numbers of inflammatory cells in the liver (Figure 9A-B). In the livers of double 
KO mice, where proliferation is not increased, there is also higher number of inflammatory 
cells. But the activation of MAPK pathway is decreased and Lats activation is increased 
(Figure 8A-B), what could explain attenuated proliferative capacity in double KO livers. 
Decreased activation of Erk would lead to lower activation of transcription of pro-
proliferative genes. Increased activity of Lats can either inhibit activity of Yap transcriptional 
activity on promoters of pro-proliferative genes like cyclin D1. If in the liver activated Lats 
would not primarily target Yap, as it recently was suggested (Zhou, Conrad et al. 2009), it 
might also regulate activity of Tp53 tumour suppressor through phosphorylation of its partner 
ASPP1 (Aylon, Ofir-Rosenfeld et al. 2010). 
In the livers of c-rafΔhep mice we detect increased numbers of Kupffer cells that is also the 
case in double KO livers compared to rassf1a-/- (Figure 9A-B). Kupffer cells (KC) can either 
proliferate in the liver or be derived from circulating mononuclear cells (Burt, Portmann et al. 
2007). It would be interesting to investigate whether the increased numbers of KCs in c-
rafΔhep and double KO livers result from their enhanced proliferation in the liver or increased 
recruitment of monocytes from the circulation. In first case the double staining for 
proliferation markers like Ki67, PCNA, or injected BrdU with markers of macrophages 
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(F4/80, CD68) could be performed. To investigate the migration one could reconstitute 
lethally irradiated mice with labelled, for instance with fluorescent protein, bone marrow and 
investigate recruitment of label-positive cells to the liver. Interesting is also what factors from 
the C-Raf-deficient hepatocytes do affect KC abundance in the liver. One of the candidates 
would be CCL2/MCP1, cytokine attracting macrophages. It might be that its expression in the 
c-raf-deficient hepatocyte is perturbed. 
Irrespective of the factor that induces increased proliferation or recruitment of macrophages to 
the livers with c-raf ablated in the hepatocytes, increased number of KCs in these animals can 
have tumour promoting role. KCs are drivers of inflammatory responses in the liver and 
respond with cytokine production to the tissue damage by sensing factors released by dying 
hepatocytes (Sakurai, He et al. 2008). They are able to secrete Il-6 and TNF-α that can 
stimulate proliferation of hepatocytes and contribute to their neoplastic transformation 
(Maeda, Kamata et al. 2005). In fact, livers of mx-cre;c-raff/f animals, that have increased 
numbers of tumours (Figure 5A-D), but are not as much more affected by the disease in 
comparison to livers from WT animals as are alfp-cre;c-raff/f (Figure 4A-D), do not exhibit 
increased macrophage numbers (Gabriele Maurer, unpublished data). This also indicates that 
opposite to its role in the hepatocyte, C-Raf might have tumour promoting role in 
macrophages. To determine this one could apply macrophage-specific c-raf ablation with the 
help of LysMCre mouse line (Clausen, Burkhardt et al. 1999). 
Classical activation of Kupffer cells is very limited in the livers of our experimental animals - 
we detected only 20-50 times less cells positive for classical macrophage marker, inducible 
nitric oxide synthase, as we did for general macrophage marker, F4/80 (Figure 9C-D). 
Classical macrophage activation is in general thought to have anti-tumour effects, by inducing 
their direct cytotoxicity towards transformed cells (Biswas and Mantovani 2010). On the other 
hand liver cancer development is largely dependent on inflammation that classically activated 
macrophages are supporting by secretion of pro-inflammatory cytokines. It might be that 
macrophages present in the tumour affected livers exhibit alternative activation type, that is 
more associated with tissue remodelling and might drive tumour promotion (Gordon and 
Martinez 2010). Therefore it would be also interesting to investigate expression of markers of 
other macrophage activation types in tumour-affected livers. 
In the tumour unaffected tissue activation of Erk is decreased in the livers from double KO 
animals (Figure 8A). Although C-Raf is able to activate Erk through Mek, in most tissues it is 
PHD THESIS BARTOSZ TARKOWSKI        
80 | P a g e  
not required for Erk activation. In this view it is not surprising that Erk activation is not 
affected in c-rafΔhep hepatocytes. But the decrease in Erk phosphorylation in the livers of 
double KO animals is not easily explainable. Rassf1a is a putative Ras effector as it contains 
Ras-association domain, but detailed investigations raise doubts about Rassf1a binding to any 
of Ras proteins under physiological conditions (Ortiz-Vega, Khokhlatchev et al. 2002). 
Nevertheless, the decrease in Erk activation in the livers of the double KO animals could 
explain attenuation of increased proliferation in comparison to the C-Raf-deficient 
hepatocytes. 
Yap protein phosphorylation is not affected in any of investigated genotypes, contrary to what 
we initially expected by genetically manipulating upstream regulators of Mst kinase. Yap 
phosphorylation induces change in its nuclear localisation but also induces proteasome-
mediated degradation (Zhao, Li et al. 2010). Therefore it is possible that Yap phosphorylation 
status that we observe in the livers after carcinogenesis is just a snapshot resulting from 
continuous degradation of its phosphorylated form. In such case, even if the activity of Yap 
kinases is affected by C-Raf or Rassf1a ablation, we might not be able to observe it at steady 
state. In fact we observe increased level of Yap in unaffected and tumour affected tissue of c-
rafΔhep and double KO mice, so wherever C-Raf is absent (Figure 8B). C-RAF is directly 
inhibiting MST2 kinase in vitro, what should lead to decreased YAP phosphorylation and 
increased stability. Therefore it seems surprising that ablation of C-Raf leads to increased 
expression of Yap in mouse livers and might be a result of some other mechanism. It would 
be therefore interesting to investigate Yap stability in c-raf-deficient hepatocytes, for instance 
in cycloheximide-treated cells, but also expression of Yap-encoding gene by investigating 
abundance of its mRNA transcript.  
Double KO animals have also decreased activation of Lats1 kinase in the liver that also could 
contribute to the attenuation of proliferation increase resulting from c-raf-ablation in the 
hepatocyte (Figure 8C). Classically Lats kinases are considered primary Mst targets, but 
recent reports indicate that this view might hold true only for mouse embryonic fibroblast in 
vitro cultures. In the liver Lats activation is not dependent on Mst kinases, and also Lats 
kinases are not mediating phosphorylation of primary Hippo pathway target, Yap in response 
to Mst activity (Zhou, Conrad et al. 2009). Recently Lats kinases 1 and 2 were shown to 
interact with ASPP1 protein, regulator of TP53 activity, and be decoupled by ASPP1 from 
Yap (Vigneron, Ludwig et al. 2010), or induce through ASPP1 TP53 proapoptotic activity 
(Aylon, Ofir-Rosenfeld et al. 2010). This suggests the possibility that increased 
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phosphorylation/activation of Lats in the livers of double KO mice might lead to increased 
activity of Tp53. It would therefore be interesting to check the Tp53 stability, localisation and 
expression of its target genes in the livers of double KO animals. 
Finally, we also observe decreased phosphorylation of p38 stress kinase in tumour unaffected 
tissue from double KO animals (Figure 8C). p38 is a MAPK activated in response to various 
stress stimuli and it plays tumour suppressive role in various cancers (Hui, Bakiri et al. 2007), 
including HCC (Hui, Bakiri et al. 2007). It is therefore surprising to see its lower activation in 
tissue of double KO animals, where tumorigenesis is compromised to WT levels. Recently it 
has been suggested that MST mutants that cannot be phosphorylated by AKT associate more 
with RASSF1A and induce p38 phosphorylation (Romano, Matallanas et al. 2010). It is then 
possible that lack of Rassf1a in our livers decreases activity of Mst towards p38, but why the 
deletion of C-Raf is also required for that to happen, is rather enigmatic. 
Effects of C-Raf, Rassf1a and alfp-cre transgene on DEN acute effects in 
the liver 
By using labelling for markers of oval cell, the liver stem cells, we could see no induction of 
this progenitor compartment 5 days, 2 weeks and 8 weeks after DEN administration (Figure 
10A-B). Oval cells can be induced with various chemical treatments in rodents, but their 
induction after DEN or phenobarbital treatment was reported only once (He, Smith et al. 
1994). DEN causes extensive liver damage, hepatocyte death and subsequent compensatory 
proliferation. Therefore the protocol itself is not inhibiting proliferation of hepatocytes, 
condition in which the induction of liver progenitors compartment is usually observed. On the 
other hand Hippo pathway was recently shown to limit expansion of liver progenitor 
compartment and in this way suppress tumorigenesis in this organ (Lee, Lee et al. 2010; Lu, 
Li et al. 2010). Nevertheless, in our protocols cells with markers expressed on oval cells were 
limited to the proximity of portal triads and their number was affected neither at any 
timepoints nor in the livers of the animals with any investigated genotype. 
All mice with alfp-cre transgene have increased lipid accumulation (steatosis) in response to 
the DEN-treatment, irrespectively of the status of c-raf or rassf1a gene (Figure 11A). Liver 
steatosis can inhibit proliferation of hepatocytes (Vetelainen, van Vliet et al. 2007) and indeed 
in our system, mice with alfp-cre transgene have inhibited compensatory proliferation 
response irrespectively of c-raf or rassf1a deletion (Figure 11B-C). Integration site of alfp-cre 
transgene within mouse genome has not been mapped so far and it is possible that it disrupts 
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some gene or regulatory element responsible for this metabolic phenotype. Furthermore it was 
shown that prolonged expression of Cre recombinase in cells, including hepatocytes, may 
have genotoxic effects (Loonstra, Vooijs et al. 2001; Takami, Kaposi-Novak et al. 2007). 
Nevertheless, effects of the Cre recombinase might be pleiotropic and difficult to predict, and 
therefore it is advisable to control the experiments that employ Cre recombinases with Cre-
positive, flox-negative animals instead of only Cre-negative littermates. It would be also 
interesting to check the site of the alfp-cre transgene integration that might help to gain some 
insight into other defects this strain might exhibit. 
Yap expression seems to be zonated in the liver, with higher expression and cytoplasmic 
localisation in the centrilobular areas and lower, nuclear expression in the periportal areas. 
Main regulator of liver zonation that determines different function of centrilobular and 
periportal hepatocytes is Wnt-β-catenin pathway (Benhamouche, Decaens et al. 2006). Wnt-
β-catenin pathway activity is regulated by proteasomal degradation of β-catenin triggered by 
ubiquitylation directed by β-TRCP protein. Lately, β-TRCP was found to recognise and direct 
for ubiquitylation also phosphorylated Yap, adding additional inhibitory mechanism on top of 
its cytoplasmic retention. It is also remarkable, that uncontrollable activation of β-catenin 
(Colnot, Decaens et al. 2004) and Yap (Camargo, Gokhale et al. 2007; Dong, Feldmann et al. 
2007) in mouse liver both lead to similar phenotype - hepatomegaly and subsequent HCC 
development. It is interesting whether Yap also participates in the zonation of the liver 
especially taking into consideration recent reports about YAP responding to β-catenin-
mediated contact inhibition signals from E-cadherin (Kim, Koh et al. 2011), controlling heart 
size by co-regulating expression of same genes as β-catenin, (Heallen, Zhang et al. 2011) and 
reports about TAZ inhibiting β-catenin signalling by hindering phosphorylation of DVL 
(Varelas, Miller et al. 2010). Carcinogen administration induces Yap nuclear translocation, 
which indicates its activation, in liver centrilobular areas (Figure 12B). The nuclear 
accumulation or amounts of total Yap are not affected by the deletion of the investigated 
genes (Figure 12B-D). This indicates that Yap activity is induced during compensatory 
proliferation after tissue injury caused by carcinogen, and might regulate hepatocyte survival 
and proliferation during that stage, but this is most likely not regulated by C-Raf or Rassf1a. 
Primary hepatocytes react to the oxidative stress with the enhanced phosphorylation of Yap 
that is higher in double KO hepatocytes. Oxidative stress induced by addition of H2O2 in 
tumour-derived hepatocyte cell culture was previously shown to induce activation of Mst 
kinases, phosphorylation of Lats and Yap (Zhou, Conrad et al. 2009). Increased Yap 
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phosphorylation in the absence of Rassf1a and C-Raf compared to C-Raf-ablation alone 
indicates that in the hepatocyte, opposite to what it does in cell lines (Matallanas, Romano et 
al. 2007) and similarly to drosophila dRassf (Polesello, Huelsmann et al. 2006), Rassf1a 
might act as Mst inhibitor. Increased oxidative stress is associated with and required for 
efficient liver tumorigenesis in mice (Sakurai, He et al. 2008; He, Yu et al. 2010). Therefore 
by negatively influencing, in the condition of oxidative stress, activation of Mst kinases that 
are crucial for the tumour suppression in the liver, Rassf1a might act as a proto-oncogene in 
this organ. 
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Materials and methods 
Mouse handling and maintenance 
Mice of all strains were kept in SPF animal facility. They were mated from 6 weeks of age on; 
pups were marked by toe-clip on 10th day after birth and weaned on 20th day after birth. 
Mouse strains 
Following strains have been used in experiments: 
• 129/Sv c-raff/f - pure 129/Sv background mice with floxed exon 3 of c-raf gene (Mikula, 
Schreiber et al. 2001). 
• 129/Sv alfp-cre+ - pure 129/Sv background mice with alfp-cre transgene (Kellendonk, Opherk 
et al. 2000). 
• 129/Sv mx-cre+ - pure 129/Sv background mice with mx-cre transgene (Kuhn, Schwenk et al. 
1995). Expression of Cre recombinase was induced by injecting mice intraperitoneally with 
13µg per g body weight poly(I:C) diluted in sterile PBS 2g/l (Cat. No. 27-4732-01 Amersham, 
GE Healthcare, Waukesha, US). 
• 129/B6 rassf1a-/- - mixed 129/Sv-C57BL/6 background mice with a germline disruption of 
exon 1α of rassf1 gene (Tommasi, Dammann et al. 2005). 
DNA methods 
DNA isolation 
Either tail or liver ~2-5µg tissue fragment was digested in 100µl of Direct PCR lysis reagent 
(Cat. No. 31-102-T, Viagen Biotech, LA, US) with 200µg/ml Proteinase K (Cat. No. P6556, 
Sigma) overnight at 55°C, followed by enzyme inactivation for 45’ at 85°C. 
PCR genotyping 
For all PCRs crude tissue lysate was used. All primer stocks were diluted in water at 100nM 
concentration. After PCR whole reaction mixture was run 40’ at 100V together with DNA 
marker (Cat. No. SM1331, Fermentas/Thermo, Waltham, US) on 2% agarose gel prepared 
with TAE buffer and ethidium bromide, and visualised under UV light. 
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Following PCR protocols were used: 
c-raf 
Mastermix - µl per reaction:  PCR Program  Primers: 
2x PCR RedMix 12,5  98°C 30”   MPXR1: 5’-tgt gcc ctt gga acc tca gca c-3’ 
Primer MPXR1 0,125  98°C 10”   MPXR2: 5’-aca acg aga tag atg agg aaa gca-3’ 
Primer MPXR2 0,125  65°C 30” 30 cycles  MPXR3D: 5’-cac tga aat gaa aac gtg aag acg-3’ 
Primer MPXR3D 0,125  72°C 45”    
H2O 9,625  72°C 1’   Products: 
DNA 2,5  21°C inf.   WT: ~280bp (primers R1 and R2) 
TOTAL: 25      flox: ~330bp (primers R1 and R2) 
        - or Δ: ~450bp (primers R2 and R3D) 
cre 
Mastermix - µl per reaction:  PCR Program  Primers: 
2x PCR RedMix 12,5  98°C 30”   MPXC1: 5'-ctg cca cga cca agt gac agc a-3’ 
Primer MPXC1 0,125  98°C 10”   MPXC2: 5'-gcc aga tta cgt ata tcc tgg ca-3’ 
Primer MPXC2 0,125  65°C 30” 30 cycles   
H2O 9,75  72°C 45”   Products: 
DNA 2,5  72°C 1’   +: ~180bp (primers C1 and C2) 
TOTAL: 25  21°C inf.   - : no product 
rassf1a 
Mastermix - µl per reaction:  PCR Program  Primers: 
2x PCR RedMix 12,5  95°C 4’   UMIOAI: 5’-ttg tgc cgt gcc ccg ccc a-3’ 
Primer UMIOAI 0,025  63°C 1’ 2 cycles  LMIIAA: 5’-tga cca gcc ctc cac tgc cgc-3’ 
Primer LMIIAA 0,025  72°C 1’   Neo48U: 5’-ggg cca gct cat tcc tcc cac-3’ 
Primer Neo48U 0,025  95°C 1’    
H2O 9,925  63°C 1’ 33 cycles  Products: 
DNA 2,5  72°C 2’   WT: 520 bp 
TOTAL: 25  72°C 10’   KO: 380 bp 
   21°C inf.    
Chemical liver carcinogenesis 
1g of DEN (Cat. No. N0258, Sigma) was diluted 1:9 in 0,9% NaCl to obtain stock solution 
and stored at RT protected from light up to 4 months. Before the injection the stock was 
diluted again 1:9 in 0,9% NaCl to obtain working solution. 
4 weeks old male mice (±2 days) were injected intraperitoneally with working solution of 
DEN (100µg per g body weight). At 8 weeks of age (±2 days) normal fodder was exchanged 
for the one supplemented with 0,07% phenobarbital (Ssniff, Soest, DE) and mice were kept 
on it until they were euthanized. 
Liver isolation and liver sample collection 
Mice were weight and euthanized by cervical dislocation, peritoneal cavities were opened by 
V-incision, gall bladders were removed, livers were separated from diaphragm, removed from 
the body and washed in ice-cold PBS. After brief drying on paper towel, livers were 
photographed, weight and separated to single lobes. Big liver lobes were fixed in PFA and 
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embedded in paraffin; single smaller lobes were snap-frozen in TissueTek O.C.T. compound 
(Cat. No. 4583, Sakura, Alphen aan den Rijn, NL) for cryo-block, and from the rest of the 
tissue tumours were separated from tumour-unaffected tissue and tumour pools, single 
tumours and tumour unaffected tissues were snap-frozen for DNA and protein analysis. 
Histology 
Stainings on paraffin-embedded liver sections 
After isolation big liver lobes were cut into 2 or 3 pieces for better penetration with the 
fixative and fixed overnight at 4°C in 4% PFA in PBS, following by 2x wash with PBS and 
1x with EtOH 70%. After that they were dehydrated and paraffinised in Shandon Excelsior 
tissue processor (Thermo) by incubating 1x in each 70, 80, 90 and 96% EtOH; 3x in 100% 
EtOH; 3x in xylene (each for 1h); and 3x in wax at 55°C (each for 1h20’). Paraffinised tissue 
was embedded in paraffin blocks. 
Paraffin embed-livers were cut on the microtome into 5µm-thick sections, straighten in water 
bath set to 45°C, transferred on coated microscope support slides (Cat. No. J4800AMNZ, 
Thermo) and allowed to dry and adhere overnight at 45°C. 
H&E staining 
Paraffin-embed liver sections were stained with hematoxylin and eosin with the help of ASS-
1 staining unit (Pathisto, Georgsmarienhütte, DE), by incubating slides with liver sections in 
the following solutions: 
 2x 10’ in xylene substitute 
 2x 5’ in 100% EtOH 
 2’ in 90% EtOH 
 2’ in 70% EtOH 
 2’ in H2O 
 6’ in hematoxylin 
 10’ in H20 
 5’’ in 0,37% HCl in EtOH 
 10’ in H2O 
 30” in 70% EtOH 
 30” in 80% EtOH 
 2” in eosin solution 
 2x 1’ in 90% EtOH 
 2x 1’ in 100% EtOH 
 2x 5’ in xylene substitute 
 Wash with xylene and mounting with entellan 
Immunohistochemistry 
General protocol 
Wash buffers: 
• TBST: 10mM Tris-HCl, 150mM NaCl, Ph 7,4, Tween-20 0,1%; 
• PBS: 9,1mM dibasic sodium phosphate, 1,7mM monobasic sodium phosphate, 150mM NaCl, 
pH 7,4; 
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Deparaffinisation: Slides were incubated 2x for 10’ in xylene, 2x 10’ in 100% EtOH, 2x 5’ 
in 90% EtOH and 2x 5’ in ddH2O. 
Endogenous peroxidase blocking: Slides were incubated in 1 or 3% H2O2 in either ddH2O 
or ddH2O: methanol 1:1 mixture or pure methanol and washed 2x 5’ with ddH2O. 
Antigen unmasking: 
• Heat-mediated: Slides in antigen unmasking solution were brought to boil in microwave and 
kept in steam cooker in sub-boiling temperature, cooled down at room temperature and 
washed 3x 5’ with wash buffer; 
citrate buffer: 10 mM sodium citrate, pH to 6.0; 
basic antigen unmasking solution: 10mM Tris-base, 1mM EGTA; 0,05% Tween-20, pH 9,0; 
• Proteolytic: slides were incubated in one of the following solutions in indicated conditions and 
washed 3x 5’ with wash buffer: 
Proteinase K: 20ug/ml in 10mM Tris-HCl in 37°C; 
Protease type XIV (Cat. No. P5147, Sigma): 0,5mg/ml in PBS 8’ at room temperature; 
Protein blocking: Slides were blocked in diluted in wash buffer serum from the species that 
secondary antibody was raised in. 
Primary antibody: Slides were incubated with primary antibody and washed 3x 5’ in wash 
buffer. 
Secondary antibody: Slides were incubated for 30’ at room temperature: 
• with HRP polymer-conjugated anti-rabbit secondary antibody solution (Cat. No. K4003, 
Dako, Glostrup, DK), and washed 3x 5’ with wash buffer. 
• with biotinilated anti-rat secondary antibody (Cat. No. BA-4000, Vector Labs, Burlingame, 
US) diluted 1:250 in wash buffer, washed 3x 5’ with wash buffer, incubated with Vectastain 
Elite ABC kit (Cat. No. PK-6100, Vector Labs) (drop of each reagent A and B in 2,5ml PBS) 
30’ at room temperature and washed 3x 5’ with wash buffer. 
Detection: Slides were incubated in developing solution: 1 tablet DAB (Cat. No. D5905, 
Sigma), diluted in 50ml PBS, with 50µl of 30% H2O2 added directly before use and washed 
briefly in ddH2O. 
Couterstaining: Slides were incubated 30-60” in hematoxylin diluted 1:20 in ddH2O and 
washed 10’ under the running water tap. 
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Dehydration and mounting: Slides were incubated, 5” in EtOH 50%, 5” in EtOH 70%, 2x 
5” in EtOH 90%, 2x 10’ in EtOH 100%, 2x 10’ in xylene and mounted with entellan. 
Specific protocols 
Ki67: wash buffer: TBST; peroxidase blocking: 10’ with 3% H2O2 in ddH2O; antigen  
unmasking: heat in citrate buffer 30’, cool down 20’; protein blocking: 1,5% normal goat 
serum; primary antibody: rabbit polyclonal anti-mouse Ki67 diluted 1:1000 (Cat. No. NCL-
Ki67p, NovoCastra/Leica, Wetzlar, DE) overnight at 4°C; secondary antibody: HRP-
conjugated anti-rabbit; detection: incubation with DAB 8’; 
pan-cytokeratin: wash buffer: TBST; peroxidase blocking: 3% H2O2 in ddH2O, 10’; antigen 
unmasking: proteolytic with Proteinase K, 2’; protein blocking: 1,5% normal goat serum; 
primary antibody: polyclonal anti-cow cytokeratin wide-spectrum screening diluted 1:500 
(Z0622, Dako) 30’ at room temperature; secondary antibody: HRP-conjugated anti-rabbit; 
detection: incubation with DAB 5’; 
INOS: wash buffer: PBS; peroxidase blocking: 1% H2O2 in ddH2O, 5’; antigen unmasking: 
basic antigen retrieval solution 30’, cool down 20’; protein blocking: 1,5% normal goat 
serum; primary antibody: rabbit polyclonal anti-human INOS diluted 1:500 (Cat. No. SC-651, 
Santa Cruz Biotechnology, Santa Cruz, US) overnight at 4°C; secondary antibody: HRP-
conjugated anti-rabbit; detection: incubation with DAB 5’; 
Yap: wash buffer: TBST; peroxidase blocking: 3% H2O2 in ddH2O, 5’; antigen unmasking: 
citrate buffer 30’, cool down 20’; protein blocking: 5% normal goat serum; primary antibody: 
rabbit polyclonal anti-human YAP diluted 1:25 (Cat. No. 4912, Cell Signaling, Danvers, US) 
overnight at 4°C; secondary antibody: HRP-conjugated anti-rabbit; detection: incubation with 
DAB 10’; 
F4/80: wash buffer: PBS; peroxidase blocking: 1% H2O2 in ddH2O:methanol 1:1, 10’; 
antigen unmasking: protease type XIV; protein blocking: 1,5% normal goat serum; primary 
antibody: rat polyclonal anti-mouse F4/80 diluted 1:50 (Cat. No. MCA497G, Serotec, 
Kidlington, UK) overnight at 4°C; secondary antibody: biotinilated anti-rat; detection: 
incubation with DAB 10’; 
TUNEL: conducted with TACS 2 TdT In situ Apoptosis Detection Kit (Cat. No. 4810-30-K, 
Trevigen, Gaithersburg, US); wash buffer: PBS; antigen unmasking: proteolytic with 
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Proteinase K, 15’; peroxidase blocking: 3% H2O2 in methanol, 5’, washed 1’; protein 
blocking: 5% normal goat serum; labelling: wash slides in labelling buffer 5’, label in 
labelling mix 1h at 37°C, wash slides with stop buffer for 5’, wash 2x with ddH2O 5’; POD 
signal conversion: incubate slides with Strep-HRP solution for 10’ at 37°C; Detection: 
incubation with DAB 5’; 
Stainings on cryo-sections 
Snap-frozen tissue in cryo-blocks was stored in -80°C and for staining cut into 7µm-thick 
sections that were transferred on coated microscope slides and before staining dried for 30’ at 
room temperature. 
MIC-1: Sections were fixed in ice cold acetone for 10’, air dried for 30’ washed in wash 
buffer (PBS with Triton X-100 0,1%) 3x 5’. Then sections were blocked in with 5% normal 
horse serum in wash buffer for 1h at room temperature and incubated with primary antibody 
(rat monoclonal anti-mouse, Cat. No. MIC1-1C3, Novus Biologicals, Littleton, US) overnight 
at 4˚C. After that slides were washed with wash buffer 3x 5’, incubated with secondary 
antibody (donkey anti-rat-alexa-594, diluted 1:500 in wash buffer Cat. No. A-21209, 
Molecular Probes/Invitrogen) 30’ at room temperature, washed with wash buffer 3x 5’, 
counterstained with DAPI (200ng/ml in PBS) 5’, washed with wash buffer 5’ and mounted 
with Mowiol with DABCO. 
OilRed: Sections were fixed in 4% PFA in PBS for 10’ at room temperature. After that they 
were washed in ddH2O 5‘, incubated in 60% isopropanol 5’, stained with filtered Oil Red 10’, 
washed in 60% isopropanol 5’ followed by brief wash in ddH2O. Finally sections were 
counterstained with hematoxylin diluted in 1:20 ddH2O 30”, washed under the running water 
tap for 10’, mounted with glycerol and sealed with nail polish. 
Image processing 
Tumour-affected area and number of tumours on H&E sections was quantified either on 
images acquired with microscopes Axio Imager.M1 and SteREO Discovery.V12 equipped 
with AxioCam MRc5 camera (Zeiss, Oberkochen, DE) (alfp-cre-mediated single KOs) or on 
scans acquired at 20x magnification with digital slide scanner Pannoramic SCAN 
(3DHISTECH/Zeiss) (Paweł Pasierbek, IMP, Vienna) (mx-cre-mediated single KOs and alfp-
cre-mediated double KOs). 
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Quantifications of immunohistochemical stainings were performed on images acquired at 20x 
magnification with Axio Imager.M1 microscope equipped with AxioCam MRc5 camera 
(F4/80, Ki67 48hrs after DEN) or regions of interests from scans acquired at 20x 
magnification with Pannoramic SCAN (Ki67 30 weeks after DEN, TUNEL, INOS). Images 
were processed in ImageJ: first colour deconvolution plugin was used to isolate DAB-signal, 
which was then thresholded and positive cells were automatically counted with the help of 
particle analyser function. 
Hepatocyte primary cultures 
Portal vein catheterisation and liver perfusion: Mice were euthanized by cervical 
dislocation and their abdomen and thorax were disinfected with EtOH 70% before opening 
peritoneal cavity by V-incision. Further, intestine and stomach were moved aside and liver 
was flipped up to visualise portal vein. Slight incision in the portal vein was made, capillary 
connected to rubber tube with perfusion solution (Cat. No. 17701, Gibco/Invitrogen, Paisley, 
UK) was introduced into the portal vein, vena cava was cut open, and the liver was perfused 
with the help of peristaltic pump at ~8ml/min for 3’. After that time pump was stopped, 
rubber tube was moved to liver digest medium (Cat. No. 17703, Gibco/Invitrogen), and 
perfusion was continued for 5’ at the same speed. Perfusion solutions were warmed up so at 
the end of the capillary their temperature reached 37°C. 
Hepatocyte isolation: Gall bladder was removed, perfused and digested liver separated from 
diaphragm and transferred to sterile petri dish, cut into pieces for better hepatocyte release 
from the liver capsule and transferred to 15ml ice-cold hepatocyte isolation medium. Cells 
were filtered through 70µm cell strainer into fresh 50ml falcon, centrifuge at 50g for 5’, re-
suspended in 10ml fresh hepatocyte isolation medium, and centrifuged at 20g for 2’ twice, 
changing medium in between. After that cells were re-suspended in 10ml 37°C-warm 
hepatocyte growth medium and their viability and number was estimated in trypan blue with 
Neubauer chamber. Hepatocytes were plated 35000 alive cells per 1cm2 culture dish surface 
on dishes coated with collagen 5µg/cm2 (Cat. No. 2586-C02-0206, Inamed, Santa Barbara, 
US). 
Hepatocytes isolation medium: RPMI, 10% FCS, pen-strep, amphotericin; 20mM HEPES; 
Hepatocyte growth medium: RPMI, 10% FCS, pen-strep, amphotericin, growth hormones 
(40ng/ml TGF-α (Cat. No. T7924, Sigma), 30ng/ml IGF-II (Cat. No. I2526, Sigma), 1,4nM 
insulin (Cat. No. I5500, Sigma)); 
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Protein methods 
Protein isolation from mouse livers 
Around 5-10 volumes of RIPA tissue lysis buffer with inhibitors was added to 5-10µg frozen 
liver tissue that was subsequently homogenised in FastPrep-24 (MP Biomedicals, Irvine, US) 
with~8 ceramic beds in tube, power 5.0, 2x 20” bursts with 2’ pause on ice in between. 
Lysates were centrifuged 2x at 20000xg for 15’ with supernatant transferred into a fresh tube. 
Protein concentration was estimated with Bradford method (Cat. No. 500-0006, Bio-Rad, 
Hercules, US) with samples diluted in ddH2O 5-10x. To achieve desired protein concentration 
in the final sample (usually 1-2 g/l) 1x RIPA buffer with detergents and inhibitors was added 
together with 3x Laemmli sample buffer to achieve final 1x concentration. 
RIPA buffer: 50mM Tris-HCl pH 8,0; 150 mM NaCl; 1% TX-100; 0.1% SDS; 5 mM EDTA; 
1 mM EGTA; 
Detergent and inhibitors added just before use: 0.5% sodium deoxycholate; 1x PIC; 1ug/ml 
pepstatin; 10mM NaF; 1mM PMSF; 1mM β-glycerophosphate; 2,5 mM sodium 
pyrophosphate; 
3x Laemmli sample buffer: 187,5mM Tris-HCl, 6% SDS, 30% glycerol, 15% β-
mercaptoethanol, 0,03% bromophenol blue; 
Protein isolation from cell cultures 
Cell culture plates were put on ice, medium was aspirated and plates were washed 3x with 
ice-cold PBS. 1x Laemmli buffer (without β-mercaptoethanol and bromophenol blue) was 
added on plates (200µl per confluent 10cm plate), cells were scraped with cell scraper and 
lysate was transferred to fresh eppendorf tube. Lysate was incubated 5’ at 95°C with shaking 
and 2x Leammli buffer was added to achieve final 1x concentration. Protein concentration 
was measured with BCA method (Cat. No. P23228, Thermo) after diluting samples 5x in 1x 
Laemmli buffer. To achieve desired protein concentration in the final sample (usually 0,5-1 
g/l) 1x Laemmli buffer was added and β-mercaptoethanol:bromophenol blue mixture in ratio 
5:2 was added to achieve final 7% concentration. 
1x Laemmli buffer: 62,5mM Tris-HCl, 2% SDS, 10% glycerol; 
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SDS-PAGE 
SDS-polyacrylamide gels were casted and run with SE250 Mighty Small II (small gels) or 
SE600 (large gels) systems (Hoefer, Holliston, US). Gels were composed of resolving and 
1cm stacking part, each allowed to polymerise in the casting apparatus after adding APS and 
TEMED for 15’. Samples (10-50µg protein per 3-7mm-wide well) were run at 60V through 
stacking gel and 90V through resolving gel until bromophenol blue exited the gel. 
SDS-PAGE running buffer: 25mM Tris, 192mM glycine, 0,1% SDS 
resolving gel - 10ml 6% 8% 10%  stacking gel - 3ml 
ddH2O 5,3ml 4,6ml 4,0ml  ddH2O 2,1ml 
30% acrylamide mix 2ml 2,7ml 3,3ml  30% acrylamide mix 0,5ml 
1,5M Tris (pH 8,8) 2,5ml 2,5ml 2,5ml  0,5M Tris (pH 6,8) 380µl 
10% SDS 100µl 100µl 100µl  10% SDS 30µl 
10% APS 100µl 100µl 100µl  10% APS 30µ 
TEMED 8µl 6µl 4µl  TEMED 3µl 
Immunoblotting 
After the run gels were washed 5 minutes with transfer buffer and assembled in 
immunoblotting sandwich with nitrocellulose membrane Hybond-C Extra (Cat. No. 
RPN303E, Amersham/GE Healthcare) in Mini Trans-Blot (small gels) or Trans-Blot (big 
gels) electrophoretic transfer cell (Bio-Rad). Transfer was run either 1h at 350mA, cooled 
with an ice block and in the 4°C cold room (small gels) or overnight at 30V cooled with heat 
exchanger set to 4°C (large gels). Quality of transfer was checked by staining transferred 
proteins on membranes with Ponceau Red. 
Transfer buffer: 25mM Tris, 192mM glycine, 20% MetOH 
Protein detection 
Membranes were blocked in TBST with 5% BSA 30’ at room temperature and incubated with 
primary antibodies diluted in blocking solution overnight at 4°C. Then membranes were 
washed with TBST 3x 5’ and incubated with respective secondary antibody in TBST with 5% 
non-fat dry milk 1hr at room temperature, and washed again with TBST 3x 5’. Detection was 
performed by soaking films in enhanced chemiluminescence substrate (Cat. No. 32106, 
Pierce/Termo) and recording signal with Hyperfilms ECL (Cat. No. 28-9068, Amersham/GE 
Healthcare). 
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Primary antibodies 
Antigen Dilution MW (kDa) Source Company Cat. No. 
p-ERK1/2 (T202/Y204) 1:1000 42/44 rabbit polyclonal Cell Signaling 9101 
ERK1/2 1:1000 42/44 rabbit polyclonal Cell Signaling 9102 
Tubulin 1:20000 55 mouse monoclonal Sigma T9026 
C-RAF 1:500 74 rabbit polyclonal Cell Signaling 9422 
p-YAP (S127) 1:1000 75 rabbit polyclonal Cell Signaling 4911 
YAP 1:500 75 rabbit polyclonal Cell Signaling 4912 
MST2 1:2000 55 rabbit monoclonal Epitomics 1943-1 
p-LATS1 (S909) 1:500 126 rabbit polyclonal Cell Signaling 9157 
LATS1 1:500 126 rabbit monoclonal Cell Signaling 3477 
Actin 1:2000 43 goat polyclonal Santa Cruz SC-1616 
p-P38α (T180/Y182) 1:1000 41 rabbit polyclonal Cell Signaling 9211 
P38α 1:1000 41 rabbit polyclonal Cell Signaling 9212 
IκBα 1:1000 35 mouse monoclonal Cell Signaling 4814 
 
Secondary antibodies  
Antigen Company Cat. No.  
mouse IgG Amersham/GE Healthcare NA931V  
rabbit IgG Amersham/GE Healthcare NA934V  
goat IgG Santa Cruz SC-2020  
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